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Parturition: Laboratory and Clinical Investigations.
The importance of the appropriate timing of parturition is highlighted by the fact that
preterm labour accounts for 85% of the deaths of normally formed babies. In
addition, there are clinical situations where induction of labour is required. Attempts
to reduce the incidence of preterm labour and facilitate induction require an
understanding of the normal processes of labour at term.
In this thesis the physiology of parturition is considered, with emphasis on
prostaglandin biosynthesis and metabolism, and the regulation thereof, processes
which are thought to be pivotal in the mechanism of labour. The physical and
biochemical changes associated with cervical ripening are discussed, as are mediators
of this process. Finally, the current understanding of ovine parturition and potential
similarities with humans is reviewed.
The laboratory studies described employ the techniques of explant and cell culture of
fetal membranes, namely amnion and chorion, to investigate firstly the changes in
synthesis and metabolism of prostaglandins E2 and F2a (PGE2, PGF2a) that occur
within these tissues in association with labour. Prostaglandin production by amnion is
increased without any effect on metabolism by chorion. The effect of amniotic fluid
on prostaglandin synthesis and metabolism in cell culture was then explored, and,
having demonstrated that amniotic fluid from labouring women stimulates PGE2 and
PGF2a production, the mechanisms controlling the response to amniotic fluid were
investigated, and found to be dependent on new protein synthesis and
protein kinase C.
In the clinical situation pharmacological ripening of the cervix was studied in two
randomised, placebo-controlled clinical trials. The efficacy of recombinant human
relaxin and mifepristone (RU 486) was investigated in women with an unfavourable
cervix, modified Bishop score < 4, in whom induction of labour was indicated.
Vaginal administration of relaxin (1,2 and 4 mg) was without effect on cervical
ripening. The first part of a dose finding study with mifepristone demonstrated that a
dose of 50 mg may have some preparatory effect on the cervix with regard to ripening,
but that a higher dose is required for successful induction of labour.
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Chapter One
A Review of Parturition
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1.1 Pregnancy and Parturition.
Parturition is a complex series of events which ideally should culminate in the delivery
of a healthy baby to a healthy mother. In order for the process to be successful,
physiological changes in the maternal genital tract must occur in synchrony, and at the
appropriate gestation. Traditionally labour was thought to be entirely the result of
contractility of the uterine corpus. However, recognition of the uterine cervix as a
distinct entity, in which important physiological changes occur that are a prerequisite to
normal labour, has altered this view. The function of the uterus and cervix changes as
gestation advances. In early pregnancy the uterus is relatively quiescent while the
cervix is a rigid structure, and it is the combination of these two features that prevents
the untimely expulsion of the fetus. As pregnancy progresses, myometrial contractility
increases and the cervix softens and becomes more compliant enabling it to dilate and
allow the safe passage of the fetus. It can be seen, therefore, that the onset of labour is
not a sudden event but rather the end point of a phase of increased myometrial
responsiveness and cervical ripening, referred to as prelabour.
The mechanisms responsible for the control of parturition are understood only in part,
and the exact stimulus for the onset of labour remains elusive. Any interruption to the
fine tuning of events leading to the onset of labour can have important clinical
implications, and it is for this reason that continuing research endeavour in to the
control of parturition is essential on at least two counts. Preterm labour, which occurs
in approximately 10% of pregnancies, is responsible for 85% of the deaths of
normally formed babies. This remains one of the major clinical challenges in obstetric
practise and our current management of this problem is based on our present
knowledge about the process of parturition. Reducing the incidence of preterm labour
is dependent on advancing our knowledge further. Apart from obvious concerns
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about the timing of the onset of labour, it is widely accepted that the course of labour is
least complicated when its onset is spontaneous. Clinical situations arise necessitating
early termination of the pregnancy on account of maternal or fetal pathology, or
intervention may be indicated owing to prolonged pregnancy. In these cases it is
recognised that the success of labour induction is closely correlated with the cervical
state (ie. ripeness), and that pharmacological cervical ripening / induction of labour
should replicate physiological events as closely as possible.
The work presented in this thesis focuses on two areas. Firstly, the role of human
fetal membranes in the production of potent myometrial contractile agents, namely
prostaglandins, and factors which control their synthesis and metabolism. Secondly,
the use of pharmacological agents for cervical ripening prior to induction of labour in
women with an unfavourable cervix. In view of this, the physiology of parturition
will be introduced.
1.2 Myometrial Contractility.
1.2.1 Physiology of Myometrial Contractility.
The uterus is never entirely quiescent, neither in the pregnant or the non-pregnant
state. Caldeyro-Barcia and colleagues (1958) studied the pattern of myometrial
contractility in pregnancy in detail, and demonstrated the presence of contractile
activity throughout gestation, with an increase in both frequency and intensity of
contractions in the 5-6 weeks prior to the onset of recognised "clinical labour".
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The myometrium is composed of smooth muscle cells embedded in extracellular
material consisting mainly of collagen fibres. It therefore differs in this respect from
skeletal muscle which is a more homogeneous tissue. The smooth muscle cells are
arranged in bundles and exist in two distinct layers: outer longitudinal and inner
circular according to the configuration of the bundles. Communication between the
cells is facilitated by the collagenous ground substance and by gap junctions.
Gap Junctions.
Gap junctions facilitate intercellular communication which has been shown to be
important in a number of physiological processes including the coordination of smooth
muscle contraction (Garfield et al, 1977). They consist of two symmetrical portions of
plasma membrane from apposing cells. Intramembranous proteins (connexins) from
these apposing cells align themselves, creating pores from the cytoplasm of one cell to
the other. These pores provide sites for low-resistance electrical or ionic coupling
between cells and are thought to synchronise myometrial contractility by conduction of
electrophysiological stimuli during labour.
There are at least 16 types of connexin gap junction proteins, all of which share the
same general structure (Orsino et al, 1996). However, the pattern of distribution of
connexins is complex: some are broadly expressed in many tissues (eg. connexin 43
[Cx-43]), and others show a restricted pattern of distribution (eg. Cx-33). Cx-43 is
the major myometrial gap junction protein (Lye et al, 1993). It has been demonstrated
that the expression of myometrial Cx-43 messenger RNA is elevated near term and is
maximal during delivery in the rat (Lye et al, 1993), sheep (McNutt et al, 1994) and
human (Chow and Lye, 1994).
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Gap junction regulation.
The fact that expression of myometrial Cx-43 mRNA is elevated at term and in
association with labour suggests that regulation of gap junction proteins may depend,
at least in part, on hormonal steroid concentrations. In the rat and sheep Cx-43
expression is associated with an increase in the plasma oestrogen: progesterone ratio
(Lye et al, 1993; McNutt et al, 1994). Investigation into the regulation of transcription
of the Cx-43 gene in myometrium in animal models has demonstrated that this gene is
oestrogen responsive, and that oestrogen increases mRNA encoding the nuclear
transcription factors Fos and Jun. Therefore, oestrogen could stimulate transcription
of the Cx-43 gene directly via putative oestrogen responsive elements or indirectly via
increased expression of c-fos or c-jun (Lefebvre et al, 1995). The finding that
incubation of bovine myometrial cells with the antioestrogen EM 139 inhibits Cx-43
mRNA expression by up to 40% (Doualla-Bell et al, 1995) lends further support to the
theory that steroids are important regulators of gap junctional proteins and hence
myometrial contractility.
An increase in the oestrogen: progesterone ratio will therefore favour induction of the
Cx-43 gene and hence positively influence myometrial contractility. Progesterone can
block oestrogen-induced expression of Cx-43 mRNA (Petrocelli and Lye, 1993)
raising the possibility that there may be progesterone response elements in the Cx-43
gene. However, whether progesterone withdrawal itself has a positive effect on gap
junction formation, or whether this is simply secondary to the relative increase in
oestrogen concentrations that occurs as a result has not been established.
The mechanisms that regulate gap junction synthesis and function have not been
identified in humans. There is no change in peripheral progesterone concentrations in
humans prior to the onset of labour suggesting that any change in
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oestrogen/progesterone ratio that might regulate gap junction formation would have to
occur at a local level. It has been suggested that it is not the level of steroid hormones
that is important in regulating Cx-43 expression, but rather the concentration of
myometrial steroid receptors (Chow and Lye, 1994). It has been demonstrated that an
increase in mRNA encoding myometrial oestrogen receptors may occur with labour
onset, enabling increased oestrogen activity (with a change in the
oestrogen/progesterone ratio) which would not be reflected in the peripheral circulation
(Mitchell et al, 1982).
Myosin and Actin.
Myosin and actin filaments within the smooth muscle cell are central to the process of
muscle contraction. Myosin differs from actin in that in addition to being a structural
protein, which is organised in thick filaments, it is also an enzyme responsible for
hydrolysing ATP during contraction and relaxation. Myosin is composed of one pair
of heavy chains of about 200 kDa and two pairs of light chains of 15 and 20 kDa. The
head of the myosin molecule has three important sites: the actin combining site; the
ATPase site and the 20 kDa light chains. The actin-combining site is where myosin
interacts with actin, the other major muscle protein. It is a globular protein of 45 kDa,
organised into thin filaments. Smooth muscle contraction occurs when covalent cross-
linking bonds form between the actin and myosin filaments as they slide past each
other. Whereas in skeletal muscle the direction of contraction is always aligned with
the axis of the muscle fibres, owing to the organisation of the filaments in smooth
muscle it is able to exert pulling forces in any direction.
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1.2.2 Regulation of Myometrial Contractility.
Myosin light chain kinase fMLCKV
MLCK is the enzyme responsible for phosphorylation of the 20 kDa myosin light
chains. This reaction results in the release of energy required to form the cross-linking
bonds between the actin and myosin filaments. MLCK therefore has an integral
regulatory role in smooth muscle contractility. The enzyme itself is controlled by a
number of factors. Activation of MLCK is effected by phosphorylation of the
enzyme, brought about by calmodulin. Calmodulin is a calcium-binding protein,
which may in fact be part of the MLCK molecule itself, which on binding to calcium
alters its steric properties enabling it to phosphorylate MLCK. Clearly, calcium is also
a pivotal regulator ofMLCK activity and will be discussed in more detail below.
Second messengers.
Another mechanism by which MLCK activity is modulated is via adenosine 3,5-mono-
phosphate, commonly known as cyclic AMP (cAMP). This nucleotide acts as a
second messenger in the action of many hormones. It is formed from ATP by the
action of adenylate cyclase, a membrane-bound enzyme. Adenylate cyclase is
activated when a hormone binds to its specific receptor on the cell membrane, and the
result is increased concentrations of cAMP within the cell. The cAMP then acts within
the cell to alter the rate of one or more processes.
In the case of smooth muscle contractility, cAMP can stimulate the calcium pump of
the sarcoplasmic reticulum which leads to a reduction in cytoplasmic concentrations of
free calcium, resulting in muscle relaxation. In addition, cAMP can activate cAMP-
dependent-protein kinase A, by binding to its regulatory subunit. Activated protein
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kinase A is then able to phosphorylate MLCK, this time reducing its ability to bind
calmodulin and thereby inhibiting uterine contractility. Alternatively, activated protein
kinase A can phosphorylate a membrane binding site for calcium resulting in decreased
intracellular calcium concentrations.
It must be remembered that MLCK has two sites available for phosphorylation: one
leading to activation of the enzyme, and the other resulting in its inhibition. There is,
therefore, a complex chain of events surrounding the regulation of myometrial
contractility, and potential for its modulation by various hormones and
pharmacological agents. Stimulation of adenylate cyclase will result in myometrial
relaxation through increased cAMP concentrations, as will inhibition of the enzyme
responsible for cAMP degradation, phosphodiesterase.
Calcium.
In human myometrium the extent of myosin light chain phosphorylation correlates
strongly with the intracellular free calcium concentration (MacKenzie et al, 1990). The
major intracellular store of calcium is the sarcoplasmic reticulum (Somlyo et al, 1985),
the membranes of which contain an intracellular ATP-dependent calcium transport
pump which can facilitate large variations in intracellular free calcium concentrations.
Release of calcium from the sarcoplasmic reticulum can be promoted by inositol 1,4,5-
triphosphate (IP3), another second messenger, which is produced as a result of the
action of phospholipase C on the membrane glycerophospholipid phosphatidylinositol.
In addition to the intracellular sources of calcium, extracellular calcium can enter the
cytoplasm, following the appropriate stimulation, to increase free calcium
concentrations. There are two main routes for calcium entry: voltage and receptor-
operated channels (Hurwitz, 1986). The voltage-operated channels depend on
membrane depolarisation to a threshold level at which the channels become activated
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and allow influx of calcium to the cell. Receptor-operated channels, on the other hand,
become activated and open in response to ligands such as hormones and
neurotransmitters.
1.2.3 Hormonal regulation of myometrial contractility.
Progesterone.
Progesterone is traditionally regarded as the hormone responsible for the maintenance
of uterine quiescence throughout gestation (Csapo, 1975). Potential mechanisms for
this include uncoupling of the excitation-contraction process and inhibition of
prostaglandin or gap junction formation. Uncoupling of the excitation-contraction
process can be effected by altering membrane permeability or influencing postreceptor
events. Progesterone promotes membrane-binding of calcium, and sequestration of
calcium within the sarcoplasmic reticular pools, thus reducing intracellular free calcium
concentrations (Currie and Jeremy, 1979). This is in part due to an action on the
myometrial cell membrane phospholipids, inhibiting release of phosphatidylinositol
and the second messenger IP3. A post-receptor effect has been demonstrated by work
on the rabbit showing an increased response to (3-adrenergic receptor stimulation in the
presence of progesterone, and that the rate of cAMP synthesis was much greater under
the influence of progesterone compared with oestrogen (Riemer et al, 1986).
Progesterone is capable of inhibiting both calcium ionophore- and arachidonic acid-
stimulated production of prostacyclin (PGI2) and thromboxane (TXB2) in nonpregnant
rat myometrium (Jeremy and Dandona, 1986). Since both of these prostaglandins
may be involved in uterine contractility in the rat (Williams et al, 1979) it has been
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proposed that progesterone exerts some of its quiescent effect by inhibiting
endogenous prostaglandin synthesis.
Oestrogens.
During late pregnancy oestrogens promote uterine contractility in most species. They
are essential for the induction of protein synthesis in the uterus, particularly the
contractile proteins (Csapo, 1969) and are capable of increasing myometrial sensitivity
to a variety of oxytocic agents, for example oxytocin and PGF2«- This is likely to be
the result of an increase in receptor synthesis, and there is evidence from several
studies to suggest that prostaglandin and oxytocin receptor concentration is under the
control of ovarian hormones (Soloff et al, 1977). Administration of oestrogen will
increase the number of uterine receptors sensitive to oxytocin and a-adrenergic
agonists (Nissenson et al, 1978; Roberts et al, 1977) and this increase can be blocked
by the simultaneous administration of progesterone.
In addition to increasing receptor synthesis, oestrogen has been shown to increase
prostaglandin synthesis and release from human uterine tissue (Thorburn and Challis,
1979). These events in part explain the stimulatory effect of oestrogen on uterine
contractility. Finally, oestrogen can also influence intracellular calcium concentrations,
calmodulin and MLCK activity (Matsui et al, 1983).
Oxytocin,
Oxytocin is a posterior pituitary hormone which when bound to its receptor inhibits the
myometrial cell membrane calcium ATPase, responsible for pumping calcium to the
extracellular environment. In addition, calcium influx from both the sarcoplasmic
reticulum and the extracellular area is promoted. These actions result in an increase in
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intracellular free calcium concentrations which as previously discussed favours the
contractile process. High affinity oxytocin receptors are present in human
myometrium and increase in concentration towards term (Fuchs et al, 1984). Oxytocin
receptors appear at the same time as gap junctions and it has been proposed that they
may be important in regulating the function of these gap junctions (Garfield and Beier,
1989). As well as being present in myometrial cells, oxytocin receptors have been
demonstrated in the decidua parietalis at term (Fuchs et al, 1984). In addition oxytocin
mRNA has been demonstrated in amnion, chorion and decidua, with levels being
highest in decidua (Chibbar et al, 1995). Oxytocin gene expression was 3-4 fold
higher in choriodecidual tissue collected following spontaneous labour. The
production of decidual oxytocin has importance with regard to stimulating contractility
in the adjacent myometrium. Also, since the decidua is an important site for
prostaglandin synthesis, production and binding of oxytocin to its receptor may
influence prostaglandin production. Finally, oxytocin stimulates the
phosphatidylinositol pathway (Molnar and Hertelendy, 1990) leading to the release of
the second messenger IP3 which in turn increases intracellular calcium concentrations.
Adrenergic drugs.
Human myometrium contains ocj, 0C2 and P2 adrenoreceptors, and these effect either
smooth muscle contraction or relaxation depending on their interaction with the
regulatory mechanisms discussed above. P2 receptors stimulate cAMP (Litime et al,
1989) and hence muscle relaxation, providing the rationale for the use of P agonists in
the prevention of preterm labour. The stimulatory effect of P agonists on cAMP
formation appears to be maximal prior to 35 weeks gestation, and is subsequently lost
as pregnancy advances to term (Litime et al, 1989). This is thought to represent
uncoupling of the P2 receptor to adenylate cyclase rather than a decrease in receptor
number.
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P2 receptors may promote smooth muscle relaxation by a mechanism independent
from cAMP. In guinea-pig myometrium ^-adrenergic receptor activation is linked to
inhibition of voltage-operated calcium channels (Khac et al, 1992), and inhibition of
these channels prevents phospholipase C activation and thus inhibits IP3 release, aj
receptors are linked to phospholipase C (Breuiller-Fouche et al, 1991) and hence
stimulate uterine contractility via IP3. 0C2 receptors have dual function: they can
stimulate uterine contractions by inhibiting adenylate cyclase, resulting in decreased
cAMP concentrations (Breuiller et al, 1990), or they can inhibit calcium channels
leading to uterine relaxation.
Prostaglandins.
Prostaglandins (section 1.3) are capable of stimulating myometrial contractility
throughout pregnancy. The pregnant uterus is more sensitive than the non-pregnant,
but it is not clear whether there is increasing sensitivity with advancing gestation.
Prostaglandins are not universally uterotonic, and it is the balance between stimulation
and inhibition that is likely to be important in regulating uterine activity throughout
pregnancy and labour. They exert their effects by binding to specific receptors located
in the plasma membranes of myometrial cells. There appears to be no change in
receptor number or affinity in association with labour, but rather, the increased
myometrial contractility is a direct result of increased prostaglandin concentrations
(Huszar and Naftolin, 1984).
There are three different types of PGE receptor in the human uterus (Coleman, 1991):
EPi and EP3 receptors are stimulatory, while EP2 receptors are inhibitory. This helps
to explain the in vitro effects of PGE2 which at low doses is stimulatory, but at high
doses has a biphasic action of rapid contraction followed by prolonged relaxation.
EPi and EP3 receptors both activate phosholipase C, and EP3 receptors also inhibit
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cAMP formation. EP2 receptors exert their effect by generating cAMP. Prostaglandin
F2« is purely stimulatory and binding to its specific receptor results in activation of
phospholipases C and A2 (Molnar and Hertelendy, 1990).
The stimulatory receptor interactions result in a final common event which is an
increase in intracellular free calcium. This occurs either as a result of increased
transport from the extracellular space, or release from intracellular stores. Calcium is
not only essential for smooth muscle contractility, but is also required for
prostaglandin synthesis. Incubation of cell cultures with calcium channel blockers will
inhibit prostaglandin synthesis, whereas calcium ionophores lead to increased
production (Olson et al, 1983a). There are therefore two mechanisms which make
calcium channel blockers potentially useful in the arrest of preterm labour. Other
prostaglandins (and their receptors) that influence myometrial contractility include
PGI2 (prostacyclin), which is inhibitory as a result of increased adenylate cyclase
activity (Tanfin and Harbon, 1987), and thromboxane which is stimulatory via
phospholipase C (Hirata et al, 1991). In addition to their post receptor effects
prostaglandins can modulate gap junction formation in vitro (Garfield et al, 1980).
Prostaglandins E2 and F2« induce gap junction formation, while others such as PGI2
are inhibitory. There is therefore a balance between stimulatory and inhibitory
prostaglandins and their receptors within the myometrium which is likely to be
important in the regulation of uterine activity. In addition, the location of these
receptors in different regions of the uterus may be central to the facilitation and
coordination of uterine contractility.
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1.3 Prostaglandin Biochemistry.
Prostaglandins are thought by many to be central to the process of parturition (section
1.4) and therefore basic principles of prostaglandin biochemistry will be discussed in
the following section.
1.3.1 Nomenclature and Structure.
The chemical structure of the naturally occurring prostaglandins was elucidated by
Nugteren et al, 1966. They are oxygenated, unsaturated hydroxy fatty acids
containing 20 carbon atoms. The underlying structure of all prostaglandins is the
prostanoic acid molecule which consists of a cyclopentane ring with two aliphatic side
chains (Figure 1.1). Traditionally, the carbon skeleton is numbered consecutively
from the terminal carboxyl function. The individual prostaglandins are characterised
by the number of substituents on different carbon atoms, and the structure of the
cyclopentane ring. Prostaglandins E (ether soluble) and F (fosphate soluble [Swedish
spelling]) were the first to be named, followed by prostaglandins A, B, C, D, G, Ft
and I. Prostaglandins contain one or more double bonds, the number of which is
indicated by a numerical subscript (1-3) which follows the corresponding letter
referring to the parent structure. All prostaglandins contain a 13,14-trans double
bond, while the presence of a second double bond at the 5,6 position, and a third one
at the 17,18 position characterises prostaglandins of the 2 and 3 series respectively.
Prostaglandins of the F series have an additional subscript (a or (3) which denotes the
orientation of the hydroxyl group at C-9. The cyclic endoperoxides prostaglandins G2
and H2 are short-lived intermediates in the biosynthetic pathway leading to the
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formation of the classical prostaglandins, and prostaglandin I2 (prostacyclin) and
thromboxane (TXA2) have ring configurations which differ from the basic structures
of the other prostaglandins. The structures of the cyclic endoperoxides and the
common prostaglandins are illustrated in Figure 1.2.
2 ^COOH
Figure 1.1


































All naturally occurring prostaglandins are synthesised from one of three essential 20
carbon unsaturated fatty acids. Arachidonic acid (5, 8, 11, 14-all-cis-eicosatetranoic
acid) is the most important and leads to the synthesis of prostaglandins of the 2 series.
The other two are 8, 11, 14-all-cis-eicosatrienoic acid and 5, 8, 11, 14, 17-all-cis-
eicosapentanoic acid which give rise to prostaglandins of the one and three series
respectively. Arachidonic acid is present in cells in the esterified form, usually in the
sn2 position of the glycerophospholipid. It is the liberation of arachidonic acid that is
thought to be the rate-limiting step in eicosanoid biosynthesis (Kunze and Vogt,
1971).
The release of arcahidonic acid from glycerophospholipids is accomplished either by
the direct action of the enzyme phospholipase A2, or by the sequential actions of
phospholipase C, monoacylglycerol and diacylglycerol lipases. The liberated
arachidonic acid can then be metabolised by at least three major pathways (Figure 1.3)
resulting in formation of prostaglandins, hydroxyeicosatetraenoicacids or leukotrienes.
The pathway leading to prostaglandin synthesis involves the conversion of arachidonic
acid to the key intermediates prostaglandin G2 and then prostaglandin H2 by the action
of the enzyme fatty acid cyclooxygenase (COX, also known as prostaglandin
endoperoxide synthase [PGHS] ) which contains an inherent peroxidase activity. Two
isoenzymes of COX are known to exist and are discussed in section 1.5.2.
Prostaglandins G2 and H2 thus formed can be converted either non-enzymatically to
PGE2, or enzymatically to PGE2, PGF2a, PGI2 and TXA2 depending on the cell type


























Figure 1.3 The Arachidonic Acid Cascade
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Prostaglandin biosynthesis can be inhibited by a number of different agents. The most
important group is the non steroidal anti-inflammatory drugs (NSAIDs) which inhibit
the action of COX. It has been demonstrated that the mode of action of NSAIDs
differs according to the preparation. Aspirin causes irreversible inhibition of COX,
where recovery of the enzyme is dependent on new protein synthesis, whereas other
drugs such as diflunesal act as reversible inhibitors (Lands and Hanel, 1983).
Structural analogues of arachidonic acid, such as arachidynoic acid, will act as
competitive inhibitors of prostaglandin synthesis (Ahem and Downing, 1970), and
anti-inflammatory steroids will inhibit the release of precursor acids by inhibiting
phospholipase A2.
1.3.3 Prostaglandin Metabolism.
Prostaglandin metabolism takes place mainly in the lung, but the enzymes involved in
this process are also found in the kidney and liver (Anggard et al, 1971). In
pregnancy chorion is the major site of intrauterine prostaglandin metabolism and since
this thesis concentrates on the metabolism of prostaglandins E and F in relation to
parturition, they will be discussed more specifically here. However, the following
description does apply, in general, to all prostaglandins.
The first step in prostaglandin metabolism is the oxidation of the allylic alcohol group
at the site of carbon-15 by the enzyme 15-hydroxyprostaglandin dehydrogenase
(PGDH). This reaction yields 15-keto-prostaglandins which are biologically inactive
compounds. Following this, reduction of the A-13-double bond leads to formation of
15-keto-13,14-dihydro-prostaglandins, the metabolites which are found in the
circulation. These metabolites have a circulating half-life of approximately 8 minutes,
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unlike their parent prostaglandins which have an estimated half-life of less than 15
seconds in the circulation. Because of their short half-life, and the fact that platelets,
which are invariably activated on plasma collection, synthesise PGE2 and PGF2a
(Samuelsson et al, 1975), estimation of primary prostaglandins in circulation is of no
value. In contrast, estimation of stable prostaglandin metabolite concentrations can be
used to monitor changes in prostaglandin biosynthesis.
The 15-keto-13,14-dihydro-prostaglandins undergo further metabolic degradation to
yield metabolites with 18, 16 and 14 carbon atoms which are the major urinary
metabolites (Samuelsson et al, 1975). This involves a series of (3 and to oxidation
reactions. [3 oxidation removes 2 carbon atoms from the carboxyl side-chain and one
or two steps of [3 oxidation will result in di-nor or tetra-nor compounds respectively.
CO oxidation at the CD end of the molecule gives rise to a hydroxyl or carboxyl group at
this site, which also undergoes (3 oxidation yielding CD dinor and CD tetranor dioic acid
compounds. As a result of these reactions the major urinary metabolites of PGE2 and
PGF20C are 7a-hydroxy-5,l l-diketotetranorprostane-l,16-dioic acid and 5a,7a-
dihydroxy-1 l-ketotetranorprostane-l,16-dioic acid respectively. A simplified



















Simplified metabolic pathway for PGF2(X.
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1.4 Prostaglandins and Parturition.
There is a large body of evidence to support a role for prostaglandins in human
parturition. A number of prostaglandins were identified in amniotic fluid by Karim
(1966), who also demonstrated that prostaglandin-rich extracts of amniotic fluid were
capable of increasing the intensity of spontaneous myometrial contractions (Karim and
Devlin, 1967). In addition, concentrations of PGE and PGF were significantly greater
in amniotic fluid obtained following spontaneous labour compared with those found in
amniotic fluid collected prior to labour onset (Karim and Devlin, 1967). These
findings have been confirmed by other workers in this field (Keirse et al, 1977a;
Mitchell et al, 1979). Prostaglandin metabolite concentrations are also increased
during labour, and the approximate increase in the prostaglandins and their metabolites
are as follows: PGE2 10-fold, PGF20C 12-fold (Dray and Friedman, 1976), 13,14-
dihydro-15-keto-PGF2a 6-fold (Keirse et al, 1977a), 6-keto-PGFla 2-fold (Mitchell
et al, 1979) and thromboxane B2 4-fold (Mitchell et al, 1978a). Similarly,
prostaglandin metabolite concentrations in maternal plasma are increased in association
with labour (Mitchell et al, 1978b; Johnston et al, 1993). Urinary metabolite
concentrations have also been studied during pregnancy and the daily excretion of
PGFM increases with advancing gestation, and doubles just prior to labour onset
(Hamberg, 1974).
Prostaglandins are known to be successful in inducing labour at all stages of
pregnancy (Novy and Liggins, 1980), and chronic administration of the NSAID
aspirin, which inhibits COX and hence the conversion of arachidonic acid to the cyclic
endoperoxides, results in prolongation of gestation (Collins and Turner, 1975).
Likewise, administration of indomethacin following induction of midtrimester abortion
will prolong the induction-to-abortion interval (Waltman et al, 1972).
25
1.5 Fetal Membranes and Prostaglandin Biosynthesis.
The fetal membranes and decidua vera are an important source of the prostaglandins
involved in parturition. All three tissues, amnion, chorion and decidua, contain PGHS
activity and while PGE2 is the major product of the amnion and chorion, decidua
produces PGE2 and PGF2« in equal amounts (Mitchell et al, 1978c; Okazaki et al,
1981a). PGHS activity is greater in amnion compared with chorion and decidua, and
it is significantly greater in amnion collected following spontaneous labour compared
with pre-labour (Okazaki et al, 1981a). Although the precise source of the
prostaglandins integral to the initiation of labour has not been clarified, the increased
production of PGE2 by amnion is thought to be important in a complex cascade of
events.
Since amnion is avascular, substances that influence prostaglandin production by this
tissue are likely to be present locally, either in the amniotic fluid, chorion laeve or
decidua. The theory that the fetus may play a role in controlling the timing of
parturition is an attractive one. As will be discussed later there is some evidence to
support interaction between the placental unit and the hypothalamo-pituitary-adrenal
(HPA) axis of the fetus. Maturation of the fetal HPA axis may influence the content
of the amniotic fluid, which in turn could regulate prostaglandin production by the fetal
membrane and thus effect myometrial contractility (MacDonald et al, 1974). Because
of the crucial role of the fetal membranes and decidua in this cascade the previous
account of prostaglandin biosynthesis and metabolism, and the regulation therof, will
now be related to these tissues.
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1.5.1 Arachidonic Acid.
As discussed earlier unesterified arachidonic acid is the obligate precursor of
prostaglandins of the 2-series (Lands and Samuelsson, 1968) and release of
arachidonic acid from esterified forms may be a rate limiting step in prostaglandin
synthesis. The concentration of arachidonic acid in amniotic fluid increases 6-10 fold
during labour (MacDonald et al, 1974) and this increase is 4 times greater than that of
other unesterified fatty acids. In addition, the concentration of arachidonic acid in
amniotic fluid has been shown to be related to cervical dilatation (Keirse et al, 1977b).
Arachidonic acid accounts for approximately 20% of total fatty acids in amniochorion
(Schwarz et al, 1975), and the arachidonic acid content of fetal membranes is
significantly lower in tissue obtained after labour compared with that collected pre-
labour. Over 45% of the arachidonic acid in glycerophospholipids is present in
phosphatidylethanolamine (PE) (Okita et al, 1982a). The arachidonic acid content of
PE, and another glycerophospholipid phosphatidylinositol (PI), is reduced by about
42% and 35% respectively in amnion during early labour (Okita et al, 1982a). Smaller
but significant reductions in the arachidonic acid content of these glycerophospholipids
were also seen in chorion.
Enzymatic Release of Arachidonic Acid.
Phospholipase A2
Phospholipase A2 (PLA2) is capable of releasing arachidonic acid esterified at the sn-2
position of glycerophospholipids. PLA2 activity has been demonstrated in a number
of intrauterine tissues (Schultz et al, 1975) and in amniochorion it is largely distributed
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in microsomal and cytosolic fractions (Okazaki et al, 1978). PLA2 has been shown to
be substrate specific in amniochorion, promoting the release of arachidonic acid from
PE, but not from PI, and in general its activity is calcium dependent (Okazaki et al,
1978).
Multiple forms of PLA2 have been identified and characterised into two functionally
distinct groups: secretory PLA2S and cytosolic PLA2. Messenger RNAs encoding two
secretory PLA2 isoenzymes (Types II and IV) have been identified and expression of
these mRNA transcripts and that of cytosolic PLA2 has been investigated in the
intrauterine tissues at term. Cytosolic PLA2 mRNA is most abundant in amnion,
compared with choriodecidua or placenta, whereas secretory mRNA transcripts are
most abundantly expressed in placenta (Freed et al, 1997). These findings suggest
that cytosolic PLA2 is the principal isoenzyme mediating arachidonic acid release in
term amnion, whereas secretory PLA2 isoenzymes are integral to placental
phospholipid metabolism.
Phospholipase C
Phospholipase C (PLC) is also a calcium-dependent enzyme, and a Pi-specific
phospholipase C has been isolated in amnion, chorion and decidua (Di Renzo et al,
1981). PLC will not itself release unesterified arachidonic acid from PI, but leads to
the production of diacylglycerol (DAG) rich in arachidonic acid. The diacylglycerol
content of human amnion is greater in tissue obtained during early labour compared
with that obtained prelabour, supporting the theory that arachidonic acid is released
from PI in amnion during parturition (Okita et al, 1982b). DAG is then hydrolysed at
the sn-1 position by the action of DAG lipase which is present in fetal membranes and
decidua (Okita et al, 1982b). This reaction results in monoacylglycerol (MAG) which
is subsequently hydrolysed by monoacylglycerol lipase to release the fatty acid in the
sn-2 position which is rich in arachidonic acid (Okazaki et al, 1981b).
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Regulation of Arachidonic Acid Mobilisation.
It has been demonstrated in vitro that the activities of PLA2 and PLC increase during
gestation, and that this increase is confined to amnion (Okazaki et al, 1981c). This is
unlike the activities of DAG lipase and MAG lipase which remain constant throughout
gestation. In spite of the gestational changes in PLA2 and PLC activity, there is no
further change in the activity of these enzymes in fetal membranes or decidua vera in
association with labour. Both PLA2 and PLC are calcium dependent, and the calcium
concentration necessary to support maximal activity of these enzymes in vitro is
greater than that found in amnion cells under resting conditions. Factors present in
amniotic fluid may have the potential to increase calcium concentrations in amnion
cells. Platelet activating factor (PAF), which has been identified in amniotic fluid
(Billah and Johnston, 1983), is able to induce rapid increases in intracellular calcium
concentrations leading to activation of phospholipases, arachidonic acid release and
prostaglandin production (Roukin et al, 1983). PAF will also stimulate PGE2
production from amnion tissue culture (Di Renzo et al, 1984).
1.5.2 Cyclooxygenase.
Cyclooxygenase (COX), otherwise known as prostaglandin endoperoxide H synthase
(PGHS), protein has been identified in human fetal membranes and decidua from early
gestation to term by immunocytochemistry (Bryant-Greenwood et al, 1987). COX
catalyses the conversion of free arachidonic acid to the unstable cyclic endoperoxides,
which are in turn converted to prostaglandins, prostacyclin or thromboxane depending
on the cell type. The activity of this enzyme is therefore an important rate-limiting step
in prostaglandin biosynthesis. Two isoenzymes of COX have been identified, and
each one is the product of a different gene (Xie et al, 1993; Wen et al, 1993). COX-1
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is a 68.5 kDa protein which is constitutively expressed in fetal membranes, and in situ
hybridisation has localised the expression of this isoenzyme to the amniotic epithelium,
amniotic mesoderm and chorionic layers (Slater et al, 1995). COX-2 is the inducible
form of the enzyme, weighing 69 kDa, and its expression can be stimulated by various
agents including cytokines (Mitchell et al, 1993a). It has been localised specifically to
the epithelial and mesodermal layers of the amnion with very little expression in
chorion (Slater et al, 1995).
COX activity in amnion is known to increase with advancing gestation, with a further
increase in association with the onset of labour (Teixeira et al, 1993). In addition, a 4
fold increase in COX activity in amnion collected from idiopathic preterm labour has
been demonstrated, suggesting that increased COX activity is a common factor to both
preterm and term labour (Teixeira et al 1994). Investigation of mRNA levels for
COX-1 and 2 in human amnion has revealed that COX-2 mRNA, but not COX-1
mRNA, is increased in association with labour onset, suggesting that increased COX-
2 expression is responsible for the increased COX activity seen at this time (Hirst et al,
1995). COX-1 has a short half life of approximately 4 minutes, and COX-2 appears
to have similar kinetics (Xie et al, 1992). Therefore, if COX activity is to be
maintained there must by continuous enzyme synthesis, and this rate of synthesis will
have to increase if enzyme activity is to be enhanced. Based on these findings COX-2
activity is thought to be of principal importance in producing the increase in
prostaglandin concentrations seen with the onset of labour.
Regulation of COX.
A number of agents have been shown to stimulate de novo synthesis of COX,
including epidermal growth factor (EGF), interleukin-1 (IL-1), dexamethasone and
TPA (Olson et al, 1990). The effect of corticosteroids on prostaglandin production
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does vary, however, with the type of culture employed. For example, while
glucocorticoids stimulate PGE2 synthesis in confluent cell cultures, they inhibit
prostaglandin synthesis in dispersed cell or explant cultures (Gibb and Lavoie, 1990).
Cortisol has been shown to reduce the amount of immunoreactive PGHS in amnion
tissue (Zakar et al, 1994), and in the same experiments TPA, an activator of protein
kinase C, stimulated COX activity. Contrary to these findings, glucocorticoids can
increase the level of COX-2 mRNA in confluent primary amnion cell cultures,
resulting in increased conversion of arachidonic acid to PGE2 in these cells (Zakar et
al, 1995).
1.5.3 Protein Kinase C.
Protein kinase C (PKC) is a calcium and lipid-dependent protein kinase which
regulates cellular function. Activation of PKC occurs as a result of increased
intracellular diacylglycerol (DAG) concentrations. DAG binds to PKC and in so doing
increases the enzymes affinity for calcium (Nishizuka, 1988). PKC can therefore
become fully activated without a detectable change in intracellular calcium
concentration (Nishizuka, 1988). PKC activity has been demonstrated in amnion
(Okazaki et al, 1984) and activation of this enzyme is associated with the increased
prostaglandin synthesis seen with the onset and maintenance of labour (Olson et al,
1990). This process of activation, which involves phosphorylation, appears to require
DAG, phosphatidylserine and calcium (Okazaki et al, 1984).
It has been proposed that PKC is involved in arachidonic acid mobilisation, and the
activation of COX via RNA and protein synthesis-dependent mechanisms (Zakar and
Olson, 1988). PKC exists in multiple isoforms (Nishizuka, 1988), and a number of
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stimulants and inhibitors of the enzyme have been identified. Phorbol esters, such as
phorbol 12-myristate 13-acetate (PMA) and 12-0-teradecanoylphorbol-13-acetate
(TPA), are tumor-promoting agents which are structurally similar to DAG and are
capable of activating PKC. They have been shown to stimulate prostaglandin
production from amnion, chorion and decidua (Sander and Myatt, 1990; Lundin-
Schiller and Mitchell, 1991a; Schrey et al, 1987). Phorbol ester stimulation of amnion
PGE2 production is dependent on mRNA and new protein synthesis. Cycloheximide,
an inhibitor of translation, will inhibit TPA-stimulated PGE2 production in a dose-
dependent manner. Actinomycin D, an inhibitor of transcription, has a similar effect
(Zakar and Olson, 1988). These findings suggest that phorbol esters may induce de
novo synthesis of enzymes involved in prostaglandin synthesis. This is further
supported by the finding that pretreatment of amnion cells with acetylsalicylic acid
does not affect subsequent TPA stimulation of PGE2 production (Zakar and Olson,
1988), implying that the protein kinase C-mediated effect of the phorbol ester results in
de novo synthesis of COX.
Prolonged exposure to phorbol esters will, however, result in down regulation of
PKC and abolish or reduce PGE2 production by amnion exposed to stimulatory agents
such as oxytocin (Moore and Moore, 1990). Staurosporine is a PKC inhibitor which
will completely inhibit the stimulation of PGE2 production induced by agents such as
EGF, dexamethasone, oxytocin and phorbol esters (Moore and Moore, 1990). The
effect of interleukin-l(3 (IE-1 (3), another stimulant of amnion PGE2 production, is also
attenuated by PKC down regulation (Mitchell et al, 1993b). However, it has also been
shown that staurosporine treatment can enhance PGE2 stimulation by IL-1 [3 (Mitchell
et al, 1994). The regulation of PKC is clearly complex, and the diverse actions of this
enzyme may reflect the differential responsiveness of its various isoforms.
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As well as having a regulatory role in COX activity, PKC may also be involved in
control of arachidonic acid release. As previously stated, activation of PKC leads to
phosphorylation of a number of proteins, which results either in their activation or
inhibition. Lipocortin is an antiphospholipase A2 protein which is present in amnion
(Mitchell et al, 1988a). Phosphorylation of lipomodulin, a lipocortin-like protein,
reduces its ability to inhibit PLA2 (Hirata, 1981). Activation of PKC may therefore,
by phosphorylating endogenous lipocortin and thus reducing PLA2 inhibition, increase
arachidonic acid release.
1.5.4 15-Hydroxy-Prostaglandin Dehydrogenase.
Two types of 15-hydroxy-prostaglandin dehydrogenase (PGDH) are known to exist
(Hansen, 1976), and they are distinguished by cosubstrate specificity. Type I PGDH
is the NAD+- dependent form, whereas the cosubstrate for PGDH type II is
nicotinamide-adenine dinucleotide phosphate (NADP+). In the human, chorion is the
major site of prostaglandin metabolism (Okazaki et al, 1981a) reflecting the higher type
I NAD+-dependent PGDH activity in placenta and chorion compared with amnion and
decidua (Schlegel and Greep, 1975). This enzyme catalyses the transformation of
prostaglandins into their 15-keto derivatives which represents the first step in their
degradation.
The distribution and localisation of PGDH in fetal membranes and placenta have been
determined by immunocytochemical studies (Cheung et al, 1990, Sangha et al, 1994).
These demonstrated that immunoreactive PGDH was absent from the subepithelial and
epithelial layers of the amnion; confined to the trophoblast layer of the chorion; and
absent from decidual stromal cells, but present in trophoblast cells that had invaded the
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decidua. In the placenta PGDH was localised to intermediate trophoblast and
syncytiotrophoblast. In the same experiments labour did not influence PGDH
localisation within the placenta or membranes suggesting that changes in PGDH
distribution or activity are unlikely to be responsible for the increase in prostaglandin
concentrations seen with parturition. This is in keeping with the findings of Cheung
and Challis (1989) who demonstrated no change in the metabolism of exogenous
prostaglandins by chorion obtained pre- and postlabour.
PGDH is thought to represent a metabolic barrier to the transfer of prostaglandins,
allowing only small amounts of unmetabolised, active prostaglandins synthesised by
the amnion to pass through the fetal mebranes to the myometrium, where they then
exert their uterotonic effect. It has been demonstrated that while there is no difference
in the localisation of immunoreactive PGDH between patients delivered by caesarean
section or following spontaneous labour at term, there is a significant decrease in
immunoreactive PGDH in patients delivered preterm in the absence of infection
(Sangha et al, 1994), and the amount of PGDH mRNA in the chorio-decidua is lower
in this group of patients. These findings support the concept of prostaglandins
escaping metabolism owing to a deficiency of chorionic PGDH, and thus effecting
myometrial contractility prematurely. However, it has also been shown that PGDH is
distributed heterogeneously in chorion raising the possibility that it does not present a
complete barrier to prostaglandin transfer (Cheung et al, 1990).
Concentrations of placental PGDH increase in early pregnancy, with a tenfold increase
in activity between 7 and 17 weeks gestation (Keirse et al, 1985). The increase is such
that, when expressed per mg protein, PGDH activity has already reached levels seen at
term by the end of the first trimester. For obvious reasons it is not possible to sample
normal pregnancies in the second half of gestation and therefore any changes occurring
in PGDH over this period remain unknown.
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Regulation of PGDH.
Possible mechanisms controlling the activity of PGDH have been suggested. There is
a certain amount of evidence to support hormonal regulation of the enzyme. In the
normal menstrual cycle, prostaglandin metabolism in the endometrium is greatest in the
mid-secretory phase of the cycle when progesterone concentrations are at their highest
(Casey et al, 1980). Experiments in the pregnant guinea-pig employing the
antiprogestin RU 486 have shown that this agent reduces prostaglandin catabolism in
the myometrium, membranes and decidua, with a 9-fold reduction in the catabolic
activity of the chorion (Kelly and Bukman, 1990). In the human, the administration of
RU486 in vivo reduces prostaglandin metabolism to some extent in decidual tissue
cultured in vitro (Norman et al, 1991). Immunocytochemical studies have also
confirmed reduced decidual PGDH activity in women treated with RU 486 in early
pregnancy (Cheng et al, 1993). Therefore, progesterone may be an important
regulator of PGDH, and a reduction in PGDH activity could contribute to the increased
sensitivity of the uterus to exogenous prostaglandins which is seen in the clinical
situation following priming with antiprogestins (Van Look and Bygdeman, 1989). It
has also been suggested that PGDH is under genetic control based on studies of
placental PGDH activity in multiple pregnancy (Erwich and Keirse, 1988). In
addition, the presence of endogenous inhibitors of PGDH has been indicated by the
fact that total enzyme activity increases after the initial step in the purification of PGDH
in the placenta (Flower, 1974). Further attempts to characterise these inhibitors have
suggested that they may be fatty acids (Mibe et al, 1992).
Transfer of Prostaglandins across fetal membranes.
Whilst it is generally accepted that prostaglandins produced by the placenta and fetal
membranes are essential to the events resulting in labour, there is some debate as to the
exact source of the prostaglandins that facilitate myometrial contractility.
Prostaglandin E2 is the major prostaglandin produced during active labour and its site
of synthesis is the amnion. In order to effect uterine contractility PGE2 must be able to
cross the chorion, escaping the high metabolic activity of this tissue owing to the
presence of PGDH, which would result in the production of inactive metabolites.
There has been some disagreement in the literature as to whether or not this is
possible. McCoshen et al (1990) demonstrated that addition of PGE2 to in vitro
culture of amnion discs resulted in transfer of approximately 25% of the prostaglandin
from the fetal to maternal side of the amnion. There was no transfer of PGE2 across
intact membranes (amnion-chorion-decidua). Similarly, Sullivan et al (1993) found
that PGE2 levels on the maternal side of cultured intact membranes were 90% lower
than on the maternal side of amnion alone. These authors conclude that the metabolic
activity of the chorion prevents transfer of PGE2 produced by amnion and that these
prostaglandins do not directly stimulate myometrial activity.
In contrast, Bennett et al (1990) have demonstrated that PGE2 and 5-
hydroxyeicosatetranoic acid (5-HETE) will cross amnion and intact fetal membranes.
Transfer of PGE2 and 5-HETE occurred at equal rates in both directions across
amnion and intact membranes, although the transfer of both agents was slower across
intact membranes compared with amnion alone. There was no metabolism of PGE2
after transfer across amnion alone, and 58% of PGE2 crossed from the fetal to
maternal surface of amnio-chorio-decidua intact. These findings are in keeping with
those of Nakla et al (1986), although Bennett et al (1990) were unable to demonstrate
any change in the rate of transfer with labour. Both groups suggest that transfer is
likely to occur by simple diffusion, because total reactivity passed in either direction,
and there was no decrease in the rate of transfer with increasing concentrations of test
compounds, supporting a lack of receptor or carrier-mediated mechanism.
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Further evidence supporting the hypothesis that prostaglandin transfer can occur
across intact fetal membranes is provided Johnston et al (1996). This work has the
advantage of being performed in vivo, overcoming some of the disadvantages of the in
vitro model. These authors developed an intra- and extra-amniotic dialysis system
within the pregnant sheep uterus. They confirmed that appreciable amounts of PGE2
can cross intact fetal membranes and that there is a relatively constant rate of transfer,
again implying a simple diffusion process. There is therefore a certain amount of
evidence to support the transfer of prostaglandins across fetal membranes inspite of the
metabolic "barrier" of the chorion.
1.6 Cytokines and Parturition.
Cytokines play a central role in a number of biological mechanisms, and their
increasing importance in reproductive processes continues to evolve. Cytokines are
soluble glycoproteins which act non enzymatically to regulate cellular function (Nathan
and Sporn, 1991), usually in an autocrine or paracrine fashion. They can be produced
by many different cell types and are capable of exerting their effects on a variety of
tissues and target organs. There is increasing evidence to support the concept of a
"cytokine network" through which these agents promote their diverse effects (Mitchell
et al, 1993a). Cytokine receptors are present on many cell types and it is through
binding to these receptors that cytokines stimulate intracellular events. The interaction
of cytokine with its receptor results in configurational changes within the receptor. G
proteins present in the cell membrane then activate enzymes on the inner cell membrane
interface leading to synthesis of a second messenger which will in turn regulate
intracellular function. The second messengers activated by cytokines are cAMP and
3 7
the IP3/DAG pathway discussed previously. Examples of cytokines include the
interleukins (numbered 1-12) and tumour necrosis factor a (TNFa), and peptide
growth factors such as transforming growth factor (TGF) a and (3 and epidermal
growth factor (EGF).
Chemokines are a group of chemotactic cytokines which have four cysteine residues
forming two disulfide bonds. They can be categorised into two families: a
chemokines in which the first two cysteines are separated by a single amino acid
residue and are termed the C-X-C subfamily, and P chemokines which have no
intervening sequence and are termed the C-C subfamily, a chemokines are encoded
on human chromosome 4 and examples include interleukin 8 (IL-8) and platelet factor
4 (PF-4). The a chemokines have 30 -50% amino acid sequence homology. Both IL-
8 and PF-4 cause neutrophil and lymphocyte infiltration in vivo. In vitro these agents
attract neutrophils, T cells and fibroblasts, a chemokines are produced by a number
of cells including monocytes and macrophages and their production is induced by
agents such as IL-1, IL-3 and tumor necrosis factor (TNF). p chemokines are found
on chromosome 17 and include monocyte inflammatory protein-la and monocyte
chemotactic peptide. The members of this subfamily have structural homology with
each other and with the a chemokine family. P chemokines,which are produced
largely by T cells, in general attract monocytes, and their production is induced by IL-
4, TGFp and corticosteroids
There is considerable interest in a potential role for cytokines in the regulation of the
onset of parturition. This has been stimulated by investigations into the underlying
mechanisms of preterm labour, implicating a role for inflammatory cytokines (IL-1, 6,
8 and TNFa) in this process. There is growing evidence for a relationship between
intra amniotic infection (defined as the presence of microorganisms in amniotic fluid
obtained by transabdominal amniocentesis [Romero et al, 1988]) and preterm labour.
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It has been demonstrated that 16% of women in preterm labour have intra amniotic
infection (Romero et al, 1988). In addition, women with positive amniotic fluid
cultures are more refractory to tocolysis, and this group have an increased incidence of
histologically confirmed chorioamnionitis when compared to women who respond to
treatment (Hameed et al, 1984).
The final common pathway in the onset of preterm labour appears to be increased
prostaglandin production (Liggins et al, 1979; Lundin-Schiller and Mitchell, 1990a).
Potential stimulants of prostaglandin production in the face of infection include bacteria
and cytokines. The bacteria colonising the amniotic fluid have not been shown to be
capable of producing prostaglandins directly themselves. However, some bacteria
possess phospholipase A2 activity (Bejar et al, 1981), and are thus able to increase
substrate availability for prostaglandin biosynthesis. Investigation into the effect of
bacteria on prostaglandin production by amnion and decidua has shown that there
appears to be a biphasic dose-response, with low doses of bacterial products
promoting prostaglandin synthesis while high doses are inhibitory (Mitchell et al,
1991a). Potentially pathogenic bacteria such as Escherichia coli, Streptococcus
viridans and Bacteroides fragilis will stimulate arachidonic acid metabolism by cultured
amnion cells via both the cyclooxygenase and lipoxygenase pathways (Bennett et al,
1987). However, the ratio of cyclooxygenase to lipoxygenase metabolism is
increased. Importantly, Lactobacillus, a member of normal vaginal flora, did not
stimulate prostaglandin production, and further experiments have confirmed that
common genital tract pathogens do not metabolise arachidonic acid to prostaglandins
or other eicosanoids (Bennett and Elder, 1992a).
Rather than a direct effect of bacteria themselves, the host response to infection,
specifically mediated by cytokines, may be the mechanism of preterm labour. This
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theory is supported by the finding that interleukins are present in amniotic fluid, and in
greater concentrations in the presence of infection.
Interleukin-1 is present in amniotic fluid from the third trimester (Romero et al, 1989a;
Romero et al, 1990a) and has the characteristics of IL-la rather than IL-ip. In
preterm labour associated with infection IL-1 activity in amniotic fluid is significantly
greater than in preterm labour either without infection, or responsive to tocolysis, and
this activity is more consistent with IL-1 p. II-1 (3 concentrations are also increased in
amniotic fluid from labouring women at term compared with non-labouring women.
Similarly, IL-6, which is present in amniotic fluid from the second trimester onwards
(Romero et al, 1990b), is increased significantly in amniotic fluid from women with
intrauterine infection. Again, there is a small but significant increase in amniotic fluid
IL-6 concentrations in association with labour at term. IL-8 can be demonstrated in
amniotic fluid from a proportion of women from mid-pregnancy onwards (Romero et
al, 1991), and it is increased in association with infection driven preterm labour. It is
also significantly elevated in amniotic fluid from women in labour at term with
negative cultures compared to nonlabouring women. TNFa is not detected in amniotic
fluid, in either pregnancy or labour, unless there is intrauterine infection (Casey et al,
1989a; Romero et al, 1989b), when substantial amounts will be found in 20-73% of
cases.
1.6.1 Intrauterine Sources of cytokines.
The fetal membranes and decidua produce a number of cytokines (Romero et al,
1989c; Dudley et al, 1992; Casey et al, 1989a) and while decidua was thought to be
their major source there is evidence to suggest that chorion may be potentially more
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important, based on the finding that basal IL-6 and IL-8 production is greater by
chorion than decidua (Mitchell et al, 1993a). However, it is likely that the majority of
cytokine production in chorioamnionitis is from infiltrating inflammatory cells rather
than from the intrauterine tissues. Following the primary stimulus for cytokine
production, which is generally an infectious or immunological challenge, there is
potential for a cascade of interactions between cytokines, their receptors, and other
cytokines. IL-1 can induce expression of IL-8, IL-6 and TNFa, while TNFa can
induce expression of these three interleukins. The fetal membranes, particularly the
choriodecidual interface, can therefore contribute to this complex interplay of cytokine
production, which are in turn capable of stimulating prostaglandin synthesis as will be
discussed below.
IL-1 and TNFa will stimulate prostaglandin production from amnion (Romero et al,
1989d), chorion (Lundin-Schiller and Mitchell, 1991b) and decidua (Mitchell et al,
1990). IL-6 stimulates prostaglandin production by amnion and chorion (Kent et al,
1993), and although decidual prostaglandin production was not stimulated in these
experiments, other investigators have demonstrated a stimulatory effect of IL-6 in this
tissue (Mitchell et al, 1991b). The concentrations of these cytokines necessary to
promote such an effect is similar to their concentrations in the amniotic fluid of women
with intrauterine infection.
The mechanisms whereby these cytokines promote prostaglandin production have also
been investigated. The stimulatory effect of IL-1 (3 on amnion cell prostaglandin
production appears after 2 hours of incubation implying an induction process (Mitchell
et al, 1993b). This effect is dependent on new protein synthesis since it is inhibited by
coincubation with cycloheximide or actinomycin D. The addition of substrate in the
form of arachidonic acid has a synergistic effect, suggesting that IL-1 (3 does not
mediate its effect by increasing substrate release from glycerophospholipids. The
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finding that cells pretreated with acetylsalycylic acid recover more rapidly when treated
with IL-1 (3 compared with control implies that induction of the enzyme
cyclooxygenase occurs, and increased COX protein has been confirmed by Western
blot analysis (Mitchell et al, 1993b). Subsequent Northern blot analysis has
demonstrated the presence of mRNA for the inducible form of the enzyme, COX-2,
within amnion. It has also been shown that the mechanisms responsible for increased
prostaglandin production by chorion, in response to IL-1P, are in keeping with those
described above (Pollard et al, 1993), and that these mechanisms are common to
TGFa and EGF stimulated prostaglandin production in this tissue.
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1.7 The Cervix and Cervical Ripening.
The cervix has numerous functions which are reflected in its unique structure. These
include, in the nonpregnant state, facilitation of sperm transport, prevention of
microbial invasion and passage of menses and uterine secretions. In pregnancy, the
cervix transforms from a rigid sphincter, acting to maintain the intrauterine contents, to
a soft, compliant structure capable of dilating to enable delivery of the fetus. These
dramatic changes in cervical structure are the result of active metabolic processes
occurring within this organ, which are described clinically by the modified Bishop


























Table 1.1. Modified Bishop score (Calder et al, 1974).
The higher the total score, the more ripe the cervix is deemed to be, and therefore the
closer the timing of labour onset. This section introduces cervical structure, the
physiological changes associated with cervical ripening, and the control thereof.
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1.7.1 Cervical Structure.
The endocervical canal is lined by columnar epithelium which contains multiple
secretory units. The main body of the cervix is composed of connective tissue, the
importance of which in relation to cervical ripening will be outlined in detail below.
External to the connective tissue, on the vaginal aspect of the cervix, is a layer of
smooth muscle which may have a minor role to play in maintaining cervical closure,
but is not considered to be nearly as important as the connective tissue in this
mechanism (Danforth, 1960). The outermost layer of the cervix is stratified squamous
epithelium.
Before discussing the connective tissue of the cervix specifically, the structure of
fibrous connective tissue in general will be briefly outlined. The extracellular matrix of
fibrous connective tissue is composed of collagen fibres and elastin separated by
ground substance. The function of collagen is to confer tensile strength, whereas
elastin gives the tissue elasticity. The exact function of the components of the ground
substance is only understood in part.
Collagen.
The basic molecule of collagen is tropocollagen, a protein with a molecular weight of
300,000 daltons. Tropocollagen itself is composed of three parallel polypeptide chains
wrapped around each other in a helical structure. Each polypeptide chain has a short
nonhelical telopeptide at either end. Apart from the telopeptides, every third residue in
the polypeptide chain is glycine and the concentration of the two uncommon amino
acids, hydroxyproline and hydroxylysine, is high. The triple helices are held together
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by cross links which determine the strength of the collagen fibril. (Fig. 1.5). The
number of cross links vary from tissue to tissue and are higher in older collagen.
Elastin.
Elastin provides tissue with the ability to stretch in length by several fold and then
return to its original length when the tension is released. It is found in most connective
tissues in association with collagen and proteoglycans (Leppert et al, 1982).
Proteoglycans.
Proteoglycans are the largest molecules in the human body with molecular weights of
up to 3 xlO6 Daltons. They are composed of glycosaminoglycans (previously termed
acid mucopolysaccharides) connected to a protein core (Fig. 1.5) The
glycosaminoglycans (GAGs) are long chains of highly negatively charged repeating
disaccharides containing one hexosamine (glucosamine or galactosamine) and one
uronic acid (glucuronic or iduronic). Examples of GAGs include heparin, heparan
sulphate, dermatan and chondroitin sulphate, each one varying in composition
according to the exact combination of hexosamine and uronic acid residues.
Proteoglycans can be defined according to their protein core and classified by their
glycosaminoglycan side chains (Ruoslahti, 1988). Decorin is the predominant
proteoglycan in the cervix and consists of a protein core with a single dermatan
sulphate chain. Biglycan carries two dermatan sulphate chains which are structurally
similar to that found in decorin. A larger proteoglycan, PG-L, contains chondroitin
and dermatan sulphate side chains (Uldberg and Malmstrom, 1991).
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Basic structure of collagen (A) and proteoglycan (B).
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Proteoglycans are able to attach to collagen via their protein cores and thus invest the
collagen fibrils. The GAG side chains can then interact with other collagen molecules,
and with each other, thereby influencing the mechanical strength of the connective
tissue (Lindahl and Hook, 1978; Liggins, 1978). GAGs bind to collagen with
increasing affinity as their chain length and charge density increase, and therefore it
can be seen that the proteoglycan/GAG composition is important in influencing the
mechanical properties of connective tissue.
Collagen Degradation.
The enzymes collagenase and elastase are capable of collagen degradation; the former
is considered essential to this process whereas the latter may be involved mainly in
collagen degradation in granulocyte-dependent inflammatory reactions. Collagenase is
a member of the matrix metalloproteinase (MMP) family. These zinc-dependent
proteolytic enzymes function extracellularly at neutral pH, and they are essential to the
degradation and remodelling of the extracellular matrix. MMPs are produced as
proenzymes which are activated in the extracellular matrix by proteolytic cleavage.
Removal of the "pro" domain of proMMPs results in active enzyme and this cleavage
is performed by other MMPs (Hulboy et al, 1997). The MMPs can be classified in to
three groups based on their substrate specificity. One of these groups, the interstial
collagenases, includes two distinct enzymes: one produced by fibroblasts (MMP-1)
and one produced by polymorphonuclear leukocytes (MMP-8). MMP-1 and -8
degrade types I, II, III, VII and X collagen. Production of MMPs is tightly regulated
by cytokines, hormones and growth factors, as is the synthesis of their specific
inhibitors - the tissue inhibitors of metalloproteinases (TIMPs) (Murphy and
Reynolds, 1993).
4 7
Secretion by fibroblasts is limited by the rate of enzyme synthesis since these cells do
not contain an intracellular pool. Leukocytes, however, store collagenase in their
granules and are therefore capable of immediate enzyme release which may account for
the rapid degradation of collagen seen in inflammatory reactions. Leukocyte elastase,
found in the azurophil granules of leukocytes, degrades elastin, collagen, fibrin,
fibrinogen and cartilage proteoglycans. Its activity with regard to collagen degradation
is thought to be different from collagenase but it has been suggested that the two
enzymes work synergistically.
1.7.2 Physiology of Cervical Ripening.
The cervical stroma is mainly composed of connective tissue containing collagen,
elastin and ground substance (proteoglycans), which constitute more than 70% of its
dry weight. The predominant types of collagen found in the cervix are type I (66%)
and type III ( 33%) (Kleissl et al, 1978). Microscopic examination of the nonpregnant
or unripe pregnant human cervix reveals densely packed collagen bundles, composed
of parallel collagen fibrils, which run in different directions. Cells are interspersed
betwen this network of which the predominant cell type is the fibroblast. As
pregnancy advances and the cervix ripens the histological appearance of the cervical
stroma changes. There is a marked increase in vascularity, along with activation of the
fibroblasts; findings which are comparable to those seen in inflammatory reactions and
wound healing (Liggins 1981). This increase in cellular activity results in dispersal of
the compact collagen bundles such that they appear scattered and partly dissolved on
microscopic examination.
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A number of changes in the biochemical properties of the cervix are known to occur in
association with pregnancy, and are thought to be central to the process of cervical
ripening which facilitates parturition. These include a reduction in cervical collagen
concentration, an increase in water content and a change in the proteoglycan/GAG
content of the tissue. These changes will now be discussed in detail.
Collagen.
Measurement of hydroxyproline concentrations in cervical biopsies obtained in the non
pregnant state and at various stages of pregnancy have established that collagen
concentration decreases by approximately 70% during pregnancy (Uldbjerg et al,
1983a). There is already a significant fall in collagen concentration by 10 weeks
gestation which is in keeping with the clinical finding of cervical softening that was
once used to diagnose pregnancy. There is a further significant fall in collagen
concentration as gestation progresses to term, but interestingly there is no further
change with labour.
The physicochemical properties of cervical collagen are also altered in relation to
gestation such that the extractability of collagen in acetic acid with pepsin is much
higher in the pregnant compared with the nonpregnant state and increases significantly
during labour. These findings are in keeping with those of other investigators (Ito et
al, 1979; von Maillot and Zimmermann, 1976). It has been demonstrated that the
relative amount of partially degraded collagen is higher in cervical biopsies collected at
term or immediately postpartum compared with those obtained from nonpregnant
women (Kleissl et al, 1978). In addition, the number of intermolecular cross links is
reduced in term and postpartum specimens. This suggests that mature collagen, which
is relatively insoluble, is being broken down and replaced by new collagen with fewer
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cross links which is soluble and therefore easy to extract, and is more readily digested
by collagenolytic enzymes.
A proposed explanation for the lack of change in collagen concentration in association
with labour itself, inspite of high collagenolytic enzyme activity, is that the relative
proportion of old and new collagen has changed. The higher concentration of new
collagen is easily digested, but it may be that the degradation products are retained in
the tissue for some time (Kleissl et al, 1978) and hence the total collagen concentration
is not affected by parturition. This would also explain the increased extractability of
collagen in postpartum biopsies. There is also histochemical evidence to support the
retention of degradation products within the cervix (Junqueira et al, 1980). It is
important to note that there is no change in the relative concentrations of type I and
type III collagen in the nonpregnant and pregnant cervix (Huszar et al, 1981). The
importance of changes in collagen content in relation to the clinical setting is illustrated
by Ekman et al (1986) who demonstrated that women in spontaneous labour with an
unfavourable cervix (low cervical score) had a higher collagen concentration than
women with a high cervical score.
Collagenase.
Collagenase has been extracted from the human cervix (Kitamura et al, 1980a) and
22% of this enzyme is present in the free, active form. Of the remainder, 69% is
complexed to a2-macroglobulin and 9% exists as proenzyme. Collagenase activity,
measured as DNP peptide hydrolytic activity, is significantly increased in early
pregnancy and continues to increase through to term (Uldbjerg et al 1983b). Similar
changes are also seen in the activity of leukocyte elastase (Uldbjerg et al 1983b).
There are contrasting findings with regard to the effect of labour on collagenase
activity. Serum collagenase activity is increased once labour is established (Rajabi et
al, 1985) and higher collagenase activity has been demonstrated in cervical biopsies
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from women in established labour compared with women at term, and not in labour
(Osmers et al, 1990; Rajabi et al 1988). However, Uldbjerg et al (1983b) found no
increase in collagenase activity during labour as did Granstrom et al (1989).
Proteoglycans
Dermatan and chondroitin sulphate are the predominant proteoglycans in the human
cervix (Uldbjerg et al, 1983a; von Maillot et al, 1979). Dermatan sulphate is a
relatively small proteoglycan with a molecular weight of 100,000 daltons. These
molecules are responsible for promoting tensile strength in the cervix. Indeed it has
been suggested that tissue rigidity is proportional to chondroitin sulphate concentration
(Bryant et al, 1968), and therefore a reduction in chondroitin sulphate could improve
cervical compliance. The total GAG content of the cervix increases during pregnancy,
indicating that active synthesis is taking place, however the actual concentration of
GAGs remains relatively unchanged (Golichowski, 1980). As alluded to previously,
a change in the relative concentrations of different GAGs could affect collagen binding
and hence tissue stability.
The concentration of sulphated glycosaminoglycans is known to be lower in cervical
biopsies obtained postpartum compared with those obtained from nonpregnant women
(Kitamura et al, 1980b; Cabrol et al, 1980). This reduction in sulphated GAG
concentration is not as marked as the decrease in collagen concentration associated
with pregnancy, and may be explained by an opposing increase in heparan sulphate
concentration, found in blood vessels within the tissue (Kitamura et al, 1980b).
Some studies have demonstrated an increase in hyaluronic acid with advancing
gestation (von Maillot et al, 1979; Golichowski, 1980). Hyaluronic acid can exist as a
free GAG, unbound to proteoglycan, and because it binds least strongly of the GAG
molecules it will act to destabilise collagen. In addition, because of its highly
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hydrophilic properties, an increase in hyaluronic acid concentration can lead to
increased tissue hydration resulting in increased cervical compliance. This could
explain the change in water content of the cervix that occurs with pregnancy,
increasing from 80% in the nonpregnant state (Liggins, 1978) to 86% in late
pregnancy (Uldbjerg et al, 1983a). However, a number of studies have not confirmed
the increase in hyaluronic acid concentration (Uldbjerg et al, 1983a; Uldbjerg and
Malmstrom, 1991) and therefore other biochemical changes within the cervix may be
important.
1.7.3 Control of cervical ripening.
The above evidence illustrates that synthesis as well as catabolism is occurring
throughout pregnancy, and that continuous remodelling is taking place within the
cervix. Cervical ripening is therefore likely to be an active process rather than a
passive one reliant on uterine contractility, as was once thought. The fact that physical
isolation of the cervix from the uterus, as demonstrated in animal studies (Ledger et al,
1985), does not prevent the ripening process lends further support to this theory. A
number of agents, including prostaglandins, oestrogen, progesterone and cytokines,
are thought to be involved in the regulation of cervical ripening and will be be
discussed in further detail.
Prostaglandins
Prostaglandins have an established role in the pharmacological ripening of the human
cervix and are able to ripen the cervix at all stages of pregnancy (Calder, 1979; Calder
and Greer, 1991). The cervix can synthesise prostaglandins and the main ones
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produced are PGE2 and prostacyclin (PGI2), with production of PGF201 occurring in
smaller amounts. Cervical prostaglandin production increases at term (Ellwood,
1979), suggesting that they have a physiological role in the ripening process. In
addition it has been demonstrated that amniotic fluid prostaglandin concentrations
correlate directly with cervical score in women at term but not in labour (Calder and
Greer, 1991). Finally, receptors for PGE2 and PGF2a can also be demonstrated in
the cervix (Crankshaw et al, 1979).
PGE2 treatment does lead to a reduction in collagen concentration and promotes
changes similar to those seen in physiological ripening (Ekman et al, 1986; Uldbjerg et
al, 1981). The exact mechanism responsible for this finding is not entirely clear since
studies investigating the effect of prostaglandin treatment on collagenase activity have
produced contrasting results. Some have reported an increase in collagenase or
collagenase-like hydrolytic activity following PGE2 administration (Ding et al, 1990),
whereas others have found no change, or a reduction in enzyme activity in association
with treatment (Uldbjerg et al 1983c; Rath et al, 1987). Indeed, in addition to
demonstrating no change in collagenase activity with prostaglandin analogue treatment,
Rath et al (1987) also found an absence of collagen degradation products on
electrophoresis of tissue biopies from the treatment group. These findings suggest that
prostaglandins may have no direct effect on collagenase activity in vivo. Similarly, in
vitro experiments have shown that PGE2 and PGF2a have no effect on collagen
breakdown (Hillier and Wallis, 1981).
Arachidonic acid, on the other hand, will increase collagen breakdown, an effect
which is blocked by phospholipase inhibitors but not cyclooxygenase inhibitors
(Hillier and Wallis, 1981). The step in the arachidonic acid cascade at which the
inhibition of the arachidonic acid induced collagen breakdown occurs implies that
prostaglandins are not the mediators of this effect. Cervical tissue treated with
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prostaglandins or arachidonic acid produces increased amounts of unidentified
arachidonic acid products which are not prostaglandins (Christensen and Bygdeman,
1985). It may be that the ripening effect of arachidonic acid is a result of leukotriene
production, which can also be stimulated by PGE2. A potential role for leukotrienes in
the cervical ripening process is in keeping with the hypothesis that this may be an
inflammatory mediated event.
As discussed above, changes in the proteoglycan/GAG composition of the cervical
ground substance will act to destabilise the collagen fibrils thus increasing cervical
compliance, and provides another potential mechanism for prostaglandins to produce
their effect. PGE2 can influence cervical fibroblast production of collagen and GAG
such that when collagen synthesis is reduced GAG production is increased (Norstrom,
1984). The increased GAG concentrations seen in response to prostaglandin treatment
may be the result of increased synthesis, perhaps mediated via induction of hyaluronic
acid synthetase within fibroblasts (Murota et al, 1977), or it may be the result of
increased breakdown of proteoglycan complexes leading to increased free GAG
molecules.
This could result in increased hyaluronic acid concentrations and hence tissue
hydration which has been demonstrated in animal models (Cabrol et al, 1987).
However, not all studies have demonstrated an increase in hyaluronic acid
concentration in response to prostaglandin treatment (Uldbjerg et al, 1983c). Further
evidence to support a role for proteoglycan breakdown or GAG production is provided
by the finding that circulating levels of dermatan/chondroitin sulphate are increased in
association with PGE2-induced cervical ripening at term (Greer, 1992), and similar
increases are seen with spontaneous labour.
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Oestrogen.
In sheep an increase in the plasma oestrogen/progesterone ratio has been clearly
demonstrated prior to the onset of parturition. This does not occur in humans, but it
has been suggested that local changes in the hormonal milieu may occur in association
with labour. There is certainly evidence to indicate that oestrogen and progesterone are
involved in the control of cervical ripening in women. Intravenous infusion of 17P~
oestradiol will promote cervical ripening at term, confirmed on histological
examination (Pinto et al, 1965). Similarly, intravenous injection of
dehydroepiandrosterone sulphate at term leads to cervical ripening within hours of
treatment. Placental metabolism of DHAS results in increased 17(3-oestradiol
concentrations in both plasma and cervical tissue, and a four-fold increase in cervical
collagenolytic activity (Mochizuki et al, 1978). DHAS treatment in rats is associated
with an increase in active collagenase concentrations and a decrease in collagenase
complexed with a2-macroglobulin (Kitamura et al, 1981).
Oestradiol has been shown to be an effective cervical ripening agent in the clinical
situation when applied topically (Gordon and Calder, 1977). This effect may be due
in part to stimulation of prostaglandin synthesis (MacKenzie, 1981). It has been
suggested that oestrogen sensitises the cervix to prostaglandins which would explain
the increase in pharmacological potency of prostaglandins as gestation advances.
Indeed, it has been demonstrated that induction of labour with prostaglandins is easier
to accomplish in women with high serum oestradiol concentrations (MacKenzie et al,
1979).
Progesterone.
Animal and clinical studies indicate that progesterone is important in the control of
cervical ripening. These studies have focused on the use of antiprogestins such as
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onapristone and mifepristone (RU 486) for cervical priming and labour induction. In
nonpregnant guinea-pigs cyclical changes occur in the extensibility and dilatation of the
cervix which are inversely related to serum progesterone concentrations (Chwalisz et
al, 1991). In pregnant guinea-pigs treated with onapristone there is dramatic softening
and dilatation of the uterine cervix, prior to the onset of labour. This is reflected
histologically by dissolution and dissociation of the collagen fibres due to oedema, and
an inflammatory infiltration of polymorphonuclear granulocytes, macrophages and
mast cells (Hegele-Hartung et al, 1989). It is interesting that both onapristone and RU
486 will induce similar changes in the nonpregnant cervix, so that pregnancy is not
essential for this response (Chwalisz et al, 1991). Administration of a pure
progesterone agonist, promegestone, will completely reverse the effects of onapristone
on the cervix, indicating that onapristone exerts its effect via the progesterone receptor.
Onapristone treatment results in a decrease in cervical collagen and glycosaminoglycan
concentrations in the guinea-pig in late pregnancy (Chwalisz et al, 1991), indicating
that collagenase-mediated collagenolysis causes cervical ripening in guinea-pigs. It
has also been demonstrated that progesterone will inhibit expression of the
procollagenase gene (Rajabi et al, 1991), and will block increased collagenase
production stimulated by oestradiol. Therefore, progesterone may act directly or
indirectly to control collagenase activity within the cervix.
Mechanisms which could be responsible for the cervical ripening effect of
antiprogestins have been investigated. It appears that prostaglandins do not mediate
the effect of onapristone and RU 486 in promoting cervical ripening. This is based on
the findings that indomethacin does not inhibit onapristone-induced cervical ripening in
guinea-pigs (Chwalisz et al, 1991), and that naproxen, another prostaglandin synthase
inhibitor, will not inhibit the effect of RU 486 on the human cervix (Radestad and
Bygdeman, 1992). As discussed above, onapristone treatment results in an
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inflammatory cell infiltrate suggesting that chemotactic agents such as cytokines may
mediate the effects of antiprogestin treatment, and further evidence for this will be
presented below.
Relaxin.
Relaxin was discovered by Hisaw (1926) who found that injection of serum obtained
from pregnant guinea-pigs into virgin guinea-pigs shortly after oestrus caused
relaxation of the pelvic ligaments. The changes in the connective tissue of the pubic
ligaments in these animals involve dissociation of the collagen bundles, a net increase
in total collagen, increased water uptake and a decrease in the viscosity of the ground
substance. Animal studies (Steinetz, 1980) suggest that relaxin-induced cervical
ripening is similar to that seen prior to parturition and that the connective tissue
changes are similar to those seen in the pubic symphysis described above. In vitro
studies on the rat pubic symphysis have demonstrated that relaxin increases tissue
levels of collagenase and collagen peptidase (Weiss et al, 1979), implying stimulation
of the collagenolytic system. Relaxin also has mitogenic properties which appear to
stimulate the replication and synthesis of new collagen. Thus relaxin appears to
promote remodelling of the target tissue by influencing both collagen synthesis and
metabolism. In addition, by increasing the water and glycosaminoglycan content of
the tissue, relaxin also decreases the viscosity of the intercellular ground substance
(Zarrow et al, 1956). The net result is a relative decrease in the collagen concentration
of the target tissue with a resultant increase in tissue distensibility.
Oestrogen priming is a prerequisite for relaxin's effect on the guinea-pig pubic
symphysis (Hisaw, 1926), and inhibition of steroid synthesis in the pregnant rat will
block relaxin's effect on the cervix (Schwabe et al, 1978). Further support for a role
for steroid hormones in the control of relaxin physiology comes from studies
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demonstrating that oestrogen may affect the release of relaxin in some animals, and
that oestrogen may stimulate an increase in relaxin receptor sites (Mercado-Simmen et
al, 1980). Prostaglandins are also implicated in relaxin's effect on cervical ripening,
since administration of prostaglandin synthetase inhibitors will block the cervical
ripening effect of relaxin in rats (Kennedy, 1976).
Because relaxin does not stimulate myometrial contractility there has been a lot of
interest in relaxin as a potentially ideal cervical ripening agent. Purified porcine relaxin
has been shown to be effective as a cervical ripening agent in humans (MacLennan et
al, 1980; Evans et al, 1983). This is inspite of the lack of structural homology
between porcine and human relaxin. The development of recombinant human relaxin
has stimulated investigation into its efficacy as a cervical ripening agent and one such
trial is discussed in chapter six.
Cytokines.
The mechanisms resulting in cervical ripening have been likened to that of an
inflammatory process (Liggins, 1981). There is an infiltration of leukocytes into the
human cervix at term and it has been proposed that these cells are responsible for
triggering the connective tissue changes that take place during the ripening process
(Junqueira et al, 1980; Osmers et al, 1992). The neutrophil is the predominant white
blood cell found in the cervix during normal parturition and since these cells, together
with macrophages, are a source of collagenases (Ito et al, 1987) they may have an
important role in cervical ripening. Investigation into cervical ripening in the guinea-
pig has demonstrated that inflammatory cells infiltrate the cervix during spontaneous
ripening at term (Hegele-Hartung et al, 1989). This influx of inflammatory cells may
be under the control of progesterone since treatment with the progesterone antagonist
onapristone will increase the cellular infiltration (Chwalisz et al, 1991).
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Cervical explants from pregnant rats (Ito et al, 1988) and pregnant women (Barclay et
al, 1993) are capable of producing IL-1 and IL-8 [(neutrophil attractant/activating
peptide-1 (NAP-1)]. As its name suggests, IL-8 is a potent neutrophil chemotactic
agent and promotes the release of collagenolytic enzymes from these cells (Peveri et al,
1988). Because of the influx of neutrophils into the cervix previously discussed, and
the fact that IL-8 concentrations in amniotic fluid are increased in association with
spontaneous labour (Romero et al, 1991) it is not unreasonable to hypothesise that IL-
8 may play a significant role in the onset of parturition at term. It has been shown that
topical application of IL-8 and IL-1 (3 can promote cervical ripening in guinea-pigs
(Chwalisz et al, 1994) and that the associated morphological changes are similar to
those induced by antiprogestational agents (Hegele-Hartung et al, 1989). In this study
(Chwalisz et al, 1994), treatment did not lead to premature labour implying that the
cytokines are exerting a local effect rather than increasing myometrial contractility.
There is evidence to support a role for progesterone in the regulation of cytokine
production in various uterine tissues. The IL-8 gene contains a
glucocorticoid/progesterone response element, so that IL-8 may be directly down-
regulated by progesterone (Matsushima and Oppenheim, 1989). Progesterone will
decrease IL-8 production by choriodecidual cells in vitro, whereas RU 486 has the
opposite effect (Kelly et al, 1992). A similar effect on IL-8 production is seen
following progesterone treatment of endometrial explants (Kelly et al, 1994), and
progesterone withdrawal will stimulate neutrophil infiltration into the endometrium in
pregnant sheep (Staples et al, 1983), and into the placenta in pregnant monkeys
(Sinosich et al, 1989), implying a cytokine-mediated effect. Thus progesterone may
be acting as an immunosuppressor within the cervix and antiprogestational treatment or
spontaneous progesterone withdrawal may activate the cytokine cascade and hence
cervical ripening (Chwalisz et al, 1994). However, treatment with the antiprogestin
RU 486 does not promote cervical ripening in all species. In contrast, RU 486 will
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stimulate uterine activity to the extent of fetal hypoxia in the monkey without
promoting cervical ripening, whereas administration of the 3(3 hydroxysteroid
dehydrogenase inhibitor epostane will successfully achieve ripening in this species
(Haluska and Novy, 1993). These data suggest that if progesterone withdrawal is
important in parturition it may not be a receptor-mediated effect.
1.8 Control of Parturition
1.8.1 Ovine Model.
The mechanisms of parturition have been investigated extensively in the sheep and
whilst these cannot be applied directly to the situation in humans, certain similarities
exist. It is therefore worth illustrating the events which culminate in labour in this
species.
It is established that the fetus plays a central role in orchestrating the timing of
parturition in the sheep. Liggins (1973) demonstrated that fetal hypophysectomy or
bilateral fetal adrenalectomy will result in prolongation of pregnancy. In contrast,
infusion of adrenocorticotrophin (ACTH) or administration of Cortisol to the fetal lamb
in utero provoked the onset of labour within a consistent time interval. These findings
are peculiar to the fetus since administration of ACTH or Cortisol to the mother, or
maternal hypophysectomy, at the same gestation did not influence the timing of labour.
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There is a large body of evidence to support maturation of the hypothalamo-pituitary-
adrenal (HPA) axis in the fetus prior to the onset of labour. During the final 20 to 25
days of gestation there is an increase in fetal plasma Cortisol concentrations (Bassett
and Thorburn, 1969) which reach a maximum two to three days prior to delivery.
This is likely to represent an increase in Cortisol secretion, and during late gestation the
adrenal gland is known to undergo both hypertrophy and hyperplasia. There is no
change in maternal Cortisol levels over the same time period, indicating that the
increased fetal concentrations are not simply the result of increased maternal transfer.
These changes in Cortisol are dependent on the fetal pituitary, since maternal ACTH
does not cross the placenta (Jones et al, 1975) and fetal hypophysectomy results in
hypocortisolaemia (Kendall et al, 1977). Radioimmunoassay techniques for ACTH
have demonstrated a progressive increase in ACTH concentration during the last 30
days of gestation, prior to the increase in Cortisol levels (Wintour, 1984).
The pituitary releases ACTH in response to corticotrophin releasing factor (CRF). In
the fetal sheep, injection of synthetic ovine CRF will stimulate ACTH release, but the
magnitude of this response depends on gestational age: a greater response is seen in
the later stages of pregnancy (Challis and Olson 1988). The same was true for Cortisol
release by the adrenal gland in these experiments. These findings support a
maturational process within the HPA axis as gestation advances, with increasing
sensitivity of both the pituitary and adrenal gland. Argenine vasopressin (AVP) is
another corticotrophic agent, and has been shown to act synergistically with CRF in
stimulating ACTH release (Durand et al, 1986). Other factors important in controlling
ACTH release may include endogenous opioids since administration of the opioid
antagonist naloxone will decrease circulating concentrations of ACTH in the fetal
sheep (Challis et al, 1991). Additionally, it has been shown that mRNA for the
precursor peptide of ACTH, pro-opiomelanocortin (POMC), increases from day 125
6 1
of gestation to term (Challis et al, 1991) suggesting increased POMC gene
transcription which may contribute to the increase in ACTH prior to labour.
Prostaglandins also make an important contribution to the regulation of ACTH and
Cortisol release. During late pregnancy the activity of COX increases in the sheep
placenta to reach a maximum at term (Thorburn and Rice, 1990). It has been proposed
that the placenta is an important source of trophic stimulus for maturation of the HPA
axis, and that the increasing amounts of PGE2 produced in late pregnancy could be
potentially important (Thorburn and Rice, 1990). A correlation between the rise in
fetal plasma Cortisol and PGE2 concentrations has been established in late pregnancy
(Thorburn and Rice, 1990), and it is also known that exogenous PGE2 will stimulate
ACTH and Cortisol production.
The importance of Cortisol in the process of parturition is that it promotes transcription
of the p450 17a gene which leads to an increase in placental 17a hydroxylase activity
(Liggins, 1973). Since progesterone is a poor substrate for placental 17a hydroxylase
in the sheep, metabolism is diverted via pregnenolone to 17-hydroxy pregnenolone
and then dehydroepiandrosterone (DHAS). DHAS can then be converted to
oestrogens by the action of placental aromatases, the activity of which is also increased
in the presence of Cortisol. These changes in the metabolism of the placental steroids
culminate in an increase in the oestrogemprogesterone ratio, and the progesterone
withdrawal characteristic of sheep parturition.
Cortisol is therefore central to the mechanisms of parturition in the sheep. It exerts a
number of feedforward effects that ensure continuing or increased Cortisol secretion
within the fetal unit. It is stimulatory to the adrenal gland itself, perhaps by increasing
ACTH receptors (Challis and Roberts, 1988). It also promotes production of
corticosteroid binding globulin (CBG) (Challis et al, 1985), which by binding Cortisol
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can maintain low free Cortisol concentrations in the fetus and therefore allow continued
CRF and ACTH release inspite of increasing total Cortisol concentrations .
1.8.2 Human Model.
While there are many similarities between ovine and human parturition evidence
supporting a major role for the fetus in the onset of parturition in the human is not as
convincing as in the sheep. Examination of data from a series of 147 anencephalic
pregnancies (Swaab et al, 1976) failed to demonstrate any difference in the gestational
length of these pregnancies compared with a control population. However, in the
anencephalic group, and in a subsequent study looking at experimental anencephaly in
monkeys (Novy et al, 1977), there was a much wider variation around the mean
gestational age at delivery suggesting that the fetus does play a more minor role in the
fine-tuning of gestational length. Clearly, the role of the fetus cannot be investigated
to the same extent in the human as in the sheep, making it necessary to postulate the
best hypothesis to draw the pieces of the jigsaw together. Some of the concepts of
parturition in the human will be discussed below.
The major difference between humans and sheep is that there is no evidence for
systemic progesterone withdrawal prior to the onset of labour in humans (Thorburn
and Challis, 1979). Extensive investigation of maternal plasma concentrations of total
and non-protein-bound progesterone and oestradiol have failed to show any difference
in the relative amounts of these hormones prior to the onset of labour (Anderson et al,
1985). However, events occurring locally within the reproductive tissues may not
necessarily be reflected in changes in systemic hormone concentrations, and regulation
of steroid hormone metabolism by the fetal membranes and decidua may be important
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in determining paracrine events. Amnion, chorion and decidua can synthesise
oestrogen and progesterone, and changes in the synthesis and metabolism of these
hormones may be important in effecting local progesterone withdrawal. Oestrone is
the major oestrogen formed by fetal membranes, although its production is not altered
by labour (Romano et al, 1986). However, in association with labour, the enzyme
17|3, 20a hydroxysteroid dehydrogenase promotes conversion of oestrone to
oestradiol, a more active oestrogen. In addition this enzyme enhances the formation of
inactive progesterone metabolites thus establishing a significant increase in the
oestrogen: progesterone ratio within chorion and amnion (Mitchell and Wong, 1993).
It has also been demonstrated that oestrogen and progesterone receptors are present in
fetal membranes and decidua and that the concentration of mRNA for the oestrogen
receptor was increased three-fold in association with labour in these experiments.
There is therefore the facility for changes in hormone concentrations and receptor
numbers within the fetal membranes.
Amnion, chorion and decidua possess 3(3 hydroxysteroid dehydrogenase activity
(3(3HSD) (Gibb et al, 1978) which is the enzyme responsible for converting
pregnenolone to progesterone. Inhibition of this enzyme, which occurs in the
presence of oestrogen (Mitchell et al, 1982), would result in a decrease in progesterone
production and effect progesterone withdrawal locally. Maternal systemic oestrogen
concentrations increase progressively in the last 5-6 weeks of pregnancy (Tulchinsky
et al, 1972), and there is also a rapid rise in amniotic fluid concentrations in the 15-20
days leading up to parturition (Turnbull et al, 1977), which could in theory modulate
3(3HSD activity.
Although the onset of labour in the human cannot be directly attributed to fetal control,
interactions between the fetus and placenta are clearly important in the regulation of
this process. Maternal plasma concentrations of CRF rise throughout gestation and
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decline rapidly following delivery (Campbell et al, 1987; Goland et al, 1986). This
phenomenon is also known to occur precociously in cases of preterm labour
(Campbell et al, 1987). The placenta is the source of this CRT and placental content of
CRF increases progressively throughout pregnancy to a maximum at term. This is
paralleled by an increase in prepro CRF mRNA, demonstrating placental CRF gene
expression (Frim et al, 1988). The syncytiotrophoblast is the site of origin of CRF
(Riley et al, 1991), with no change in immunostaining for CRF in placental tissue
collected prior to or post labour onset. Amnion, chorion and decidua also produce
CRF (Jones et al, 1989), with increased production from tissue collected following
spontaneous labour. The CRF produced in these experiments subsequently stimulated
ACTH release from ovine pituitary cells. It has been suggested that placental CRF
stimulates fetal ACTH production thus initiating important events in the fetal pituitary-
adrenal axis. Umbilical venous plasma has a higher CRF content than arterial plasma
indicating that secretion into the fetal circulation does occur (Goland et al, 1986).
CRF production by placental and fetal membrane cell cultures can be influenced by a
variety of agents. It has been demonstrated, in vitro, that progesterone will decrease
CRF production by amnion cells in early pregnancy (Jones and Challis, 1990) and by
amnion and placental cells at term (Jones et al, 1989). This leads to the hypothesis that
progesterone withdrawal, either physiological, or pharmacologically mediated, could
result in increased CRF production and hence maturation of the HPA axis. In
addition, CRF will stimulate PGE2 and PGF2« production by amnion, decidua and
placental cell culture (Jones and Challis, 1990), and such prostaglandins are capable of
facilitating cervical ripening and myometrial contractility. Prostaglandins, in addition
to cytokines and catecholamines, can stimulate CRF production (Riley and Challis,
1991), establishing a positive feedforward loop. CRF is itself able to stimulate
myometrial contractility in vitro (Quartero and Fry, 1989), an effect which is inhibited
by indomethacin, implying that it may be mediated in part by prostaglandins.
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However, Cooper et al (1994), investigating placental CRF immunostaining during
pregnancy and labour, found no evidence for regulation of CRF production by either
mifepristone or prostaglandins. The lack of effect of prostaglandins may not be
surprising given the short period of administration prior to termination of pregnancy
(TOP), but mifepristone was administered 24 hours prior to TOP and therefore any
effect of this treatment should have been apparent. The authors suggest that the lack of
effect of mifepristone may be gestationally related, since Jones et al (1989) found that
progesterone inhibited CRF release by placenta at term, but not in early pregnancy
(Jones and Challis, 1990). Also, glucocorticoids have been shown to stimulate CRF
production (Jones et al, 1989) and prepro-CRF mRNA expression by placental tissue
(Robinson et al, 1988), and since mifepristone has additional antiglucocorticoid
effects, these may be masking its antigestagenic actions to some extent.
Unlike the sheep model, fetal Cortisol does not promote events which lead to an
increase in the oestrogemprogesterone ratio. This is because 17a hydroxylase is
absent from human placenta. However, DHAS production may be of significance
since placental aromatases can metabolise it to oestrogens, thus increasing local
concentrations of oestrogen which as discussed earlier is important in promoting
synthesis of stimulatory prostaglandins, oxytocin receptors and gap junctions.
Placentally derived CRF can stimulate fetal pituitary ACTH production with a resultant
increase in adrenal production of hormones such as Cortisol and DHAS. Cortisol is
paradoxically able to stimulate further placental CRF production thus establishing a
positive feedforward cascade loop.
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1.9 Overview and Aims of Thesis
Our current knowledge dose not permit a complete understanding of the mechanisms
controlling the onset of parturition in humans. The feto-placental unit is likely to be
central to this control but evidence available to date suggests that the fetus plays a more
minor role in orchestrating events compared with other species. Whilst there is no
evidence for systemic progesterone withdrawal local events within the uterus may be
important in influencing the hormonal milieu resulting in an increase in oestrogen:
progesterone ratio. Oestrogen can then act in a paracrine manner to promote gap
junction formation, oxytocin receptor expression and prostaglandin production within
the uterine compartment to favour myometrial contractility.
Prostaglandins are important mediators of uterine contractility and are thought by many
to be critical to the labour process. The fetal membranes are an important site of
prostaglandin synthesis and metabolism, and either an increase in synthesis or a
decrease in metabolism could lead to the increase in prostaglandin concentrations
associated with labour. Prostaglandin synthesis and metabolism may be influenced in
a paracrine fashion by changes in the intrauterine hormonal milieu, and / or by factors
present for example in amniotic fluid, which may be under fetal control. There is a
strong body of evidence to support a role for cytokines in the process of labour, and it
is likely that labour and cervical ripening are inflammatory-mediated events.
Cytokines such as IL-1, IL-6 and IL-8 are increased in amniotic fluid in association
with spontaneous labour at term, and these inflammatory agents can stimulate
prostaglandin production by fetal membranes and may also mediate the histological
changes seen in cervical ripening.
Experiments employing progesterone receptor antagonists indicate that progesterone
does play an important role in human parturition. There is certainly evidence to
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suggest that progesterone exerts an immunosuppressive effect with regard to cytokine
production within the uterus since it will inhibit chorio-decidual and endometrial
interleukin-8 production. Progesterone withdrawal could therefore facilitate
inflammatory events mediated by cytokines which are central to cervical ripening and
prostaglandin production within the uterus. In addition progesterone withdrawal will
increase myometrial sensitivity to exogenous oxytocic agents thereby having a
preparatory effect on the uterus.
Whilst it is likely that cervical ripening is an inflammatory process, the role of a
number of hormonal agents in pharmacological ripening has been investigated.
Relaxin will promote connective tissue changes in oestrogen-primed animals without
stimulating uterine activity. In humans porcine relaxin has been effective in promoting
cervical ripening and this may in fact have been an inflammatory-driven process owing
to impurities of the agent. Alternatively, local increases in oestrogen: progesterone
ratio may be important in relaxin's ripening effect.
We hypothesise that parturition is ultimately an inflammatory-mediated process which
facilitates prostaglandin production and cervical ripening resulting in coordination of
myometrial contractility and dilatation of the cervix. The exact trigger for the onset of
labour is unknown but is likely to involve local changes in oestrogen: progesterone
ratio. Such changes may promote cytokine production which in turn leads to increased
prostaglandin production by fetal membranes and myometrial activity. Within the
cervix cytokines promote connective tissue changes leading to cervical ripening.
Changes in steroid hormone concentrations also have a preparatory effect on the uterus
increasing myometrial sensitivity to the oxytocic agents liberated as a result of
inflammatory mediators. Changes in the oestrogen: progesterone ratio may also have a
preparatory effect on the cervix to facilitate the action of other hormones in
pharmacological cervical ripening.
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The aims of this thesis were:
1. To investigate, in parallel, the synthesis and metabolism of prostaglandins in
explants of amnion and chorion respectively to see if alteration in either or both of
these processes is responsible for the increase in prostaglandin concentrations seen in
association with labour. Also, to determine any effect of steroid hormones and RU
486 on prostaglandin metabolism by chorion.
2. To investigate the effect of amniotic fluid on prostaglandin production by amnion
and chorion cell cultures and to establish any effect of amniotic fluid on prostaglandin
metabolism by chorion.
3. To investigate mechanisms, which could potentially be promoted by cytokines, by
which amniotic fluid may stimulate prostaglandin production by amnion and chorion
cell cultures by employing inhibitors of translation, transcription, protein kinase C and
tyrosine kinase.
4. To investigate the role of recombinant human relaxin and the progesterone
antagonist mifepristone (RU 486) in pharmacological cervical ripening in women with





2.1 Introduction to Tissue Culture.
Tissue culture was first described at the beginning of this century (Harrison, 1907) .
Harrison chose the frog as his first source of tissue, perhaps because it is a cold¬
blooded animal and therefore incubation would not be required. Initial cultures used
whole tissue, and it is only since the 1950's that there has been expansion into the field
of cell culture utilising dispersed cells. The technique of tissue culture has enabled
investigation of a number of aspects of cellular function. Intracellular activity such as
the replication and transcription of DNA and protein synthesis, and the transfer of
RNA, hormones and metabolites within the cell can be studied. In addition, the effect
of external factors, for example infection and drugs, on intracellular mechanisms can
be explored, as can the interaction of cells with each other.
The advantages of tissue culture are that the physiochemical environment can be
precisely controlled and the physiological conditions can be kept relatively constant.
Also, cultured cell lines will assume a uniform constitution as the selective pressure of
the culture conditions will favour a homogenous culture of the most vigorous cell type.
However, there are a number of disadvantages associated with tissue culture which
must be recognised. The dissociation of cells and propogation on a two-dimensional
substrate will mean that specific cell interactions characteristic of the tissue will be lost.
Also, whilst the culture environment can be constantly maintained in vitro, certain
important homeostatic regulatory mechanisms will not be present and therefore the
system may not accurately reflect the in vivo situation.
There are three main methods of establishing a culture (Schaeffer, 1979): organ culture
suggests that the original architecture of the tissue is maintained; explant culture
employs a fragment of tissue, whereas cell culture implies mechanical or enzymatic
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dispersal of tissue resulting in a cell suspension. In the primary culture a series of
selection processes take place which result in the proliferation of some cells with the
demise of other cells that are not suited to the culture conditions. As a result the
distribution of cell types will change until all available culture space is occupied
(monolayer culture). After confluence is reached (cells are in close contact with each
other and all culture space utilised) the proportion of cells that are non-sensitive to
density restriction will increase. The work presented in this thesis employs the
techniques of explant and cell culture. Before discussing the specific methods utilised
in the experiments described in this thesis, basic principles regarding the culture
environment will be introduced.
Substrate.
The majority of cells need to spread out on a substrate (solid, semi-solid or liquid) in
order to proliferate (Fisher and Solursh, 1979). The solid substrates used are
generally glass or plastic, although there is some experience with metallic surfaces
such as stainless steel (Birnie and Simons, 1967). Cell proliferation will be inhibited
if there is inadequate spreading owing to poor adhesion or overcrowding. In some
cases attachment and cell growth can be improved by pretreatment of the substrate for
example with collagen (Elsdale and Bard, 1972) or adding fibronectin to the culture
medium (Gilchrest et al, 1980).
Incubation Conditions.
Atmospheric, or lower, oxygen tensions are preferable for most cell cultures (Cooper
et al, 1958). The situation with regard to carbon dioxide is more complex as illustrated
by the following equation:
H20 + C02 v ^ H2CO3 v H+ + HCO3-
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Bicarbonate (HCO3") has a low dissociation constant with the cations available in the
culture medium and it will therefore tend to reassociate, forming sodium bicarbonate,
leaving the culture medium acid. The fall in pH that occurs as a result of increasing
atmospheric CO2 is neutralised by increasing the bicarbonate concentration of the
culture medium. Each medium therefore has a recommended bicarbonate
concentration and CO2 tension to achieve the correct pH. Buffers such as HEPES can
control pH within the physiological range (Good et al, 1966), although CO2 remains
essential, since the absence of it, or ultimately HCO3", appears to restrict cell growth.
The optimal temperature for cell culture is dependent on the body temperature of the
animal from which the cells were obtained, and incorporation of a safety factor to
allow for minor errors in incubator regulation. Regulation of temperature should be
kept within +/- 0.5 C, and temperature should be kept constant both in time and in
different parts of the incubator. An even temperature distribution is achieved if the air
is circulated with a fan, and cultures should be placed on perforated shelves, not on the
floor of, or touching the sides of, the incubator.
Media and Supplements.
There have been major advances in culture media preparation, moving away from the
"natural" media such as embryo extract and lymph, to the development of more
complex "defined" media containing essential amino acids, vitamins and salts eg.
Eagle's minimum essential medium (MEM) (Eagle, 1959); RPMI 1640 (Moore et al,
1967). Most cell lines grow well at a pH of 7.4 and therefore culture medium will
need to be buffered if there is over production of CO2 and lactic acid leading to a fall in
pH, or if there is release of CO2 (eg. open dishes) causing pH to rise. Bicarbonate is
the buffer traditionally employed, in spite of its poor buffering capacity. HEPES is a
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much stronger buffer in the pH range 7.2-7.6, and it is commonly used at 10 or 20
mM.
The essential amino acids plus cysteine and tyrosine are required by cultured cells,
although the requirements will vary from one cell to another. Glutamine is required by
most cells as a source of energy and carbon (Reitzer et al, 1979). Most cell cultures
require supplementaion of the media with serum, and the one most commonly used is
calf serum. Serum contains important proteins including albumin (Iscove and
Melchers, 1978), globulins (Tozer and Pirt, 1964) and a2-macroglobulin, a trypsin
inhibitor (DeVonne and Mouray, 1978). Platelet-derived growth factor (PDGF) is one
of the major growth factors in serum (Lechner et al, 1981), with factors such as
epidermal growth factor (EGF) and insulin-like growth factors being present in smaller
amounts (Gospodarowicz et al, 1978). Serum also contains hormones such as
insulin, which promotes uptake of glucose and amino acids (Kelley et al, 1978), and
Cortisol, which promotes cell attachment and proliferation (Guner et al, 1977). There
are, however, certain disadvantages associated with serum supplementation in that the
actions of a number of minor constituents have not been characterised, and serum
varies between batches. The effects of fetal calf serum on amnion and chorion cell
cultures is discussed in detail in section 2.2.2.
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2.2 Amnion and Chorion Dispersed Cell Method.
Described below are the techniques employed throughout this thesis.
2.2.1 Tissue Preparation.
Fetal membranes were collected directly in theatre from women undergoing elective
caesarean section. Under sterile conditions the membranes were trimmed from the
placenta, leaving a 1 cm margin, and transported in a sterile container (Sterilin) in
Dulbecco's phosphate buffered saline solution (without calcium, magnesium or
sodium bicarbonate) (Gibco, UK: 14190-094). The Dulbecco's phosphate buffered
saline solution (DPBS) contained heparin (Leo Labs.) at a concentration of lOu/mL.
The following procedures were carried out in a Microflow Biological Class 2 Safety
Cabinet (MDH Ltd, Walworth Road, Andover, Hampshire, England). The amnion
and chorion were separated and washed three times with DPBS. Any large blood clots
were removed with fine tissue forceps. Fetal membranes that were meconium stained
were not used and any "fibrous" tissue was discarded. The amnion and chorion were
separated manually and any excess decidua was peeled from the chorion with fine
tissue forceps. The tissues were weighed to enable calculation of the correct volume
of digestion medium (see later). The tissues were soaked separately in 100 mL DPBS
containing gentamicin (Sigma, UK G 1014) 40 mg/500 mL and amphotericin B
(Sigma, UK A 9528) 2.5 mg/500 mL for one hour. The tissues were then washed
four times with DPBS, using approximately 50 mL each time. The steeping and
rinsing procedures were carried out to ensure that prostaglandins released secondary to
the trauma of tissue collection were eliminated from the cultures. Using skin graft
blades (BNO 7191/2A) the tissues were shredded into 3-4 mm pieces.
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Chorion Pre-Incubation.
This was performed in order to remove as many red blood cells as possible. The
chorion was transferred to a 250 mL Erlenmeyer flask (Corning Bibby 25600)
containing a stirring magnet (Aldrich Co. Z16840/8). 100 mL of Digestion Medium
was added. The flask was stirred at setting 1 on a magnetic stirrer for 10 minutes at
37 C. Taking care to retain all the tissue the digestion medium was poured off.
Tissue Digestion.
The amnion was transferred to a separate Erlenmeyer flask containing a stirring
magnet. Digestion Medium was then added to both flasks: 5 mL per gram of amnion
and chorion tissue (total approx. 100 mL). The flasks were stirred on the magnet
stirrer (Bell Stir Multi-Stir 4; Bellco Biotechnology) at setting 1 for 40 minutes at
37 C.
There are a number of enzymes available for tissue digestion and disaggregation
including trypsin, collagenase, elastase and DNAase. Trypsin achieves the most
complete disaggregation but may damage the cells, whereas collagenase is less harmful
to the cells at the expense of incomplete digestion (Lreshney, 1987). Trypsin is the
most commonly used enzyme and it is important to minimise exposure of the cells to
preserve maximum viability. The action of trypsin is neutralised by the serum in
complete culture medium, and where serum-free medium is employed, a trypsin
inhibitor must be added. DNAase is used to disperse DNA from lysed cells since
DNA will promote reaggregation and impair proteolysis. Both trypsin and DNAase
were present in our digestion medium (section 2.2.2).
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Cell Harvest.
Each tissue was filtered through a 0.16 mm nylon mesh and the filtrate, containing the
cells, collected in a sterile container (Sterilin). Amnion and chorion were each divided
in to three separate lots and the cells dispersed mechanically using an adapted
Eppendorf pipette. The yield was harvested via the mesh into the sterile container and
complete culture medium (approx. 30 mL) was added to the remaining tissue and the
mechanical dispersal repeated three times. The total volume of harvested cells
suspended in complete culture medium was transferred to 50 mL aliquot tubes (Falcon
2098) and centrifuged at 1500 rpm (MSE centrifuge) for 10 minutes. The supernatant
was decanted and the pellets combined and resuspended in a smaller volume of
complete culture medium (approx. 30 mL). As discussed above the culture medium
will quench any further cell digestion. The process of centrifuging, decanting and
resuspension was repeated a further two times and on the last occasion, after decanting
the supernatant, the cells were resuspended in a fixed volume of complete culture
medium (CCM) prior to counting.
Cell Count.
The amnion was suspended in 10 mL of CCM and the chorion in 20 mL of CCM.
The difference in volume accounts for the fact that the amnion cells give a cleaner
culture whereas the chorion cultures tend to have more debris in them. The cells were
counted to assess number and viability using Trypan Blue exclusion. Using an
Eppendorf pipette (Gilson) 50 p.L of cells were mixed with 50 (J.L of Trypan Blue
(Gurr Microscopic Materials, supplied via MERCK). An aliquot was transferred to a
0.1 mm Haemocytometer (British Standard 748, Weber Scientific Internationa] Ltd.),
covered with a cover slip and counted under the microscope. Trypan is able to cross
the membrane of dead cells which therefore stain blue. The absence of blue staining
indicates viable cells. Having calculated the number of cells in a fixed aliquot the total
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cell preparation was diluted down in complete culture medium to give approximately 4
x 106 cells per mL of CCM. 50 pL of this cell preparation will therefore give a cell
density of 2 x 105 per well (final incubation volume 1 mL) in a standard 24 well plate
(Corning Bibby, 25820).
2.2.2 Media Preparation.
The following solutions were all prepared under sterile conditions in the Microflow
Biological Safety Cabinet.
Digestion Medium.
The digestion medium was prepared on the morning of each experiment (shelf-life: 6-8
hours), and is based on that described by other investigators (Jones et al, 1989; Riley
et al, 1992). The ingredients are culture medium RPMI 16/40 (Gibco, UK:
52400/025); Trypsin (Sigma, UK: T 8253) and DNA-ase (Sigma, UK: DN-25).
RPMI 16/40 contains L-Glutamine and 25mM HEPES Buffer and is stored at 5 C
(shelf-life 6-9 months). The digestion medium was prepared in volumes of 200 mL
DNAse, obtained in powder formulation, was dissolved in 10 mL of the RPMI and
sterile filtered via a 0.22pm filter back in to the total volume of RPMI (200 mL) to give
a final concentration of 0.02%. Trypsin, also obtained in powder formulation, was
then added to the solution, final concentration 0.5%, and allowed to dissolve at 37 C
which took approximately 1 hour.
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Complete Culture Medium.
Complete culture medium was freshly prepared for each cell preparation and again it
was prepared in volumes of 500 mL. The following agents were added to 440 mL of
culture medium RPMI 16/40 (Gibco): 50 mL of bovine fetal calf serum (heat
inactivated); 5 mL Penstrep solution, containing 5000IU Penicillin and 5000|J,g
Streptomycin per mL; and 5 mL growth factors, containing insulin 25 mg, transferrin
25 mg and sodium selenite 25 |ig. The bovine fetal calf serum (Gibco: 10108066)
was obtained in 100 mL volumes and stored at -20 C. The Penstrep solution (Gibco:
04305070H) was also stored at -20 C. The growth factors (Sigma: I 1884), a
lyophilised preparation, were reconstituted in 50 mL of sterile water (Elgastat purified
system) and stored in 5 mL aliquots at 5 C. The formula for the above preparation is
again based on that used by other workers (Jones et al, 1989; Riley et al, 1992) with
some minor modifications (Gibb and Lavoie, 1990).
The culture medium used in our experiments contains 10% fetal calf serum. A number
of experiments have been performed investigating the influence of fetal calf serum
(FCS) on the responsiveness of cell cultures. It has been demonstrated that basal
PGE2 production by amnion and chorion is reduced by 75% and 35% respectively
when cultures are performed in the absence of FCS (Edwin and Mitchell, 1992). The
difference in basal PGE2 production between cultures with or without FCS could be
fully or partially overcome by the addition of arachidonic acid in amnion and decidual
cells, but not in chorion cells. This suggests that arachidonic acid is not the only factor
in FCS regulating cell responsiveness. In the same experiments the responsiveness of
cells to stimulatory agents such as epidermal growth factor, ionomycin and interleukin-
1(3 was influenced by the composition of the culture medium.
The effect of different concentrations of FCS supplementation has also been
investigated by Gibb et al (1986). They found that the morphological appearance of
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chorion laeve cells was quite different in cultures using 0.1% FCS compared with
10% FCS. In cultures using 0.1% FCS the cells were clumped, and remained so
throughout the duration of the culture period. However, in the presence of 10% FCS,
there was no cell clumping and a single, evenly dispersed layer of cells was achieved
which reached confluence at day five. In these experiments the protein and DNA
content of the cultures was increased in the presence of 10% FCS, in contrast to 0.1%
FCS which did not stimulate either. Also, the increase in thymidine incorporation into
the cells was greater in the presence of 10% FCS, and all of these findings taken
together confirm cell replication in the cultures supplemented with 10% FCS.
These findings highlight the influence that culture medium constituents can have on the
morphological and biochemical properties of cell cultures, and the need to take this into
account when interpreting in vitro data.
Steeping Solution.
Dulbecco's phosphate buffered saline (DPBS) was stored at room temperature.
Gentamicin and amphotericin B were added to 500 mL of DPBS. Gentamicin (Sigma:
G 1014) was obtained in sterile solution, 50 mg/mL, and stored at 5 C. Using a 1 mL
Eppendorf pipette, 800 p.L of gentamicin solution was added to the DPBS giving a
final concentration of 40 mg/500mL. Amphotericin B (Sigma: A 9528) was obtained
in powder formulation in 100 mg lots and made up in sterile water to a concentration
of 10 mg/mL. This was stored at 5 C and, using a 0.5 mL Eppendorf pipette, 250 |LL
added to the DPBS giving a final concentration of 2.5 mg/500mL. The steeping
solution was stored at 5 C and has a shelf life of 3 weeks.
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2.3 Tissue Explant Culture.
Chapter three describes experiments investigating changes in prostaglandin synthesis
and metabolism by amnion and chorion respectively in association with labour.
Explant cultures were performed so that relatively intact tissue could be studied. The
culture procedures for these experiments are outlined below.
Culture preparation.
Fetal membranes were collected at the time of elective caesarean section or immediately
following spontaneous labour and delivery in the same manner as described in section
2.2.1 (paragraph 1). The initial procedures in this experiment were exactly the same
as for the cell culture experiments up to and including the steeping in antibiotics and
the thorough washing in DPBS thereafter.
Amnion Tissue Culture.
Standard 24 well plates (max. volume 2 mL: Corning-Bibby 25820) were also used
for these experiments. 900 (J.L of complete culture medium was pipetted (Eppendorf
pipette) in to each of 8 wells in the standard plate. This was then placed in the
incubator (C02 gased and humidified; Scotlab-VSL) whilst the amnion discs were
prepared. The amnion was placed on a Petri dish (150 mm diameter; NUNC
intermed) and, using a size 12 mm cork borer, eight discs were cut out. Each disc was




Four standard plates per subject were used for the chorion experiments. 800 |LtL of
complete culture medium was pipetted in to each of 8 wells per plate. These plates
were put in the incubator while the chorion discs were prepared. The chorion was
placed on a Petri dish as above and 32 discs of 9 mm diameter were cut with a cork
borer. The discs were suspended on sterile capillary matting and submerged in the
culture medium in the wells.
Preparation of capillary matting.
Fybamat capillary matting (B&Q, Edinburgh UK) was cut in to 1 cm squares. 150-
200 squares were placed in a 250 mL sterile container (Sterilin). These were steeped
in 2% Shield (Jeyes Hygiene) for approximately 1 hour and then rinsed thouroughly
under hot water in a sieve until there was no foaming. The squares were steeped in
70% ethanol overnight. The ethanol was aspirated until the squares were almost dry
and they were then steeped in DPBS for approximately 15 minutes. This was
aspirated until the squares were dry and the containers were left in the safety cabinet
overnight with the tops off to dry completely.
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2.4 Culture Treatments.
2.4.1 Cell culture treatments.
Actinomycin D (Sigma, UK: A 1410), stored at 5 C.
Cycloheximide (Sigma, UK: C 6255), stored at 5 C.
Genistein (Sigma, UK: G 6649), stored at -20 C.
Staurosporine (Sigma, UK: S 4400), stored at 5 C.
The above agents were all obtained in powder formulation. They were each made up
in complete culture medium to 10 times the concentration required in the experiments
in the sterile safety cabinet and then stored at 5 C overnight. Volumes of 100 |aL were
then added to the wells which gave the correct final concentration per mL.
2.4.2 Tissue explant treatments.
Arachidonic Acid (Sigma, UK: A9548)
Indomethacin (Sigma, UK: 17378)
Phorbol Myristoyl Acetate (Sigma, UK)
Dexamethasone (Sigma, UK: D1756)
Progesterone (Sigma, UK)
RU 486 (Roussel Laboratories, UK)
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The above agents were all obtained in powder formulation and made up in
concentrated ethanol solution, with the exception of arachidonic acid, for storage at
-20 C. Arachidonic acid is insoluble in ethanol and was therefore made up in complete
culture medium and stored at -20 C. Working solutions were obtained by diluting the
concentrated solutions in complete culture medium, again to ten times the concentration
required for the experiments. These working solutions were stored at -20 C and
thawed prior to addition to the cell culture systems. Again, a volume of 100 |J,L was
employed to achieve the correct final concentration per well. All solutions were frozen
and thawed once only; any excess was discarded.
PGEo (Upiohn Ltd. Lot 230071.
PGE2 was obtained as a sterile solution at a concentration of 10 mg/mL in ethanol. In
the safety cabinet under sterile conditions 10 flL of this solution was diluted in 20 mL
of complete culture medium to give a concentration of 5 |Ltg PGE2 per mL. This was
stored in 1.4 mL aliquots at -20 C and was thawed immediately prior to use (these
aliquots were frozen and thawed once only). Addition of 100 jaL to each well gave a
final concentration of 500 ng PGE2 per well. The maximum amount of ethanol
tolerated per well is 0.5 faL (ie. 0.05%). The above dilution results in 0.05 jiL of
ethanol per 100 p.L of PGE2 solution which equates to 0.005% per well (1 mL
volume). The remaining original solution was stored in a sterile glass vial at -20 C.
PGL2e fUpiohn Ltd. Lot 22322),
PGL2awas obtained as a sterile solution at a concentration of 5 mg/mL in aqueous
solution. In the safety cabinet under sterile conditions 20 p.L of this solution was
diluted in 20 mL of complete culture medium to give a concentration of 5 |lg PGL2a
per mL. Addition of 100 |lL of this to each well gave a final concentration of 500 ng
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PGF2a per well. This was stored in 1.4 mL aliquots at -20 C and thawed immediately
prior to use (these aliquots were frozen and thawed once only). The remaining
original solution was stored in a sterile glass vial at 5 C.
2.5 Oximation and Storage of Samples.
Upon completion of all cell and tissue explant experiments 0.5 mL of culture medium
was aspirated from each well into a Sarstedt microtube (2 mL capacity: 72694007) and
oximated with an equal volume of methyl oximating solution to promote formation of
stable methyl oxime compounds (see radioimmunassay details). These samples were
thoroughly mixed, stored at room temperature for 24 hours and then at 5 C pending
radioimmunoassay.
Methvloximating Solution tMox B).
This was prepared in 2 L volumes. 164 g of Sodium acetate (Sigma, UK; S8750) and
20 g of methoxyamine hydrochloride (Sigma, UK; Ml 139) were weighed out and
approximately 1200 mL of distilled water and 200 mL of ethanol added. The final
concentrations of these reagents were 1 M and 0.12 M respectively. These were
mixed until dissolved in the fume cabinet (Morgan & Crundy). The pH was measured
(Orion: 520) and adjusted to 5.6-5.8 with hydrochloric acid (5M) and the total volume
made up to 2 L with distilled water. This solution was stored in a glass bottle at room




A competitive-binding radioimmunoassay was employed. This works along the
following principles. The prostaglandin (antigen) of unknown quantity present in the
sample is mixed with 125 I-labelled prostaglandin of known quantity. The first
antibody is then added to this solution and the labelled and unlabelled prostaglandins
compete with each other for binding to the antibody. If the level of unknown
prostaglandin in the sample is high it will bind preferentially with antibody and the
amount of radio-labelled antigen-antibody complex will be correspondingly low.
Therefore, a low count of radioactivity represents a high level of unknown
prostaglandin in the original sample and vice versa. A second antibody, raised against
the first antibody and attached to magnetic particles, is then added to the solution and
this binds to antigen-antibody complexes, both labelled and unlabelled. The solution
is then attached to a magnet to separate the free and bound antigen. The supernatant,
containing labelled and unlabelled free antigen, is poured off. The antigen-antibody
complexes are counted by a gamma counter.
A standard curve is constructed to enable estimation of the quantities of unknown
antigen present in the samples being measured. This is done by treating a range of
samples of antigen of known concentration with radiolabel and antibody in exactly the
same manner as described above.
All samples obtained from the explant and cell culture experiments were oximated with
methyloxime solution prior to storage pending radioimmunoassay. The resultant
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conversion of the prostaglandins to their corresponding methyl oximes prevents
sample decomposition during storage or in the course of the assay since these methyl
oxime derivatives are much more stable. The process of methyloximation described
earlier (page 79) gives greater than 95% conversion of prostaglandins to their methyl
oximes when treated overnight at room temperature. The reason for obtaining greater
stability of these compounds is that there have been problems with prostaglandin
analysis in the past owing to the inherent instability of the (3 ketol ring structure which
is present in prostaglandins of the E series. This has resulted in the detection of
erroneously high levels of prostaglandins of the A series. Conversion to methyl
oximes does not interfere with assay of those prostaglandins such as PGF2a which
cannot form methyl oximes. The antiserum is therefore raised against the methyl
oxime form.
In summary, up to 50 p,L of oximated culture medium was assayed. The labels
employed are the iodinated (125 I) methyl oximes of PGE2, PGF2a, PGEM and
PGFM. The prostaglandin methyl oximes are coupled to a tripeptide Pro-gly-tyr
through the nitrogen in the proline ring. This linkage is distinct from the amide linkage
present in the original antigen against which the antiserum is raised. This ensures that
the antiserum does not have a higher affinity for the label than it has for the compound
being measured and results in a high sensitivity assay. Antisera to the respective
antigens were raised in a rabbit. A second antibody, raised in a donkey, was used to




All samples were assayed in duplicate. Sarstedt polypropylene tubes (55532) were
numbered and set up on racks supplied by Amersham Radiochemical Company.
1. Preparation of the standard curve.
The standards were supplied by Upjohn and stored at concentrations of 20 pg/mL in
ethanol at -20 C. Stock dilutions were made up in 20% Mox buffer to maintain
stability and stored at 5 C. These dilutions have a shelf-life of nine months. Working
dilutions were prepared by making a 1:10 dilution of the stock dilutions in 20% Mox
buffer to give the following range of concentrations for use in the assay: 10, 20, 40,
80 160, 312, 652, 1250, 2500 and 5000 pg/mL. The working dilutions were also
stored at 5 C and were renewed every four months.
2. In general 50 pL of each sample to be assayed was used. Where the concentration
of prostaglandins or their metabolites was expected to be high (eg. PGEM and PGFM
in the chorion experiments) a 25 |iL sample was assayed. In order to maintain a stable
pH, and so optimise antibody binding, the concentration of Mox in the samples was
kept constant at approximately 20-25%. The samples already contained 50% Mox B
(NB storage procedure). Therefore, a 50 pL sample would be made up to 100 pL
with 50 pL of assay buffer; and a 25 pL sample would be made up to a volume of 100
pL with 25 pL of assay buffer and 50 pL of 20% Mox buffer.
3. 100 pL of antiserum dilution was added to all tubes except the non-specific binding
(NSB) and total count (TC) tubes. Non-specific binding was always <2% for all
prostaglandin assays.
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4. 100 |iL of radiolabel (tracer) was added to all tubes to yield approx 15,000 counts
per minute/100 pL.
5. The racks were clipped on to a shaker (Amersham N4201) for one cycle at full
speed.
6. The racks were covered and allowed to incubate overnight at room temperature.
7. The total count tubes were set aside. 250 pL of second antibody (attached to
magnetic particles) was added to all the other tubes.
8. The tubes were mixed on the shaker for one cycle at full speed and incubated for 30
minutes at room temperature.
9. The racks were clipped to a magnet for 15 minutes to allow separation of the bound
and free antigen to occur.
10. With the racks and magnet clipped together the supernatant was decanted and the
racks allowed to drain on to paper towels for a few minutes.
11. The racks were removed from the magnets and 250 pL of assay buffer containing
1.25% Triton X/80 ml assay buffer was added to each tube. The samples were mixed
on the shaker for one cycle at full speed and free and bound antigen reseparated with
the magnet for 15 minutes at room temperature.
12. The supernatant was decanted as before and the tubes drained for a further 15
minutes.
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13. The assay tubes were counted for two minutes to assess the amount of bound
ligand using the appropriate programme on the Packard Gamma Counter.
2.6.3 Cross Reactivities.
The cross reactivities to PGE2 and PGF2a antisera are displayed in table 2.1, and
those for PGEM and PGFM antisera (raised against the 13,14-dihydro-15 keto PGE2
derivative, and the 13,14-dihydro-15 keto PGF2« derivative respectively) are
displayed in table 2.2. Cross reactivity was determined by the amount of
prostaglandin that caused 50% inhibition of binding of the appropriate labelled
prostaglandin to the antibody (Kelly et al, 1986).
The sensitivity of the assay (the amount distinguishable from zero with a 95%
confidence limit) was 2 pg in all assays. This gives a limit of detection of
approximately 40 pg per well. The intra- and inter-assay coefficients of variation are
illustrated in table 2.3 (Kelly et al, 1986; Kelly et al, 1992).
90

















All other prostaglandins <0.2%
Table 2.1. Cross reactivities to PGE2 and PGF2a antisera.
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Antiserum Compound Cross Reactivity














All other prostatglandins <0.01 %































2.6.4 Preparation of buffers.
Tris 1 M Buffer. (Tristhydroxvmethvl) methvlamine)
Made up in 1 litre volumes. 121.1 g of Tris (BDH) is dissolved in approximately
800 mL of distilled water. The pH is adjusted to 7.3 with concentrated hydrochloric
acid (BDH) (approx. 60 mL required). This is then made up to the final volume of 1 L
with distilled water and stored at 5 C. Tris acts as a secondary buffering system and
helps to maintain a constant pH and so maximise antigen-antibody binding.
Assay Buffer (Phosphate Gelatin Buffer (BDH British Drug Houses) + Trisl.
Made up in 4 litre volumes. The ingredients are NaCl, 36 g; Na2HPC>4, 34.4 g;
Na2HP04 2H20, 24.32 g; NaN3, 2g; Gelatin, 4g; Tris buffer 1M (pH 7.3), 400 mL.
The gelatin is dissolved in 500 mL of distilled water by heating. This is removed from
the heat and 2.5 L of distilled water plus the dry salts are added and stirred until
dissolved. 400 mL of the Tris buffer is added (final concentration lOOmM) and the
pH adjusted to 7.8 with 10M NaOH. This is made up to the final volume with
distilled water and stored at 5 C.
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Triton-X-100 1.25%.
1.25 mL of Triton-X-100 (BDH) is dissolved in 100 mL of assay buffer at room
temperature and stored at 5 C.
20% Mox Buffer = 20 mL Mox B
0.4 mL 1.25% Triton X
79.6 mL Assay Buffer
10% Mox Buffer = 10 mL Mox B
4 mL 1.25% Triton X
86 mL Assay Buffer
2.6.5 Preparation of tracer and antibodies.
Tracer.
The tracers were prepared and stored in ethanol at 5 C. They were then diluted in 10%
Mox buffer to yield approximately 15,000 counts per 100 |lL.
Antibodies.
The first antibody was raised in a rabbit and this was stored in lyophilised form at
-20 C. The antibody was reconstituted in assay buffer (concentration 1:100) and
stored at 5 C. Fresh working dilutions, ranging from 1:15, 000 - 40, 000 were made
up in assay buffer for each assay.
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The second antibody, donkey anti-rabbit anti-serum, was linked to magnetic particles.
Neat solution was stored at 5 C and working dilutions were made up in assay buffer
containing 1 mL 1.25% Triton-X per 80 mL assay buffer to give a dilution of 1:16.
Triton-X prevents the particles from sticking to the assay tubes.
2. 7 Amniotic Fluid Collection and Preparation.
Amniotic fluid was collected at elective caesarean section by transmembranous
amniocentesis and immediately with delivery of the baby following spontaneous
labour under aseptic conditions. The fluid was centrifuged at 2000 rpm for 20 minutes
at room temperature to remove any excess debris and divided in to aliquots for storage
at -20 C prior to use in the cell culture experiments. The fluid was thawed on the
morning of each experiment and centrifuged once more as described above and then
filtered through 0.22 jam mesh to remove any contaminating particulate matter prior to
addition to the cell culture system.
There is no method of collection of amniotic fluid from women in spontaneous labour,
other than transabdominal amniocentesis, that will ensure a sterile sample. As this is
not ethically or practically realistic in our centre we collected amniotic fluid at the time
of delivery under aseptic conditions. In so doing, only women who had laboured
spontaneously without oxytocin augmentation were sampled. The amniotic fluid had
therefore been in contact with the maternal genital tract at the time of delivery raising
the concern of bacterial contamination. It has been demonstrated that potentially
pathogenic bacteria can increase arachidonic acid metabolism by amnion cells.
However, Lactobacillus, which forms the normal vaginal flora does not (Bennett et al,
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1987). There is also the potential that bacteria themselves may synthesise
prostaglandins but it has been established that although they are capable of
incorporating arachidonic acid, common genital tract pathogens are unable to
metabolise arachidonic acid via cyclooxygenase, lipoxygenase, or epoxygenase
pathways (Gulbis et al, 1981; Bennett et al, 1992a).
It has been shown that bacterial products have a bi-phasic effect in prostaglandin
production by amnion and decidua (Mitchell et al, 1991a), with low doses stimulating
and high doses inhibiting prostaglandin synthesis. The results of the experiments in
chapters four and five demonstrate that amniotic fluid had a consistent effect on
prostaglandin production which was stimulated in a dose-dependent manner. In
addition, the amnion and chorion cells in all experiments were maintained in culture for
seven days, at the end of which time there was no evidence of bacterial infection
suggesting that any increase in prostaglandin production by these cells is not the result
of contaminating bacteria.
Background concentrations of PGE2, PGF2a and their respective metabolites PGEM
and PGFM were established in all amniotic fluid samples and appropriate subtractions
were made in the experiments described in chapters four and five. Estimation of
background cytokine concentrations in the amniotic fluid was not performed as it
would not be possible to make any distinction between cytokines which might be a







Fetal membranes were collected at elective caesarean section (n=3) and amnion and
chorion cell cultures prepared as described in section 2.1.1. Cells were plated out in
standard 24 well plates at the following densities: 0.5, 1, 2, 4 and 8 xlO5/ mL. The
plates were incubated in humidified 95% air; 5% CO2 at 37 C, and all experiments
were performed in duplicate. After 24 hours and seven days in culture, 0.5 mL of
culture medium was aspirated from each well and oximated as described in section
2.4. The primary prostaglandins PGE2 and PGF20C and their respective metabolites
PGEM and PGFM were measured by radioimmunoassay (section 2.6). All cultures
had reached confluence by seven days.
Statistical Analysis.
Statistical analysis was performed using ANOVA. Data that were not normally
distributed were log transformed prior to analysis.
Results.
In the 24 hour cultures PGE2 was the major product of the amnion, and significantly
more PGE2 was produced at densities of 2, 4 and 8 xlO5 cells/ mL compared with 0.5
xlO5 cells/ mL (Fig. 3.1; p<0.05). There was no significant difference between the
24 hour and 7 day cultures in the concentration of PGE2 produced at any cell density.
PGF20C was produced in similar concentrations at all cell densities (Fig. 3.1). Its
production was significantly lower than that of PGE2 at cell densities of 2, 4 and 8
xlO5 cells/ mL (p<0.05). Again, there was no significant difference between the 24
hour and 7 day cultures in the concentration of PGF20C produced at any cell density.
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There was no significant difference in PGEM production by chorion at any cell density
between the 24 hour and seven day cultures. Significantly more PGEM was produced
at a density of 8 xlO5 cells/ mL compared with 0.5 xlO5 cells/ mL at both incubation
times (Fig. 3.2; p<0.05). Similarly, there was no difference in PGFM production at
any cell density between the two incubation times. PGFM production by cell densities
of 1, 2, 4 and 8 xlO5 cells/ mL was significantly greater than 0.5 xlO5 cells/ mL in the
seven day cultures (Fig. 3.2; p<0.05). In addition, by the seventh day of culture
PGFM production was significantly lower than PGEM production at all cell densities
(p<0.05).
Production of primary prostaglandins and their metabolites at a density of 2 xlO5 cells/
mL was not significantly different from the higher cell densities, except in the case of
PGE2. However PGE2 production had increased significantly at 2 xlO5 cells/ mL
compared with 0.5 xlO5 cells/ mL. Cell viability data for the three cultures is
illustrated in table 3.1.
Discussion.
All cell culture experiments described in the chapters four and five employ a cell
density of approximately 2 xlO5 cells/ mL. This was chosen as it is practical allowing
stimulation and inhibition of production to be studied with ease, avoiding grossly
excessive concentrations of prostaglandins in the medium as may occur at higher cell
densities. This is also in keeping with experiments performed by Jones et al, (1989)
and Riley et al (1992). It is also within the range of densities (1 x 105 cells/ mL to 3 x
105 cells/ well) used by a number of other investigators (Olson et al, 1983b; Gibb et

















































































3.2 Duration of Culture.
It has been established by a number of studies that basal prostaglandin production, and
the response to various stimulants can be influenced by the length of time the cells
have been in culture before the experiments are performed. For example, it has been
shown that basal PGE2 production by amnion cells decreases during cell culture such
that it may be undetectable by day seven (Gibb and Lavoie, 1990). In these
experiments, the cells reached confluence between days five and eight of culture.
Similarly, the response of amnion cells to various agents was shown to change with
duration of culture. In these experiments EGF had no effect on freshly isolated cells,
but stimulated PGE2 production in confluent cells. Likewise the effect of
dexamethasone on PGE2 production switched from inhibition in fresh cells to
stimulation in confluent cells. This stimulatory effect of dexamethasone on confluent
cell PGE2 production has been confirmed in other studies (Mitchell et al, 1988a;
Potestio et al, 1988), and it has been suggested that this effect is most likely regulated
at the level of COX (Potestio et al, 1988). The effects of dexamethasone on
prostaglandin production are discussed in more detail in chapter three.
Further evidence supporting changes in cell responsiveness with culture duration is
provided by the finding that in the first and second 24 hours of culture amnion and
chorion cells are unresponsive to interleukin 1(3, but by day five of culture PGE2
production by both cell types was stimulated by this cytokine (Alnaif et al, 1994). A
number of suggestions have been proposed by these authors to account for the
differences. It may be that COX activity is reduced after the first 48 hours of culture,
and it is only once this has occurred that the stimulatory effect of IL-1J3 can be seen.
Alternatively receptor damage may occur during cell dispersal, but as receptor turnover
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is achieved between 2 and 12 hours a response to IL-1 (3 should be seen in the second
24 hours of culture if this were the explanation.
Lundin-Schiller et al (1991b) described prostaglandin production by chorion cells and
the response to inflammatory mediators. Their cultures reached confluence on day
three, and basal prostaglandin production was significantly greater at this time
compared with day ten. This is in keeping with the results of Gibb et al (1988) who
found that PGE2 production by chorion cells was maximal on day one or two of
culture, and then declined to low levels. Lundin-Schiller et al (1991) observed a large
variation in basal prostaglandin production between tissues from different pregnancies,
and this is a consistent feature of such cell culture work (Gibb et al, 1988; Alnaif et al,
1994). The responsiveness of the chorion cells to TNFa , IL-1 (3 and endotoxin was
significantly greater at day ten compared with day three of culture, reflected by
increased PGE2 production. Again these authors speculate that this may be due to
recovery of receptors as the cultures progress. Alternatively, they suggest that there
may be a relative increase in a subpopulation of chorion cells that are responsive to
cytokines compared with other cells, after several days in culture.
The above findings illustrate the quantitative and qualitative changes that occur in cell
culture systems with time, and the caution with which in vitro results must be
interpreted in relation to the in vivo situation.
In view of the above we compared production of PGE2, PGF2« and their respective
metabolites PGEM and PGFM by cells cultured for 24 hours and seven days and




Fetal membranes were collected at elective caesarean section (n=3) and amnion and
chorion cell cultures prepared as described in section 2.2.1. They were plated out at
densities of 0.5, 1, 2, 4 and 8 xlO5 cells/ mL. After an incubation period of 24 hours
or seven days, in humidified 95% air; 5% CO2 at 37 C, the following additions were
made: lOOnM PMA (to all cell densities), lOOOu TNFa (to 2xl05 cells/mL) or culture
medium (to act as control). The cells were incubated for a further 24 hours, and then
0.5 mL of culture medium aspirated for oximation and radioimmunoassay as described
in sections 2.5 and 2.6. All experiments were performed in duplicate.
Statistical Analysis.
Statistical analysis was performed using ANOVA. Data that were not normally
distributed were log transformed prior to analysis.
Results.
PGE2 and PGF2a production by amnion cells cultured for 24 hours was significantly
stimulated by PMA (Fig. 3.3, 3.4; p<0.05). Following seven days in culture PGE2
production was only stimulated by PMA at a cell density of 8 xlO5/ mL, and the
phorbol ester had no effect on PGF2a production after this length of culture (Fig. 3.3,
3.4). PMA significantly stimulated PGEM production by chorion cells after 24 hour
culture at all densities (Fig. 3.5; p<0.05), and PGFM production was stimulated at
densities of 2, 4 and 8 xlO5 cells/ mL (Fig. 3.6; p<0.05). Following seven days in
culture PMA continued to stimulate production of both metabolites at certain cell
densities (Fig. 3.5, 3.6).
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TNFa significantly stimulated PGE2 production by amnion after 24 hours in culture
(Fig. 3.7; p<0.05) and this stimulation was maintained after seven days in culture.
PGF20C production was not affected by TNFa at either time point (Fig. 3.7).
However, baseline production of PGF20C is very low compared with that of PGE2.
TNFa had not effect on PGEM production by chorion after 24 hours in culture, but in
the seven day cultures PGEM production was stimulated, although this failed to reach
significance (p=0.057). There was no effect on PGFM production at either time point
(Fig. 3.7).
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These findings suggest that in amnion PKC-dependent mechanisms lose their
responsiveness with increasing duration of culture. PKC can increase prostaglandin
production via two pathways. Firstly, through its stimulatory effect on phospholipase
A2, PKC can increase the release of substrate arachidonic acid from membrane
phosphatidylethanolamine. Secondly, PKC is able to stimulate transcription and
translation, resulting in de novo synthesis of COX. Although there was no difference
in basal production of prostaglandins between the 24 hour and seven day cultures, the
capacity to increase production, either by substrate release or new enzyme synthesis is
obviously lost in these amnion cultures. In the chorion cultures some response to
PKC was maintained after seven days, possibly reflecting different metabolic
properties of this cell type.
TNFa is a member of the cytokine family which acts non-enzymatically to regulate
cellular function. The biological actions of cytokines are mediated via cell surface
receptors and second messengers. A number of cytokines, including IL-1 and TNFa,
have been shown to stimulate prostaglandin production by human amnion cells
(Romero et al, 1989d; Lundin-Schiller and Mitchell, 1991). We have demonstrated
increased PGE2 production by amnion cells suggesting that receptors of TNFa are
present at both culture time points. There was no response of chorion cells to TNFa
after 24 hours in culture which may reflect a loss of receptors by this layer, perhaps as
a result of trypsin digestion. There was some, albeit non-signifcant, stimulation of




This methodology has confirmed that production of PGE2 and PGF2a> and their
respective metabolites is taking place at both 24 hours and seven days of culture.
Although PGE2 and PGFM production was less in the seven day cultures compared
with 24 hours, and PGEM production was higher after seven days in culture, there
was no significant difference in production between the two culture time periods,
unlike the findings of other investigators (Gibb and Lavoie, 1990; Lundin-Schiller et
al, 1991).
However, there were changes in the way the cultures responded to the phorbol ester
PMA with increasing culture duration. By seven days of culture, responsiveness of
amnion cells to PMA had been lost, and the chorion cells were not as uniformly
responsive at seven days as they had been after 24 hours in culture. In view of the
importance of protein kinase C (PKC) in substrate release and COX synthesis, and
hence prostaglandin production, the experiments described in chapters four and five
were therefore carried out in the first 48 hours of culture to avoid any loss of effect of
PMA, as seen in the longer cultures. Chapter six describes experiments specifically
investigating the effect of PKC inhibition on prostaglandin production, further
illustrating the importance of employing a short term (<48 hour) culture period.
The increased PGE2 production seen in response to TNFa suggests that the digestion
process with trypsin has not damaged amnion receptors. Although we have not
specifically investigated any receptor-mediated effects in the experiments described in
chapters five and six, we have suggested that cytokines could be potential mediators of
the stimulatory effect of prostaglandin production by amnion.
A cell density of 2 xlO5 /mL was employed throughout the culture experiments
described in chapters five and six. Prostaglandin production at higher cell densities
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was not significantly different for 2 xlO5 /mL, with the exception of PGE2 at
8 xlO5 /mL. This cell density was chosen as practical and is in keeping with the cell
culture work of other investigators in this field (Jones et al, 1989; Riley et al, 1992).
3.3. Response of Explant Cultures to Phorbol Myristoyl Acetate.
Methods.
Fetal membranes were collected at elective caesarean section (n=3) and amnion and
chorion explant cultures prepared as described in section 2.3. All discs were
suspended in 900 pL of culture medium. The discs were treated as follows: overnight
incubation (approx. 24 hours) with 100 nM PMA; overnight incubation with no
additions (control); overnight incubation followed by the addition of 100 nM PMA and
further incubation for 24 hours; overnight incubation with no additions and further 24
hour incubation (control). The plates were incubated in humidified 95% air; 5% CO2
at 37 C, the final culture volume was 1 mL, and all experiments were performed in
duplicate. 0.5 mL of culture medium was aspirated from each well and oximated as
described in section 2.5, pending radioimmunoassay (section 2.6).
Statistical Analysis.
Statistical analysis was performed using ANOVA. Data that were not normally
distributed were log transformed prior to analysis.
Results.
PMA stimulated prostaglandin production by the amnion explants. The increase in
PGE2 production failed to reach significance in the explants treated in the first 24
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hours of culture, but was significant in the explants treated in the second 24 hours of
culture (Fig. 3.8; p<0.005). Stimulation of PGF2a production by PMA was
significant at both time points (Fig. 3.8; p<0.001). PGEM production by chorion,
reflecting PGE2, was also stimulated by PMA treatment at both time intervals (Fig.
3.9; p<0.05), whereas the phorbol ester had no effect on PGFM production by

















































The above experiments confirm, that using the explant culture technique described,
production of prostaglandins E2 and F2«, and their respective metabolites, by elective
caesarean section tissue can be recorded. The response of these cultures to the phorbol
ester PMA has demonstrated that protein kinase C-dependent mechanisms are
functioning in these cultures. As discussed in section 3.2 PKC is an important
mediator of prostaglandin production via its promotion of substrate release
(arachidonic acid), and activation of COX. The experiments described in chapter four
investigate changes in prostaglandin synthesis and metabolism in fetal membranes
collected after elective caesarean section and spontaneous labour. In these experiments
we investigated the effect of exogenous substrate, PMA, and the COX inhibitor
indomethacin on prostaglandin production. In order to look at any effect that
parturition might have on synthesis and metabolism we elected to carry out these
experiments in the first 24 hours of culture, accepting that in the above experiments the
stimulatory effect of PMA with regard to PGE2 production just failed to reach
significance. However, as described in the experiments in chapter four, PMA




Changes in Prostaglandin Synthesis and Metabolism Associated with




Prostaglandins are intimately involved in the process of parturition. This is evidenced
by the increase in concentrations of PGE2, PGF2a and their metabolites in maternal
plasma (Green et al, 1974; Lackritz et al, 1978, Satoh et al, 1979), urine and amniotic
fluid (Satoh et al, 1979; Keirse et al, 1977a) at the onset of spontaneous labour. The
fetal membranes appear to be the source of the increase in prostaglandins seen with
labour. The amnion produces PGE2 and has little metabolising activity (Okazaki et al,
1981a) whereas the chorion is the major site of prostaglandin metabolism, being rich
in prostaglandin dehydrogenase (Okazaki et al, 1981a; Cheung et al, 1989; Cheung et
al, 1990). This enzyme converts PGE2 and PGF2ot to their respective metabolites
13,14-dihydro-15-keto-PGE2 (PGEM) and 13,14-dihydro-15-keto-PGF 2ot (PGFM).
There are two mechanisms by which this increase in prostaglandin levels can be
effected: firstly, an increase in their synthesis, or secondly, a decrease in their
metabolism.
It is well established that prostaglandin production by amnion is increased in
spontaneous labour (Cheung et al, 1989; Skinner and Challis, 1985; Reddi et al,
1990). However, in order to exert their uterotonic effect on the myometrium,
prostaglandins synthesised by the amnion would have to escape the metabolic activity
of prostaglandin dehdrogenase within the chorion, and there are conflicting reports as
to whether or not this is possible. Some reports have confirmed that transfer of
prostaglandins across full-thickness membranes does occur, with the majority of the
prostaglandin remaining intact (Bennett et al, 1990; Nakla et al, 1986), whereas others
have shown that transfer does not take place (McCoshen et al, 1990). Any reduction
in the metabolising capacity of the chorion could potentially enhance prostaglandin
transfer. There is little information available on changes in prostaglandin metabolism
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associated with labour, with one report suggesting that there is no difference in the
metabolising capacity of pre- and post- labour tissues (Cheung et al, 1989).
Although the effect of steroid hormones on prostaglandin production has been
examined extensively (Mitchell et al, 1988a; Potestio et al, 1988), this is not the case
for prostaglandin metabolism and no previous study has examined prostaglandin
metabolism in parallel. It has been shown that antiprogestagenic steroids alter
prostaglandin metabolism in the guinea-pig (Kelly and Bukman, 1990), but there is
little information on the effect of progesterone and corticosteroids on prostaglandin
metabolism in chorion.
The aim of this study was to assess, in parallel, the alterations in prostaglandin
synthesis and metabolism in amnion and chorion respectively that are associated with
spontaneous labour and to investigate the effect of steroid hormones on prostaglandin
metabolism.
Subjects and Methods.
Fetal membranes were obtained from women at term with uncomplicated pregnancies.
Group one laboured spontaneously and achieved a vaginal delivery without oxytocin
augmentation (n=12), and group two underwent elective caesarean section for either
breech presentation or previous caesarean section (n=12).
Amnion and chorion explant cultures were prepared as described in section 2.3.1. The
explant discs of amnion were treated with the following (final concentrations): lOOpM
arachidonic acid (Sigma, UK); lOOnM phorbol myristoyl acetate (PMA) (Sigma, UK);
2.8mM indomethacin (Sigma, UK) or complete culture medium, the latter to act as
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control. The solutions of arachidonic acid, PMA and indomethacin were made up in
complete culture medium (section 2.4.2). The volume added was 100|itL and the discs
were therefore cultured in a total fluid volume of lmL. All experiments (n=12 in each
group) were performed in duplicate (ie. 2 discs per experiment per patient giving 8
discs in total per patient).
The plates were incubated for 18 hours in humidified 5% C02 in air at 37 C.
Following incubation, 0.5mL of incubation medium was aspirated from each well and
oximated with an equal volume of methyl oximating solution. These samples were
thoroughly mixed, stored at room temperature for 24 hours and then at 5 C pending
radioimmunoassay.
The chorion explant discs were treated with one of the following (final concentrations):
ImM dexamethasone, ImM progesterone (both Sigma, UK), ImM RU 486 (Roussel
Laboratories) or complete culture medium alone to act as control. The explants were
incubated for 18 hours in humidified 5% C02 in air at 5 C.
The following solutions were added (final concentrations): lOOmM arachidonic acid;
500ng PGE2 (Upjohn Ltd, UK); 500ng PGF2a (Upjohn Ltd, UK) and complete
culture medium, the latter to act as control. The total volume of culture fluid was
maintained at lmL. All experiments (n=12 in each group) were performed in duplicate
(ie. 2 discs per experiment per patient giving 8 discs in total per patient). The explants
were incubated for a further 4 hours and then 0.5mL of incubation medium aspirated
from each well for oximation as described in section 2.5.
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Radioimmunoassay.
The competitive binding radioimmunoassay employed in these experiments is
described in detail in section 2.6.
Statistical Analysis.
Analysis of variance (ANOVA) was used to analyse the data. Where the data were not
normally distributed, log transformation was employed prior to ANOVA.
Results.
The Effect ofLabour on Prostaglandin Synthesis by Amnion and Chorion (Fig. 4.1).
Basal production of PGE2 and PGF2a was significantly higher in amnion obtained
following spontaneous labour compared with elective caesarean section (p<0.05).
PGEM and PGFM production did not differ significantly between spontaneous labour
and caesarean section tissue. PGF2oc production was substantially less than that of
pge2.
PGEM was the major product of the chorion in both spontaneous labour and caesarean
section groups, and production was significantly higher in the spontaneous labour
tissue (p<0.05). PGFM was produced in smaller amounts and only minimal levels of
PGE2 and PGF2oc were recorded. There was no significant difference in the
production of either primary prostaglandin or PGFM between the two groups.
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PGE2 PGF2a PGEM PGFM
Figure 4.1
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The Effect of Arachidonic Acid, Phorbol Myristoyl Acetate and Indomethacin on
Prostaglandin Synthesis in Amnion (Fig. 4.2) .
The addition of arachidonic acid resulted in significant stimulation of PGE2 and
PGF2a synthesis by amnion obtained following both spontaneous labour and
caesarean section in comparison with the basal synthesis by the two groups (p<0.05)
(Note: PGE2 expressed in ng/ml; PGF2a in pg/ml). The percentage increase in
prostaglandin production over basal levels was greater in the caesarean section tissue
and this was significant for PGF2a (p<0.01). PMA stimulated PGE2 production from
amnion in both groups (p<0.05). There was no significant stimulation of PGF2a
production following the addition of PMA in either group. Indomethacin inhibited
PGE2 production in both groups (p<0.05). Also, PGF2a production was inhibited by
indomethacin in amnion obtained following spontaneous labour (p<0.05).
The Effect ofLabour on Prostaglandin Metabolism in Chorion (Fig. 4.3):
Metabolism of exogenous PGE2 to PGEM was the same by chorion from both
groups. Similarly, there was no difference in the metabolism of exogenous PGF2a to
PGFM between the groups.
The Effect ofSteroids on Prostaglandin Metabolism in Chorion (Fig. 4.4):
Dexamethasone and progesterone had no effect on prostaglandin metabolism.
However, RU 486 decreased the metabolism of added PGE2 by chorion obtained























































































The aim of this study was to compare changes in prostaglandin synthesis and
metabolism in parallel by looking at both the amnion and chorion collected from each
subject. The major product of the cultured amnion explants was PGE2 which is in
keeping with reports from others (Okazaki et al, 1981a; Mitchell et al, 1978c). We
were able to demonstrate a significant increase in PGE2 production by amnion
obtained following spontaneous labour, in keeping with the findings of previous
studies (Cheung et al, 1989; Skinner et al, 1985; Reddi et al, 1990). Although
measured in much smaller concentrations, we also found a significant increase in the
production of PGF2a by the amnion following spontaneous labour which could not be
explained by any cross-reactivity as PGE2 cross-reactivity with PGF2a assay was
<0.02%. Okazaki et al. (1981a) were unable to demonstrate PGF2oc production by the
amnion. However, Mitchell et al. (1978c) detected small amounts of PGF2a in their
superfusates of amnion tissue. It is established that the main intrauterine source of
PGF2a is the decidua and any contribution that the amnion makes to increased PGF2a
concentrations is likely to be negligible. Indeed, the presence of PGF2a in the culture
system could be explained by non-enzymatic conversion from PGE2, or by production
by fibroblasts or macrophages present within the deeper layers of the amnion.
Production of both PGEM and PGFM by the amnion was minimal, reflecting the
virtual absence of prostaglandin dehydrogenase activity in this tissue (Cheung et al,
1990).
The production of PGE2 was decreased in both groups when the amnion explants
were incubated with the cyclooxygenase inhibitor indomethacin. This finding
confirms that the PGE2 measured has been synthesised de novo in the culture system
rather than being residual prostaglandin remaining within the tissue. Similarly,
PGF2a production was inhibited in the spontaneous labour group. There was no
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significant inhibition in the caesarean section group, however basal concentrations
were very low suggesting that minimal production was occurring, and therefore an
inhibitory agent would have little effect. This resultant decrease in prostaglandin
synthesis by the amnion underlines the rationale for prescribing indomethacin in the
management of preterm labour.
In our experiment, the addition of arachidonic acid resulted in significant stimulation of
PGE2 and PGF2a production by amnion obtained both before and after labour
compared to basal concentrations. Arachidonic acid is the obligatory precursor of
prostaglandins of the 2 series and related compounds. It has been shown that there is
an increase in the arachidonic acid concentration of amniotic fluid during labour
(MacDonald et al, 1974), and in particular that the increase in arachidonic acid
concentration is disproportionately high compared to other free fatty acids. The
mobilisation of arachidonic acid from membrane glycerophospholipids is thought to be
the rate-limiting step in prostaglandin production, and this involves the enzyme
phosholipase A2. An increase in the activity of this enzyme with advancing gestation
has been described (Okazaki et al, 1981c), but an increase in activity associated with
the onset of labour was not demonstrated. The significant difference between the two
groups in basal production of both primary prostaglandins was lost following the
addition of arachidonic acid substrate. These findings suggest that the availability of
arachidonic acid is a limiting factor in prostaglandin production by the elective section
tissue.
The difference in basal production of PGE2 and PGF2a between the groups could be
explained by a difference in the activity of cyclooxygenase (COX) in pre- and post-
labour amnion. Cyclooxygenase (COX) is responsible for the conversion of
arachidonic acid to the cyclic endoperoxides which are in turn converted to the primary
prostaglandins. Lopez Bernal et al. (1987) compared PGE2 production by
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spontaneous preterm and term amnion cells and showed that the prostaglandin output
of term cells remained significantly greater than the preterm cells in the presence of
arachidonic acid, suggesting a maturation in the activity of COX toward term. Further
results supporting this theory come from Olson et al. (1991) who found a bimodal
distribution of COX activity in amnion collected at elective caesarean section implying
that there is maturation of the enzyme system prior to the onset of labour. Indeed,
increased expression of the cyclooxygenase gene has been demonstrated in human
fetal membranes and placenta with the onset of labour (Bennett et al, 1992b).
However, in our experiment the significant difference in prostaglandin production
between the groups was not maintained following the addition of arachidonic acid. If
there was increased cyclooxygenase activity in the spontaneous labour tissue we
would expect this difference in prostaglandin production to remain. In fact, the
increase in production of both PGE2 and PGF2a over basal levels appears to be
greater in caesarean section compared with spontaneous labour tissue, and this was
statistically significant for PGF2oc. This finding suggests that, provided adequate
substrate is available, both groups have similar capacities for prostaglandin
production. However, the effect of exogenous arachidonic acid on cyclooxygenase
activity is not known, and it is possible that the arachidonic acid may have induced and
saturated the enzymes thus abolishing any differences seen previously.
The addition of PMA resulted in increased production of PGE2 by amnion in both
groups compared with control values. Phorbol esters, such as PMA and tumor
promoter phorbol ester (TPA), act by stimulating the activity of the enzyme protein
kinase-C (PKC), a calcium- and lipid-dependent protein kinase which is involved in
the regulation of many cellular functions. PKC activity has been identified in human
amnion and decidua vera tissues (Okazaki et al, 1984) and it is thought to be involved
in arachidonic acid release and the activation of COX (Zakar and Olson, 1988). There
is evidence to support the existence of multiple isoforms of COX (Xie et al, 1992;
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Kujubu et al, 1991; O'Banion et al, 1991). COX-1 is the constitutive form of the
enzyme, whereas COX-2 can be induced by a number of agents including phorbol
esters. Previous reports have shown that tumor promoter phorbol ester significantly
increases PGE2 production when added to cultured human amnion cells (Zakar and
Olson, 1988). This study of amnion explants confirmed the stimulatory effect of
phorbol ester on PGE2 production. We did not find a similar effect with regard to
PGF2a production, but this may simply be related to the lower levels of this
prostaglandin being synthesised by the tissue in comparison to PGE2 (347 v 4364
pg/ml). The response of the amnion cultures to PMA was variable, particularly in the
spontaneous labour tissues, a finding that has also been noted in previous work using
TPA (Zakar and Olson, 1992). Reports have shown that phorbol ester treatment can
enhance PGE2 production by amnion cells isolated both before (Sander and Myatt,
1990) and after (Zakar and Olson, 1988) labour. There was no significant difference
in response to PMA between the spontaneous labour and caesarean section amnions in
our experiment. These results suggest that COX activity is the same in both groups.
One explanation for this is that COX-2 activity has been maximally induced by PMA
and any original difference in COX activity has been lost.
Significant PGEM production occurred in the chorion, which is likely to reflect PGE2
production because of the metabolising capacity of the chorion for prostaglandins via
15-hydroxy-prostaglandin dehydrogenase (PGDH), the predominant enzyme in this
tissue (Okazaki et al, 1981a). PGFM, reflecting PGF2a production, was substantially
less than PGE2/PGEM. These results are in accordance with Okazaki et al. (1981a).
We found no difference in the metabolism of added PGE2 and PGF2oc to their
respective metabolites confirming the report of Cheung and Challis (1989) who
demonstrated no change in the metabolism of PGE2 added to cell cultures of chorion
obtained pre- and post-labour. This is compatible with the finding that PGDH
localisation in the placenta and membranes is not altered in association with labour
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(Cheung et al, 1990), although it has been demonstrated that PGDH mRNA in chorio-
decidua is reduced in assocation with spontaneous labour (Sangha et al, 1994). It
therefore appears that the increase in prostaglandin concentrations associated with
spontaneous labour are not the result of a decrease in metabolic activity within the
chorion.
Mifepristone (RU 486) is a well established medical abortifacient and has more
recently been successfully employed as an agent for labour induction at term (Frydman
et al, 1992). In vitro studies exploring the effect of RU 486 on endometrial (Kelly et
al, 1986b) and early decidual cells (Smith and Kelly, 1987) have shown that
prostaglandin synthesis is stimulated, and metabolism inhibited by the antiprogestin.
In addition, work in the guinea-pig has shown decreased prostaglandin metabolism in
myometrium and chorion following in vivo treatment with RU 486 (Kelly and
Bukman, 1990). In our experiment, there was no difference in the basal production of
prostaglandin metabolites by the chorion explants following in vitro treatment with
RU 486. This was the same for both spontaneous labour and elective section tissue.
However, the metabolism of exogenous PGE2 to PGEM was significantly reduced in
the spontaneous labour tissue following RU 486 treatment. A similar trend was seen
in the metabolism of exogenous PGF2ot in the spontaneous labour group, although
this did not reach significance. There was no decrease in the metabolism of either
prostaglandin by elective section tissue. These findings point to a reduction in the
activity or amount of prostaglandin dehydrogenase in the tissue following treatment
with RU 486. Recent work on decidua obtained from women pre-treated with
RU 486 in early pregnancy has shown, by both a direct enzymatic method and
immunohistochemistry, that the activity of PGDH is reduced in this tissue compared
with control (Cheng et al, 1993). This decrease in the metabolic capacity of the
chorion following treatment with RU 486 would reduce the threshold for
prostaglandin synthesis necessary to generate uterine activity and could explain the
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clinical effects of this agent with regard to labour induction. It was surprising that the
reduction in PGE2 metabolism following treatment with RU 486 was confined to
spontaneous labour tissue and was not found in caesarean section tissue. Although
basal levels were comparable there may still be a lower degree of prostaglandin
dehydrogenase activity in tissues obtained following spontaneous labour which may
not be evident under basal conditions in the culture system. When RU486 is added an
additive or synergistic effect may result, so explaining the results seen in the
experiments on chorion taken from women in spontaneous labour. Such a lower
degree of prostaglandin metabolism within the tissue with RU 486 may be in keeping
with previous in vivo studies (Cheng et al, 1993). The increase in prostaglandin
concentrations at the level of the fetal membranes which would result from such
inhibition of metabolism could contribute to the enhanced uterine activity seen both in
spontaneous labour and following treatment with RU486. Clearly an endogenous
tissue factor associated with labour is required as the effect was not seen with tissues
treated with RU 486 taken from women not in labour. It is also possible that the
difference between changes in metabolism seen following in vivo treatment compared
with that following in vitro treatment with RU 486 may reflect an intermediate step in
this process.
Dexamethasone has been shown to inhibit prostaglandin production from placental and
amnion cell cultures (Riley et al, 1992). This occurred in a dose dependent manner
and the addition of arachidonic acid to the placental cell cultures did not abolish the
inhibitory effect of dexamethasone suggesting that this steroid is acting at the level of
COX activity. An alternative mechanism, resulting in decreased prostaglandin
concentrations, would be an increase in PGDH activity with an associated increase in
prostaglandin metabolism. An increase in the tissue activity of PGDH in rat lung and
kidney following treatment with prednisolone has been reported (Moore and Hoult,
1980). However, we were unable to demonstrate increased prostaglandin metabolism
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in response to dexamethasone in our chorion explants. Similarly, Gibb et al (1988)
were unable to demonstrate an increase in prostaglandin metabolism to account for the
reduction in PGE2 output by their chorion cells incubated in the presence of
dexamethasone.
In the sheep, progesterone withdrawal is a prerequisite of the onset of labour. In
humans, there is no decrease in circulating systemic progesterone concentrations prior
to the onset of spontaneous labour. However, systemic steroid concentrations may
not reflect local changes in steroid environment within the fetal membranes which may
control the process of parturition in a paracrine fashion. In our experiment the addition
of progesterone had no effect on prostaglandin metabolism. This is in contrast with
the inhibitory effect of RU 486. One possible explanation for this is that endogenous
progesterone is exerting tonic control over prostaglandin metabolism which could not
therefore be altered by additional progesterone, but could be overcome by the
antiprogestin.
In summary, this study has shown that prostaglandin synthesis by fetal membranes is
increased in association with parturition, but that there is no alteration in prostaglandin
metabolism by chorion in association with labour. However, metabolism in
spontaneous labour tissue can be inhibited by the addition of RU 486.
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Chapter Five
The Influence of Amniotic Fluid on Prostaglandin Synthesis and
Metabolism in Human Fetal Membranes.
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Introduction.
As previously discussed, prostaglandins are thought by many investigators to be
central to the process of parturition. Since amnion is principally involved in PGE2
synthesis it has been extensively investigated as a potential regulator of prostaglandin
dynamics in association with parturition.
Amnion is an avascular tissue which is in contact with both the maternal and fetal
environment. Production of PGE2 could therefore be regulated by a factor(s) present
in amniotic fluid, the nature of which may be controlled by the fetus. Alternatively,
the decidua, which is maternal in origin, or the chorion, may influence prostaglandin
production by the amnion. Amniotic fluid contains stimulators and inhibitors of
prostaglandin production. An endogenous inhibitor of prostaglandin synthase has
been demonstrated in amniotic fluid (Saeed et al, 1982), the activity of which
decreases with advancing gestation and the onset of spontaneous labour. This
suggests that the amnion is under tonic inhibition which is gradually lost as pregnancy
progresses. Further evidence supporting the role of inhibitory activities includes the
finding that conditioned media from amnion obtained at caesarean section will inhibit
endometrial cell prostaglandin output (Manzai and Liggins, 1984), and that amniotic
fluid contains compounds that appear to inhibit phospholipase activity (Wilson et al,
1985). Stimulatory activities exist in amniotic fluid (Dowling et al, 1991; Cohen et al,
1985) and there is an increase in this activity with advancing gestation. There is
therefore a reciprocal change in the stimulatory and inhibitory properties of amniotic
fluid that is gestation-dependent (Cohen et al, 1985). Examples of agents that
stimulate amnion cell prostaglandin production include epidermal growth factor
(EGF), transforming growth factor a (TGFa) and platelet activating factor (PAF), all
of which are present in amniotic fluid in increasing concentrations during labour
(Mitchell, 1988b; Romero et al, 1989b).
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The chorion is an important site of prostaglandin metabolism, and any change in
metabolic activity within this tissue could significantly alter active prostaglandin
concentrations. Since amniotic fluid contains factors which influence prostaglandin
production by amnion, it is possible that these agents could also alter the metabolic
activity of the chorion. As no previous studies have assessed the effect of amniotic
fluid on production and metabolism simultaneously, the purpose of this study was to
determine the effect of amniotic fluid on prostaglandin production and metabolism by
the fetal membranes, amnion and chorion.
Subjects and Methods.
Amniotic fluid was collected from two groups of pregnant women at term (37-42
weeks) with an uncomplicated pregnancy. The first group laboured spontaneously
and achieved a vaginal delivery without oxytocin augmentation (n=24); the second
group was delivered by elective caesarean section for either breech presentation or
previous caesarean section (n=24). Fetal membranes were collected from a third
group of women undergoing uncomplicated elective caesarean section at term (n=4).
Cell Culture Preparation.
Amnion and chorion cell cultures, at a density of 2xl05 cells per well, were prepared
as described in section 2.2.1. All cultures were maintained for seven days, at which
time the cells remained at confluence and there was no evidence of bacterial
contamination.
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Effect ofamniotic fluid on amnion and chorion prostaglandin production:
The plates of amnion and chorion were incubated in humidified 95% air; 5% CO2 at
37 C for 24 hours. Amniotic fluid obtained at elective caesarean section (n=6) and
following spontaneous labour (n=6) was added to the cells in volumes of 50, 100, 200
and 400 p.L. Cells were also incubated in media alone, to act as control, and with
phorbol myristoyl acetate lOOnM (Sigma, UK) to confirm that prostaglandin synthesis
could be induced in these preparations. The total volume of each well was maintained
at 1 mL. Amniotic fluid (100|iL) from each subject was also incubated alone for
estimation of background primary prostaglandins and their metabolites. All
experiments were performed in duplicate. The plates were incubated for a further 24
hours and then 0.5mL aspirated from each well for prostaglandin measurement. The
above experiment was repeated on a second set of fetal membranes using amniotic
fluid from different subjects (again, n=6 for both groups).
Amniotic fluid and chorion cell metabolism ofexogenous prostaglandins:
Plates of chorion cells were incubated for 24 hours in humidified 95% air; 5% CO2 at
37 C. Amniotic fluid collected following elective caesarean section (n=6) and
spontaneous labour and delivery (n=6) was added to the cells and the plates incubated
for a further 24 hours. Chorion cells and 400|lL of each amniotic fluid sample were
incubated alone to enable estimation of background levels of the primary
prostaglandins and their metabolites. The following additions were made (final
concentrations): 500ng PGE2 (Upjohn Ltd, UK) and 500ng PGF2« (Upjohn Ltd,
UK). For the final four hour incubation the plates therefore comprised wells
containing: chorion cells alone; cells+400)J,L amniotic fluid+500ng PGE2;
cells+400p.L amniotic fluid+500ng PGF2«; cells+500ng PGE2 (control); cells+500ng
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PGF2« (control); 400|iL amniotic fluid alone. The final incubation volume in all wells
was lmL. All experiments were performed in duplicate. The incubation fluid
(0.5mL) was oximated and stored pending radioimmunoassay. The experiment was
repeated on a second set of chorion with different amniotic fluids (again, n=6 for each
group).
Radioimmunoassay.
The competitive binding radioimmunoassay employed in these experiments is
described in detail in section 2.6.
Statistical Analysis.
One and two factor analysis of variance (ANOVA) was used to analyse the data.
Where the data were not normally distributed, log transformation was employed prior
to ANOVA. Background concentrations of prostaglandins and their metabolites in the
amniotic fluid were subtracted in all experiments prior to statistical analysis.
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Results.
The effect ofamniotic fluid on prostaglandin production by amnion and chorion:
The stimulatory effect of amniotic fluid, in a dose-dependent manner, on prostaglandin
E2 and prostaglandin F2a production by amnion is illustrated in Figures 5.1 and 5.2
respectively. Amniotic fluid from spontaneous labour stimulated significantly greater
production of both prostaglandins compared with elective caesarean section fluid:
PGE2, p<0.001; PGF2a> p<0.05. Amniotic fluid from spontaneous labour produced
significantly more PGEM from chorion, in a dose-dependent manner, than caesarean
section amniotic fluid, p<0.0001 (Fig. 5.3). This was not confirmed in the second
culture. Production of PGFM by chorion cells, reflecting PGF2a> was significantly
greater in the presence of spontaneous labour amniotic fluid, compared with elective











































































The effect of amniotic fluid on metabolism of exogenous prostaglandins by chorion
cells:
Spontaneous labour and elective section amniotic fluid, in a dose of 400|J,L,
significantly stimulated PGEM and PGFM production in chorion cell culture
compared with control, p<0.05 (Fig. 5.5) The production of both PGEM and PGFM
was significantly greater in the presence of spontaneous labour amniotic fluid
compared with elective section fluid, p<0.05. In addition, the responsiveness of the
chorion cells to phorbol myristoyl acetate, a stimulator of protein kinase C, is
illustrated in Figure 5.5. In both cultures, amniotic fluid from elective section
stimulated significantly more PGEM production compared with PGFM, p< 0.0005
(Fig. 5.6). Amniotic fluid from spontaneous labour stimulated significantly more
PGFM production in comparison to PGEM, p< 0.05 (Fig. 5.6), but was not
statistically significant in the second culture (p= 0.056). The ratio of PGFM to PGEM
production was 0.38 for chorion cells cultured with elective section amniotic fluid,
compared with and FM:EM ratio of 4.6 when cultured in the presence of spontaneous
labour amniotic fluid. This represents a 12-fold increase in FM:EM ratio.
There was no difference in PGEM production by chorion, following the addition of
500ng PGE2, when cultured in the presence of amniotic fluid from spontaneous labour
or elective section compared with control (cells+500 ng PGE2) in both cultures (Fig.
5.7). Similarly, there was no difference in the production of PGFM, following the
addition of 500ng PGF2a, by chorion cells cultured in the presence of amniotic fluid
from elective section (both cultures) (Fig. 5.8). Amniotic fluid from spontaneous
labour had no effect on PGFM production, following addition of PGF2a, in one
culture, and stimulated significantly greater PGFM production compared with control
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We have demonstrated that amniotic fluid from spontaneous labour and elective
caesarean section at term is capable of stimulating prostaglandin production by amnion
cell culture. This is in keeping with other workers who have shown increased PGE2
production by amnion cells (Dowling et al, 1991) and bovine seminal vesicles (Cohen
et al, 1985) incubated with amniotic fluid. In our experiments PGE2 production was
stimulated by amniotic fluid in a dose-dependent manner, confirming the findings of
Mitchell et al (1984a) who demonstrated PGE2 stimulatory activity in amniotic fluid at
all gestations. However, these workers did not find a difference in PGE2 production
in relation to parturition, unlike our experiments where amniotic fluid obtained at
spontaneous labour had a significantly greater stimulatory effect than elective section
fluid. Similarly, PGF2a production was stimulated in these experiments and again
responded to amniotic fluid in a dose-dependent manner. The response to
spontaneous labour fluid was significantly greater than elective section fluid. It has
previously been demonstrated that amniotic fluid will stimulate PGF20C production by
amnion, chorion and decidua (Rehnstrpm et al, 1983) but in these experiments there
was no difference between spontaneous labour and elective section fluid. Reddi et al
(1987) revealed that amniotic fluid obtained late in labour significantly stimulated
PGF20C production by sheep seminal vesicle prostaglandin synthase, whereas fluid
obtained before labour had no such effect. In our amnion cells caesarean section fluid
had little effect on PGF2« production, although a significant dose-response curve was
achieved in one culture. In all cultures significantly more PGE2 was produced
compared with PGF2« in response to both spontaneous labour and elective section
fluid confirming that this is the major prostanoid synthesised by amnion (Okazaki et al,
1981a; Skinner and Challis, 1985).
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There was some variability in the response of the chorion cell cultures to amniotic
fluid. PGEM production, reflecting PGE2 synthesis, was stimulated by spontaneous
labour amniotic fluid in a dose-dependent manner in one culture. Elective section
amniotic fluid had a dose-related stimulatory effect on PGEM production in both
cultures. Similarly, PGFM production, reflecting PGF2a synthesis, was stimulated
by amniotic fluid from the two groups in both cultures. There was a significant
difference in the stimulatory effect of spontaneous labour amniotic fluid compared with
that of elective section with regard to PGFM production. In the metabolism studies we
confirmed the stimulatory effect of amniotic fluid (400 (iL) from spontaneous labour
and elective section on PGEM and PGFM production in both chorion cultures,
although elective section fluid had no significant effect on PGFM production in one
culture. Spontaneous labour amniotic fluid stimulated significantly more PGEM and
PGFM production compared with elective section fluid in both cultures. In all chorion
cultures elective section fluid stimulated significantly greater PGEM production than
PGFM, whereas spontaneous labour fluid, although not significant in all cultures,
tended to favour PGFM production.
We have shown, therefore, that amniotic fluid obtained at elective section and
spontaneous labour is capable of stimulating prostaglandin production by both amnion
and chorion and that there is a preference for which prostaglandin is produced:
spontaneous labour favours PGE2 and PGFM production by amnion and chorion
respectively, while elective section fluid stimulates PGE2 synthesis by both tissues
(reflected as PGEM in chorion). These findings are in keeping with the fact that under
basal conditions PGEM is the main product of the chorion (Cheung and Challis,
1989), whereas PGF20C is thought to be integral to the maintenance of established
labour, with concentrations of this prostaglandin increasing as cervical dilatation
advances (Keirse et al, 1974; MacDonald and Casey, 1993) There is a significant
difference in the stimulatory activity of the amniotic fluid in relation to parturition, but
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we do not know from these experiments whether this is a result of gestationally related
changes in inhibitory or stimulatory properties of the fluid. These findings are not
dissimilar from those of Reddi et al (1987) who found that as labour progressed there
was a simultaneous reduction in stimulatory activity and increase in inhibitory activity
in amniotic fluid with respect to PGE2 production, whilst the converse was true for
PGF2a production.
It has been postulated that changes in the metabolic capacity of the chorion may be just
as important in the regulation of prostaglandin concentrations as any direct stimulatory
effect on prostaglandin synthesis (Khan et al, 1991). In this study amniotic fluid from
spontaneous labour or elective section had no effect on the concentration of PGEM or
PGFM recovered from the chorion cell cultures, following the addition of PGE2 and
PGF2« respectively, compared with control (cells + PG alone). These findings
suggest that amniotic fluid has no significant effect on the metabolic pathway for
prostaglandins in chorion, and in particular that there is no reduction in metabolism in
relation to labour which could result in the increased prostaglandin concentrations seen
at this time. This is in keeping with previous reports showing no change in
prostaglandin metabolism in association with spontaneous labour (Skinner and
Challis, 1985) and the results discussed in chapter 4. This also accords with the
finding that the localisation of immunoreactive PGDH in chorion does not change with
labour (Cheung et al, 1990). In contrast, in cases of preterm labour associated with
chorioamnionitis, it has been demonstrated that immunoreactive staining for PGDH is
significantly reduced as a result of trophoblast destruction (Van Meir et al, 1996).
This would enable prostaglandins to escape metabolism and thus facilitate myometrial
contractility. In the present study, the metabolism by chorion of exogenous PGE2 to
its inactive metabolite PGEM was significantly greater than that of exogenous PGF2«
to PGFM (p=0.0001). The same was true in the presence of spontaneous labour
amniotic fluid (p<0.005) and elective section fluid (p=0.0001). This is in keeping
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with the fact that the prostaglandin metabolising enzymes are more able to inactivate
PGE2 compared with PGF2« (Casey et al, 1989b; Ishihara et al, 1991).
We have confirmed that amniotic fluid can stimulate prostaglandin production by fetal
membranes and demonstrated that it has no effect on prostaglandin metabolism in these
tissues. What factor(s) present in amniotic fluid is responsible for the increased
production has still to be clarified. It has been hypothesised that, since amniotic fluid
at term is largely composed of fetal urine, the signal for the onset of parturition may
come from the appropriately mature fetus. (Mitchell, 1984b) Fetal urine has been
shown to stimulate PGE2 production by amnion in a concentration-dependent manner
(Casey et al, 1983), and urine obtained from fetuses following spontaneous labour
stimulates greater production of PGE2 compared with fetuses delivered by elective
caesarean section (Strickland et al, 1982). Alternatively, recruitment of mediators such
as interleukins and TNFa, resulting in an inflammatory process, may play a role in the
onset of parturition, and prostaglandins will enhance the inflammatory role of such
cytokines. Indeed, such a mechanism has been proposed for the changes associated
with cervical ripening (Eiggins, 1981). An example of cytokine recruitment is the
increased concentration of IE-1 (3 in amniotic fluid which has been reported in women
in preterm labour associated with infection (Romero et al, 1989e) and in women in
spontaneous labour at term (Romero et al, 1990a), and this cytokine is known to be
capable of stimulating PGE2 production by amnion cell culture (Mitchell et al, 1993b).
Although we have looked at prostaglandin synthesis and metabolism by fetal
membranes in parallel, it must be remembered that the in vitro situation is not
necessarily a true reflection of events occurring in vivo. The amnion and chorion were
separated in these experiments and therefore any modulatory effect that these tissues
may exert on each other will have been lost. Chorion-conditioned medium stimulates
PGE2 production by amnion (Lundin-Schiller et al, 1990b), and chorion cells
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themselves are capable of interleukin production (Lundin-Schiller and Mitchell,
1991b). Importantly, the membranes were devoid of decidua, which may influence
these avascular tissues in a paracrine fashion. In particular, studies have shown that a
decidual product is capable of inhibiting prostaglandin production by amnion (Romero
et al, 1987) and that decidual cells contain an inhibitor of cyclooxygenase I (Sun et al,
1994).
In summary, these experiments confirm the stimulatory effect of amniotic fluid on
prostaglandin production by amnion and chorion and demonstrate that this activity is
greater in association with spontaneous labour. However, labour had no effect on the
metabolising capacity of the chorion suggesting that it is increased production rather
than a reduction in prostaglandin metabolism which is responsible for the increased
prostaglandin concentrations related to parturition.
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Chapter Six
Mechanisms Involved in the Stimulatory Effect of Amniotic Fluid on
Prostaglandin Production by Human Fetal Membranes.
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Introduction.
The amnion is the most extensively investigated of the intrauterine tissues with regard
to the control of prostaglandin production. Since prostaglandins are not stored, but
rather released immediately following synthesis in response to external stimuli, the
major control of prostaglandin action lies with the regulation of its synthesis. The
release of arachidonic acid, the obligatory precursor of prostaglandins of the 2-series,
from membrane phospholipids is thought to be a rate-limiting step in prostaglandin
synthesis. Protein kinase C (PKC) is a calcium- and lipid-dependent enzyme which
has a crucial role in cell surface signal transduction, leading to the activation of many
cellular functions. PKC activity has been identified in human amnion, and it has been
suggested that PKC participates in the mobilisation of arachidonic acid, and the
activation of cyclooxygenase (COX), thus facilitating prostaglandin synthesis.
Two isoenzymes of COX have been identified and each enzyme is the product of a
separate gene (Xie et al, 1993; Wen et al, 1993). COX-1 is constitutively expressed in
fetal membranes, whereas COX-2 is the inducible form of the enzyme whose
expression can be stimulated by a number of agonists (O'Sullivan et al, 1992; Mitchell
et al, 1993b). COX activity is known to increase with advancing gestation, with a
further increase in association with labour (Teixeira et al, 1993). Investigation of
mRNA levels for COX-1 and 2 in human amnion has revealed that COX-2 mRNA,
but not COX-1 mRNA, is increased in association with labour onset, suggesting that
increased COX-2 expression is responsible for the increased COX activity seen at this
time (Hirst et al, 1995). This finding of increased COX-2 expression in association
with labour has been confirmed by other investigators (Slater et al, 1995), lending
further support to the theory that COX-2 activity may be of principle importance in
producing the increase in prostaglandin concentrations seen with the onset of labour.
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The purpose of this study is to investigate potential mechanisms involved in the
stimulatory effect of amniotic fluid on prostaglandin production by fetal membranes.
Subjects and Methods.
Amniotic fluid was collected from two groups of pregnant women at term (37-42
weeks) with an uncomplicated pregnancy. The first group laboured spontaneously
and achieved a vaginal delivery without oxytocin augmentation (n=6); the second
group was delivered by elective caesarean section for either breech presentation or
previous caesarean section (n=6). Fetal membranes were collected from a third group
of women undergoing uncomplicated elective caesarean section at term (n=2).
Mechanisms ofstimulation ofprostaglandin production by amniotic fluid:
Fetal membranes were collected from women undergoing elective caesarean section
and amnion and chorion cell cultures prepared as described in section 2.2.1. A cell
density of 2x10 5 per well was employed The plates were incubated in humidified
95% air; 5% CO2 at 37 C for 24 hours. Amniotic fluid obtained at elective caesarean
section (n=3) and following spontaneous labour and delivery (n=3) was used in the
experiment. 400 |lL of amniotic fluid was added to each well before addition of the
following treatments (final concentrations): 1 |lM and 10 [iM staurosporine (inhibitor
of PKC); 1 |LtM and 10 (tM genestein (inhibitor of tyrosine kinase); 2 |Llg and 4 |ig
actinomycin D (inhibitor of transcription); 10 |ig and 20 |ig cycloheximide (inhibitor of
translation). The doses of the above agents were chosen because they are within the
range expected to inhibit prostaglandin production should the stimulatory effect of
amniotic fluid be dependent on transcription, translation, protein kinase C or tyrosine
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kinase alone or in combination (Zakar and Olson, 1988; Zakar and Olson, 1992;
Pollard et al, 1993). The effect of a 10-fold increase in dose was studied for all agents
apart from actinomycin D owing to limited substrate and the fact that the effect of
actinomycin D on radiolabeled amino acid uptake plateaus at concentrations 4
|lg/mL (Zakar and Olson, 1988).
Cells were incubated in culture medium alone and in the presence of amniotic fluid to
act as control. In addition, 400 |lL of amniotic fluid was incubated alone for
estimation of background primary prostaglandin and metabolite concentrations. The
final incubation volume in all wells was 1 mL and all experiments were performed in
duplicate. The plates were incubated for a further 24 hours in humidified 95% air; 5%
CO2 at 37 C. The incubation medium was oximated and stored pending
radioimmunoassay. The experiment was repeated on a second set of amnion and
chorion cell cultures with different amniotic fluids (again, n=3 for each group).
Radioimmunoassay.
The competitive binding radioimmunoassay described in section 2.6 was employed in
these experiments.
Statistical Analysis
One and two factor analysis of variance (ANOVA) were used to analyse the data.
Where the data were not normally distributed, log transformation was employed prior
to ANOVA. Background prostaglandin and metabolite concentrations in amniotic fluid




Spontaneous labour and elective section amniotic fluid significantly stimulated PGE2
production by amnion in both cultures (p<0.05), and this effect was significantly
greater in the presence of spontaneous labour fluid compared with elective section fluid
(p<0.05). The same was true for PGEM production by chorion cells in both cultures
(p<0.05). Spontaneous labour amniotic fluid significantly stimulated PGFM
production by chorion in both cultures (p<0.05), but elective section amniotic fluid
had no effect in either culture.
Cycloheximide (Figs. 6.2, 6.3)
Cycloheximide significantly inhibited baseline PGE2 production by amnion (p<0.05).
The stimulatory effect of amniotic fluid was also significantly inhibited but not
abolished in the presence of cycloheximide, at both concentrations, compared with
control (p<0.05).
Similarly, cycloheximide, 10 and 20 jLXg, significantly inhibited baseline PGEM
production by chorion, and significantly inhibited PGEM production previously
stimulated by spontaneous labour and elective section amniotic fluid (p<0.05).
Cycloheximide, at either concentration, had no effect on baseline or amniotic fluid-



































Actinomycin D (Figs. 6.4, 6.5)
Actinomycin D, 2 and 4 jLlg, significantly inhibited baseline PGE2 production by
amnion (p<0.05). The stimulatory effect of spontaneous labour amniotic fluid was
significantly inhibited at doses of 2 and 4 pg, and that of elective section fluid was
inhibited at a dose of 4 pg (p<0.05).
Actinomycin D had no effect on baseline PGEM production by chorion, but
significantly inhibited the stimulatory effect of spontaneous labour amniotic fluid at
doses of 2 and 4 pg (p<0.05). However, there was a variabiltiy in the response
between different cell cultures in that actinomycin D did not inhibit the stimulatory
effect of spontaneous labour amniotic fluid in the second cell culture. Actinomycin D
2 pg inhibited baseline PGFM production (p<0.05), but otherwise had no effect on
PGFM.
Genestein (Figs. 6.6, 6.7)
Genestein 10 pM significantly inhibited baseline PGE2 production (p<0.05). In
addition, the stimulatory effect of amniotic fluid from both groups was significantly
inhibited but not abolished by genestein 10 pM.
Genestein inhibited baseline PGEM production (p<0.05) and the stimulatory effect of
spontaneous labour amniotic fluid was inhibited by genestein 1 and 10 pM (p<0.05).
Genestein had no effect on elective section amniotic fluid-stimulated PGEM
production. Genestein had no effect on PGFM production by chorion.
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Staurosporine (Figs. 6.8, 6.9)
Staurosporine, 1 and 10 pM, significantly inhibited baseline PGE2 production
(p<0.05). The stimulatory effect of amniotic fluid from both groups was also
inhibited in the presence of staurosporine (p<0.05). At a dose of 10 pM staurosporine
completely abolished the stimulatory effect of elective section amniotic fluid. This was
not the case for spontaneous labour fluid which continued to stimulate greater PGE2
production compared with cells treated with staurosporine alone.
Staurosporine, 1 and 10 pM, significantly inhibited baseline PGEM production by
chorion (p<0.05), and also inhibited the stimulatory effect of amniotic fluid from both
spontaneous labour and elective section (p<0.05). Staurosporine had no effect on
baseline PGFM production by chorion, but significantly inhibited the stimulatory





































The results of these experiments confirm the stimulatory effect of amniotic fluid
obtained at spontaneous labour and elective caesarean section on PGE2 production by
amnion, as demonstrated by other investigators (Dowling et al, 1991; Cohen et al,
1985). Spontaneous labour amniotic fluid promoted significantly greater
prostaglandin production compared with caesarean section fluid suggesting the
presence of either increased stimulatory activity or decreased inhibitory activity in
association with labour. In addition, spontaneous labour amniotic fluid significantly
stimulated EM and FM production in chorion, reflecting increased prostaglandin
synthesis within this tissue, which is in keeping with our previous findings (chapter
five).
Prostaglandin synthesis is regulated at a number of points. Protein kinase C, by acting
on phospholipase A2 (PLA2), can stimulate the direct release of substrate arachidonic
acid from phosphatidylethanolamine. This is supported by the finding that the PLA2
inhibitor quinacrine will prevent phorbol ester-induced stimulation of prostaglandin
synthesis, even in the presence of exogenous arachidonic acid (Sander and Myatt,
1990). Alternatively, PKC can increase arachidonic acid concentrations indirectly at
the level of phospholipase C, which mediates release of diacylglycerol (DAG) from
phosphatidylinositol, that is subsequently metabolised to arachidonic acid. The DAG
released serves to further enhance PKC activity. Via both of these mechanisms PKC
increases availability of arachidonic acid for conversion to the prostaglandin
endoperoxides, PGG2 and PGH2, a reaction which is dependent on the enzyme COX.
In addition to its effect on substrate release, PKC is also able to stimulate transcription
and translation, resulting in de novo synthesis of COX enzyme. This is demonstrated
by the finding that new protein and messenger RNA synthesis are essential for the
increased prostaglandin synthesis seen in response to phorbol esters, known
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stimulators of PKC, and that irreversible inhibition of COX by acetylsalicylic acid
pretreatment does not diminish their stimulatory effect (Zakar and Olson, 1988).
Stimulatory factors in amniotic fluid could therefore increase prostaglandin production
by a direct effect on PKC, resulting in increased substrate release and COX synthesis.
Alternatively, the site of action may be at the level of the phospholipases, again leading
to increased substrate availability. The DAG produced in these reactions could then
have a secondary effect on PKC, and thus COX synthesis.
We employed staurosporine (a PKC inhibitor) to investigate a possible role for PKC in
the increased prostaglandin production by amnion seen in response to amniotic fluid.
Phospholipid-dependent PKC activity has been demonstrated in human amnion
(Okazaki et al, 1984), and activation of PKC has been associated with stimulation of
prostaglandin synthesis in the initiation and maintenance of parturition (Olson et al,
1990). Known activators of PKC include phorbol esters, in particular 12-0-
tetradeconylphorbol-13-acetate (TPA), and they have a stimulatory effect on
prostaglandin production by amnion (Zakar and Olson, 1988; Lytton and Mitchell,
1988). This effect can be inhibited by a number of PKC inhibitors including
staurosporine (Sander and Myatt, 1990; Zakar and Olson, 1992). In our experiments
the addition of staurosporine to the amnion cultures resulted in significant inhibition of
basal prostaglandin synthesis, and inhibition of amniotic fluid-stimulated prostaglandin
synthesis, both spontaneous labour and elective section. The finding of decreased
basal prostaglandin synthesis suggests that in our amnion cultures PKC has a role in
maintaining basal prostaglandin production, but is not the sole mechanism involved
since prostaglandin synthesis was not abolished by staurosporine. This is in contrast
to the findings of other investigators who showed that staurosporine had no significant
effect on unstimulated prostaglandin production (Zakar and Olson, 1992; Mitchell et
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al, 1994), and may reflect differences in the duration of the cell cultures as the cells
ability to respond changes with time (Gibb et al, 1990).
The inhibition of amniotic fluid-stimulated prostaglandin synthesis by staurosporine
confirms that PKC is involved in this process. However, spontaneous labour
amniotic fluid continued to stimulate significantly greater prostaglandin production
than caesarean section amniotic fluid, or basal output suggesting an additional
mechanism/s in this process. The stimulatory effect of caesarean section amniotic fluid
was completely abolished by staurosporine 10 p.M, reducing prostaglandin production
to similar levels as basal output under the same conditions. This could be due either to
the presence of lower concentrations of stimulatory factors in amniotic fluid prior to
the onset of labour, or to the absence of stimulatory factors necessary to activate
alternative or additional mechanisms of prostaglandin synthesis.
Cycloheximide significantly inhibited baseline prostaglandin production in our
cultures, indicating that new protein synthesis, is occurring in the amnion cultures at
this time. This is in keeping with the findings of Zakar and Olson (1992), and
confirms that the PGE2 accumulating in the medium was produced de novo in a
protein synthesis dependent manner. Cycloheximide consistently inhibited the
stimulatory effect of amniotic fluid, spontaneous and elective section, on prostaglandin
production, indicating that new protein synthesis is necessary in this process. This
suggests that COX production may be reduced. Since the inhibitory effect of
cyclohexamide on amniotic fluid stimulated prostaglandin production is greater than its
effect on baseline PG production, it may be production of COX-2 that is being
inhibited. Amniotic fluid may therefore contain a factor which increases mRNA for
COX-2.
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Actinomycin D, an RNA synthesis inhibitor, significantly inhibited basal prostaglandin
production by amnion suggesting that continuous RNA synthesis was contributing to
prostaglandin output by these cell cultures at that time point in the culture system. This
is in contrast to the findings of Zakar and Olson (1992), who found that unstimulated
prostaglandin output was not affected by actinomycin D. Our findings with regard to
the effect of actinomycin D on amniotic fluid-stimulated prostaglandin production were
inconsistent between the two different cultures. However, within each culture the
trends were the same suggesting that culture variability may play a part in this
inconsistency. The effect of actinomycin D is known to be dose-dependent (Lytton
and Mitchell, 1988; Zakar and Olson, 1992), with low concentrations leading to
stimulation of phorbol ester-induced prostaglandin production, and high
concentrations abolishing this effect, but at the doses employed in our experiments we
would have expected inhibition if RNA synthesis was essential for the effect seen with
amniotic fluid, and this reached significance in one culture. The finding that new
protein synthesis, and perhaps mRNA production, are required for the stimulatory
effect of amniotic fluid on prostaglandin production suggests that this effect is
mediated by new enzyme synthesis, and it may be production of cyclooxygenase that
is being inhibited by these agents. However, it cannot be assumed that cycloheximide
and actinomycin D are inhibiting transcription and translation processes specific to
amniotic fluid since these agents will inhibit all such mechanisms within cell cultures.
Again, the finding that spontaneous labour amniotic fluid continued to stimulate
significantly more prostaglandin production by cells treated with cycloheximide than
caesarean section amniotic fluid suggests the presence of additional factors in
spontaneous labour fluid which may increase prostaglandin production by stimulating
alternative pathways. Or, this may simply reflect an increased concentration of a
single stimulatory factor in association with labour. Alternatively, caesarean section
fluid may promote translation of existing mRNA leading to increased protein
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synthesis, presumably COX-2, whereas spontaneous labour amniotic fluid may
stimulate both transcription and translation resulting in greater total protein production.
Futhermore, fluid from spontaneous labour may have a greater effect on substrate
availability (PLA2 / PKC) which would promote increased prostaglandin production
without increasing the amount of COX in the cell.
We have demonstrated that in these amnion cultures the stimulatory effect of amniotic
fluid on prostaglandin production is mediated, at least in part, by protein kinase C
activation and new protein synthesis. In our chorion cultures, the stimulatory effects
of amniotic fluid, spontaneous labour and elective section, were inhibited by
staurosporine and cyclohexamide implicating PKC activity and new protein synthesis
as seen in the amnion cultures. New mRNA appears to be involved in the stimulatory
effect of spontaneous labour amniotic fluid. Thus, there is probably a dual mechanism
operating, one increasing enzyme production and one increasing substrate availability,
and PKC could be responsible for both.
In addition to PKC, tyrosine kinase has a pivotal role in controlling signalling within
the cell, and hence influencing cellular metabolism, the cell cycle and growth. The
receptors for a number of growth factors including insulin and the cytokine epidermal
growth factor (EGF) have been shown to possess tyrosine kinase stimulatory activity
(White, 1991). Activation of tyrosine kinase systems results in concommitant
activation of several different protein kinases, and it is becoming increasingly apparent
that there is a complex cascade of cell signalling involving significant interplay
between various transduction pathways (Gupta, 1993). For example, it has been
suggested that activation of PKC by TPA may result in activation, either directly or
indirectly, of a number of tyrosine specific kinases (Gilmore and Martin, 1983). We
investigated a potential role for tyrosine kinase in the amniotic fluid-stimulated increase
in prostaglandin production by employing the tyrosine kinase inhibitor genestein in our
177
cell cultures. The effect of spontaneous labour amniotic fluid was consistently
inhibited in both amnion and chorion cell cultures. This finding demonstrates that
activation of tyrosine kinase, either directly or indirectly, is occurring in response to
amniotic fluid, and confirms that signal tranduction processes are important in
mediating amniotic fluid's stimulatory effect.
We have not attempted to characterise regulatory substances in amniotic fluid and
therefore can only speculate as to what these agents might be. There is considerable
interest in the role of cytokines in the process of parturition, which stems from
investigations into preterm labour associated with intraamniotic infection. In this
setting significantly higher concentrations of inflammatory cytokines such as IL-1,
IL-6 and TNFa are found in the amniotic fluid compared with women in preterm
labour in the absence of infection ( Romero et al, 1989b; Romero et al, 1989e; Romero
et al, 1990b). Cytokines are also found in higher concentrations in amniotic fluid
obtained from spontaneous labour at term compared with term elective caesarean
section, implying a role for them in the onset of labour at this time. Indeed, it has been
suggested that parturition is an inflammatory-mediated process, similar to the events
taking place during cervical ripening. Such agents could be involved in the regulatory
process of prostaglandin production through PKC and tyrosine kinase stimulation, and
stimulation of transcription and translation for essential enzymes such as
cyclooxygenase.
Chorion and decidua are able to synthesise a number of cytokines including IL-1,
IL-6, IL-8 and TNFa (Romero et al, 1989c; Dudley et al, 1992; Casey et al, 1989a),
and these cytokines are capable of regulating their own production and that of each
other (Mitchell et al, 1993a). In addition, it has been demonstrated that cytokines can
stimulate prostaglandin production by amnion and chorion (Mitchell et al, 1991b; Kent
et al, 1993; Romero et al, 1989d; Lundin-Schiller and Mitchell, 1991b) thus facilitating
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myometrial contractility. There is therefore potential for a complex network of events
at the choriodecidual interface which could in turn, via the amniotic fluid, influence the
timing of parturition.
One attractive cytokine for a role in the regulation of parturition is EGF. This is a
single chain polypeptide which may in part be derived from the fetal kidney (Haigh et
al, 1989) supporting the hypothesis of fetal signalling in the control of labour.
EGF/TGFa activity, as measured by radioreceptor assay, has been shown to be
increased four fold in amniotic fluid collected from women in spontaneous labour
(Romero et al, 1989f). EGF binding sites have been demonstrated in fetal membranes
and decidua (Rao et al, 1984), and EGF is capable of stimulating PGE2 production by
human amnion (Mitchell, 1987) and chorion (Lundin-Schiller and Mitchell, 1991a).
The mechanisms involved in the stimulatory actions of cytokines on prostaglandin
production within the intrauterine tissues have been investigated in a number of
studies. For example, phorbol myristoyl acetate (PMA) will potentiate the action of
EGF in stimulating prostaglandin production by amnion cells (Kniss et al, 1990) and
this EGF-stimulated prostaglandin production is inhibited by staurosporine.
However, down regulation of PKC by prolonged exposure to phorbol ester did not
reduce the stimulatory effect of EGF. These findings suggest that PKC has a role in
modulating the action of this cytokine, but that PKC-independent pathways also exist
whereby EGF exerts its effect.
The function of PKC in fetal membrane prostaglandin production is, however,
complex as illustrated by the fact that the stimulatory effect of IF-1 (3 on amnion PGE2
production can be attenuated by down regulation of PKC, and in contrast
staurosporine has been shown to enhance the effects of IF-1 (3 (Mitchell et al, 1994). It
has been suggested that these contrasting results may be due to interaction at different
sites of the PKC molecule. An attractive alternative explanation is that the different
179
isoforms of PKC, which are now known to exist (Nishizuka, 1988), respond to
activators in a differential manner.
Mitchell et al (1993b) have demonstrated that IL-1 (3's stimulatory effect on amnion
PGE2 production does not occur until after two hours of incubation, implying an
induction process. This effect is dependent on new protein and RNA synthesis since it
is inhibited by cycloheximide and actinomycin D (at concentrations > 1 |lg and 10
jig/mL respectively). They also showed in these experiments that IL-1J3 treated cells
recovered more quickly from pretreatment with acetylsalicylic acid than controls,
suggesting that the action of IL-1 (3 involves induction of COX protein. Further
investigation employing Western blot analysis confirmed an increase in COX protein,
and Northern blot analysis demonstrated the presence ofmRNA for an inducible form
of COX, now known as COX-2.
Similar experiments have been conducted on chorion cell cultures (Pollard et al, 1993).
The stimulatory actions of IF-1(3, EGF and TNFa on PGE2 production in this tissue
are all inhibited by treatment with actinomycin D and cycloheximide, supporting a role
for new protein and mRNA synthesis. Again, recovery from acetylsalicylic acid
pretreatment was quicker in response to all three cytokines, suggesting that de novo
synthesis of COX is involved in mediating their effect. These investigators also found
that addition of exogenous arachidonic acid enhanced the stimulatory effect of EGF,
IL-1 (3 and TNFa on prostaglandin production, and concluded therefore that these
cytokines act to enhance conversion of arachidonic acid to prostaglandins, rather than
promote arachidonic acid release via phospholipase activation.
The experiments described in this chapter indicate that PKC and new protein synthesis
are important in the stimulatory effect of amniotic fluid and this would be compatible
with inflammatory mediators such as cytokines being central to this process.
180
Chapter Seven
Recombinant Human Relaxin as a Cervical Ripening Agent
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Introduction.
In order that induction of labour replicates the normal physiological process of
parturition as closely as possible, the question of cervical ripening must be addressed.
The success of labour induction is influenced by the state of the cervix. Induction of
labour in the presence of an unripe cervix is associated with an increase in both
maternal and neonatal morbidity (Calder, 1979). Cervical ripening occurs during the
phase known as pre-labour. Its exact mechanism remains unclear but the process
results in structural changes within the cervix making it more compliant. These
include a decrease in collagen concentration, an increase in water content and an
alteration in proteoglycan/glycosaminoglycan ratio within the tissue. It is this process
that we are striving to mimic when ripening the cervix pharmacologically. The ideal
cervical ripening agent should have a selective effect on the cervix without any
additional effect on uterine contractility, and in theory the polypeptide hormone relaxin
would meet these requirements.
Relaxin was first identified by Hisaw (1926) who demonstrated its capacity to promote
separation of the pubic symphysis in guinea-pigs. Relaxin facilitates connective tissue
remodelling, and in some animals also inhibits myometrial contractility. In most
species, cervical ripening prior to the onset of labour is associated with an increase in
serum relaxin concentrations. However, this is not the case in humans and the exact
role of this hormone in human parturition remains uncertain. Early clinical trials
(Eisenberg, 1957; Decker et al, 1958) employing porcine relaxin for cervical ripening
in human subjects reported conflicting results which probably reflected the impurity of
the agent at that time. The subsequent purification of porcine relaxin (Sherwood and
O'Byrne, 1974) led to renewed interest in this hormone. A number of studies showed
that porcine relaxin had some therapeutic benefit as a cervical ripening agent in women
(MacLennan et al, 1980; Evans et al, 1983), despite the primary peptide structure of
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porcine relaxin having only about 50% homology with that of human relaxin. The
development of recombinant human relaxin by Genentech Inc. (San Francisco, CA,
USA) has provided an agent that could potentially have superior cervical ripening
properties in women and has stimulated further research in this field.
Phase I studies conducted by Genentech demonstrated that recombinant human relaxin
was safe and not associated with serious adverse effects, and that there was no
maternal development of antibody to rhRIx following treatment (Spanski and Perlman,
1991; Spanski and Perlman, 1991). Phase II studies were therefore initiated in
Australia and the UK. Presented in this chapter are the results of the UK double-
blind, three-centre study investigating the effect of recombinant human relaxin,
administered as an intravaginal gel, on cervical ripening in pregnant women at term
with an unfavourable cervix.
Subjects and methods.
Ethical approval for this study was obtained from the local ethics committees of the
three participating centres.
Ninety-six women, comprising nulliparous and parous patients, were recruited to the
study. All women had a singleton pregnancy of at least 37 weeks gestation with a
cephalic presentation and a modified Bishop score (Calder 1974) of four or less.
Women with a uterine scar, ruptured membranes or evidence of placental abruption or
placenta praevia were not recruited to the study. Other exclusion criteria were
significant systemic disease, recent ingestion of aspirin or other non-steroidal anti¬
inflammatory drugs, fetal malformation, growth retardation or macrosomia and oligo-
or polyhydramnios. The decision to induce labour was made by the woman's
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attending obstetrician and written informed consent was obtained prior to recruitment.
The most common indications for induction were pregnancy induced hypertension and
prolonged pregnancy.
The study involved a randomised, double-blind comparison of four treatment
regimens: 0 (placebo), 1, 2 or 4 mg of recombinant human relaxin (rhRIx) in a gel
vehicle. The randomisation sequence was generated in blocks of four by the
Genentech Biostatistical Department and the code was stratified according to parity. A
randomisation list accompanied each drug shipment. Primiparous women were
assigned sequential numbers starting from the top of the list, and multiparous women
were assigned sequential numbers starting from the bottom of the list. The study
medication was supplied by Genentech Inc. as a two-part administration set: a
stoppered 20 cc glass vial of lyophilized rhRIx or placebo and a 5 cc syringe of gel.
The vial contained 0 mg or 12 mg rhRIx in isotonic citrate buffer. The syringe
delivered 3.0 mL of sterile 4% methylcellulose gel in isotonic citrate buffer. The active
doses were made by reconstituting 12 mg of lyophilized study medication in either 12,
6 or 3 mL of sterile water and combining this with the fixed 3 mL volume
methylcellulose gel.
Women were admitted to hospital in the afternoon prior to the day of induction. A
medical and obstetric history was taken and a general examination performed. Fetal
weight and liquor volume were estimated by ultrasound scan and a cardiotocograph
performed. Blood was taken for haematology, coagulation profile, biochemistry,
serum relaxin level and serum antibody to relaxin. Upon randomisation, the study
medication was reconstituted using sterile water by one of the hospital pharmacy staff
and delivered to the labour ward. The baseline modified Bishop score was recorded
and the study gel administered intravaginally to the posterior fornix that evening. The
woman remained recumbent for 1 hour following gel application. Blood pressure,
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pulse, respiration rate, uterine activity and fetal heart rate were monitored hourly for
four hours post-treatment, and then every four hours for at least 24 hours or until
delivery. Observations were suspended overnight if the patient was asleep. Blood
was taken at 1, 4, 15 and 24 hours after gel administration for serum relaxin
concentrations.
The following morning, at approximately 15 hours post-treatment, a vaginal
examination was performed by the same investigator and the modified Bishop score
recorded after which prostaglandin E2 (PGE2) gel 2 mg was instilled intravaginally.
Further PGE2 gel, 1 or 2 mg, was given after a six hour interval as required.
Amniotomy was performed when the cervix was at least 3 cm dilated and fully effaced
and oxytocin administered according to hospital protocol. Uterine activity and fetal
heart rate were monitored continuously throughout labour. If labour occurred prior to
the planned 15 hour assessment, the modified Bishop score was recorded at the onset
of labour and the patient managed as above. The onset of labour was defined as the
onset of regular painful contractions with evidence of progressive cervical dilatation of
the cervix. For women delivered by caesarean section prior to the second stage of
labour, the length of the first stage was taken to be the total length of labour.
Umbilical cord blood was taken at delivery for assay of relaxin concentrations and
blood gas analysis, and maternal blood was collected to measure serum relaxin
concentrations. Apgar scores were recorded at 1 and 5 minutes post-delivery. Twenty
four hours after delivery, maternal blood was collected for repeat haematology,
coagulation and routine biochemistry profiles, and serum relaxin concentration
measurement. A general physical examination was also performed. Women were
reviewed six weeks post-delivery when serum relaxin conccentrations were measured
and any postnatal problems documented.
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The primary outcome measure was the change in modified Bishop score between
baseline and 15 hours post-treatment. Secondary outcome measures included duration
of first and second stage of labour; prevalence of "spontaneous" labour and caesarean
section, need for oxytocin and total PGE2 requirement. Maternal safety measures
included vital signs, haematology and biochemistry screening. Fetal safety measures
included stillbirth, neonatal death, fetal heart rate disturbances, Apgar scores, cord
blood gases, need for resuscitation and incidence of neonatal morbidity.
Sample Size and Power Consideration.
Ninety-six patients were recruited to the study with 24 patients in each of the four
treatment groups. The primary efficacy variable, change in modified Bishop score,
was first to be analysed by ANOVA to take account of any effect of dose influencing
modified Bishop score. If a significant effect was demonstrated subsequent pairwise
comparisons were to have been performed. The determination of sample size was
based on such pairwise comparisons. Assuming that the standard deviation and the
between-treatment difference with respect to the change in cervical score are equal, a
two-sided t-test with a significance level of 1.67% will have 84% power to detect such
a difference.
Statistical Analysis.
All data were recorded on standardised case record forms and analysed at Genentech
Inc. in California. Analysis of variance tests were performed on all continuous
variables, and Cochran Mantel-Haenszel tests employed for discrete variables.
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Results.
Randomisation of patients to the four treatment groups was as follows: placebo - 23,
1 mg - 23, 2 mg - 25 and 4 mg - 25. There were no statistically significant differences
in the characteristics of the women in the four groups (Table 7.1).
The mean changes in modified Bishop score were 1.64 for placebo, 1.35 for 1 mg
relaxin, 1.76 for 2 mg relaxin and 1.32 for 4 mg relaxin. There was no statistically
significant difference in the increase in modified Bishop score between the four groups
(Table 7.2). In addition, there was no significant difference between the four groups
when nulliparae and parous women were analysed separately (data not shown). The
length of the first and second stages of labour was similar in all treatment groups.
There were no differences in the time from treatment to first stage of labour or from
treatment to delivery between the groups (Table 7.2). Excluding the patients delivered
by caesarean section from the analysis did not alter the results for any of the above
variables (data not shown).
The majority of women required induction of labour 15 hours after study medication
and only a few subjects laboured before this time (Table 7.3). The use of PGE2 and
oxytocin is also illustrated in table 7.3. There was no statistical difference in
requirement for either drug between groups, and the doses employed were similar in
each treatment group. There was no significant difference in the mode of delivery
between the groups with the majority of women achieving a spontaneous vaginal
delivery (Table 7.4). The overall caesarean section rate for the study was
approximately 20% and the apparent increase in section rate in the 2 mg group did not
reach statistical significance. Again, there was no statistical difference in the variables
displayed in tables 7.3 and 7.4 when primigravid and parous women were analysed
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separately, or when women delivered by caesarean section were excluded from the
analysis (data not shown).
Maternal and neonatal safety outcomes.
There was no significant difference in pre- and post-treatment measurements of pulse
and respirations between the four groups. There was a tendency to lower blood
pressures in the treatment groups when compared with placebo and this was
statistically significant for diastolic blood pressure: placebo-83 mm Hg; 1, 2 and 4 mg
rhRIx -77, -77 and 70 mm Hg respectively (p < 0.012). This effect was seen over the
first 14 hours following the start of treatment. Haematological and biochemical
profiles were within the normal range for pregnancy. There was no association
between other maternal outcome measures such as postpartum haemorrhage, infection
and urinary retention and treatment group.
There were significantly higher fetal heart rates in the treatment groups: placebo -133
beats per minute (bpm); 1, 2 and 4 mg rhRIx -136, -141 and 137 bpm respectively
(p < 0.011). This effect was evident for approximately 24 hours post-treatment.
There were no significant differences in 1 and 5 minute Apgar scores, or cord blood
gas results between the groups. Neonatal outcome measures such as meconium
stained amniotic fluid, hypoglycaemia and hyperbilirubinaemia occurred with the same




Maternal serum relaxin concentrations were assayed by Genentech. Concentrations
following intravaginal administration of 1, 2 and 4 mg rhRIx were no different from
the endogenous relaxin levels measured in the placebo group (Fig. 7.1). There was no
correlation between baseline serum relaxin concentration and baseline modified Bishop
score, or maximum serum relaxin concentration and change in modified Bishop score.
The majority of cord blood relaxin concentrations were below the level of detection of















































































































































































































































































































































A precise role for relaxin in the physiology of human parturition has yet to be defined.
In a number of animals (eg. pig and rat), the onset of labour is clearly preceded by a
surge in serum relaxin concentrations and this appears to facilitate connective tissue
remodelling in the reproductive tract. In human pregnancy serum relaxin
concentrations peak at approximately ten weeks gestation and thereafter concentrations
fall progressively towards term (Bell et al, 1987). Labour itself is not associated with
any further change in relaxin concentrations (Bell et al, 1987). If relaxin plays a key
role in cervical ripening it would be during the time of pre-labour that changes in
serum relaxin concentrations might occur.
The corpus luteum is the primary source of relaxin during pregnancy, although extra-
ovarian sites of production have been identified (Sakbun et al, 1990). The fact that
relaxin is not a prerequisite for cervical dilatation has been demonstrated by the
successful induction of labour in a woman with premature ovarian failure in whom
serum relaxin levels were unrecordable (Eddie et al, 1990). This finding also
highlights the fact that relaxin production by other tissues is very small compared with
ovarian production.
This study did not show any therapeutic effect of recombinant human relaxin on
cervical ripening when administered as an intravaginal gel. There was no significant
difference in mean change in modified Bishop score following treatment with 1, 2 or
4 mg of rhRIx compared with placebo. This is not surprising since pre- and post-
treatment serum relaxin concentrations were the same in the placebo and active groups
suggesting that relaxin was not absorbed from the preparation when administered
vaginally, or that the dosages were too small. There was no association between
endogenous serum relaxin levels and baseline modified Bishop score, or maximum
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serum relaxin concentrations and change in modified Bishop score. In addition, there
was no change in endogenous levels throughout induction, labour and delivery which
confirms previous findings. RhRIx appears to be safe and not associated with any
clinically significant side effects. In view of the lack of evidence for absorption of
rhRIx, which is reflected in the absence of clinical effect, the changes in maternal
diastolic blood pressure and fetal heart rate, which were small and clinically irrelevant,
may well have been spurious.
These findings are in keeping with a smaller study (Bell et al, 1993) employing
recombinant human relaxin in a dose of 1.5 mg which also failed to demonstrate a
significant effect on cervical ripening. Similarly, this dose of recombinant human
relaxin was not associated with any adverse maternal or fetal complications. One
explanation for a role for relaxin in cervical ripening without any parallel increase in
circulating relaxin concentrations would be if it were acting at receptor level.
However, to date, a receptor for relaxin in humans has not been identified.
The reduction in cervical collagen concentration necessary for cervical ripening can, in
part, be explained by an increase in enzymatic collagen degradation. Labour is
associated with an increase in circulating collagenase levels (Rajabi et al, 1985) and
collagenase activity within cervical tissue. It has been reported that relaxin increases
collagenase activity (von Maillot et al, 1977). Relaxin receptors have been identified
on human fibroblasts (McMurty et al, 1980), which along with leucocytes are capable
of collagenase production. A number of clinical trials have demonstrated a cervical
ripening effect of porcine relaxin in pregnant women (MacLennan et al, 1980; Evans et
al, 1983). However, these trials were small and the patients were of mixed parity. In
addition, in one study (MacLennan et al, 1980), patients in the treatment group tended
towards higher baseline Bishop scores limiting the conclusions that can be drawn.
Cervical ripening has been likened to an inflammatory response (Liggins, 1981) and
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one potential mechanism whereby porcine relaxin, although purified, could stimulate
cervical ripening is by provoking an immunological reaction resulting in neutrophil
degranulation and release of collagenase perhaps mediated by interleukin-8, production
of which has been demonstrated in the human cervix (Barclay et al, 1993).
The effect of relaxin on myometrial contractility in different species is varied. An
inhibitory effect of purified porcine relaxin on the spontaneous contractility of non¬
pregnant human myometrium has been demonstrated in vitro (Szlachter et al, 1980).
This effect has been confirmed on non-pregnant and pregnant myometrium from rats
and pigs. However, porcine relaxin had little, if any, effect on spontaneous or
induced, pregnant or non-pregnant, human myometrial contractility in vitro
(MacLennan, 1983). More recently, human relaxin has been shown to have only a
minor effect on human myometrial contractility in late pregnancy (MacLennan and
Grant, 1991). The data for uterine activity in this clinical trial were not assessed, but
as there was no difference in duration of labour or need for augmentation between
groups it is likely that contractility was unaffected.
Prostaglandins are currently the most successful agents for ripening the cervix
pharmacologically (Keirse, 1993) but they have the disadvantage of simultaneously
stimulating uterine activity. Although theoretically relaxin meets the requirements for
the ideal cervical ripening agent, that is ripening without contractility, this study has
not demonstrated any cervical ripening effect of recombinant human relaxin. This may
simply be due to incorrect choice of dosage. However, it seems more likely that the
route of administration for this large polypeptide hormone was inappropriate. The
intravenous route may be more suitable and deserves to be investigated before we can
discard relaxin as a ripening agent.
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Chapter Eight
Mifepristone for Cervical Ripening and Labour Induction at Term
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Introduction.
Until labour pregnancy is characterised by myometrial quiescence. It has been
suggested that progesterone is the hormone responsible for this (Csapo, 1975). Csapo
(1975) proposed that progesterone withdrawal converts the uterus from an inert state
to one of increased responsiveness to both endogenous and exogenous uterotonic
agents. His suggestion that progesterone withdrawal also induces release of
endogenous myometrial stimulants is supported by the finding that, in a number of
species including rat, rabbit and sheep, progesterone withdrawal is the signal for the
onset of parturition. However, a decline in peripheral circulating progesterone
concentrations cannot be demonstrated in humans prior to the onset of labour. Csapo
believed that where the placenta is the major source of progesterone as pregnancy
advances, peripheral progesterone concentrations do not accurately reflect
progesterone concentrations within the uterine target tissues. It is clear from studies
investigating the efficacy of the progesterone antagonist mifepristone (RU 486) that
progesterone does play an integral role in the timing of labour onset in "progesterone-
independent" species such as humans.
Mifepristone, a potent antagonist of progesterone and glucocorticoid action (Spitz and
Bardin, 1993), was first synthesised in 1981 by Roussel-Uclaf (Romainville, France).
It is an orally active drug with a 70% absorption rate, and 40% bioavailability after
first pass metabolism through the liver (Van Look and Bygdeman, 1989). It is
protein-bound in the serum and has a half-life of approximately 20 hours. Mifepristone
acts at the level of the progesterone receptor. The progesterone receptor, located in the
cell nucleus, undergoes configurational changes when progesterone binds to it (Tsai
and O'Malley, 1994) The resulting receptor complex can bind to the promoter region
of progesterone-responsive genes and increase the transcription rate of genes
responsible for mediating progesterone-dependent effects. Alternatively, when
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mifepristone binds to the progesterone receptor, the resulting complex renders the
DNA-bound receptors in the progesterone responsive genes transcriptionally inactive,
interrupting the effects of progesterone. Based on this mode of action, antiprogestins
such as mifepristone have a number of clinical applications, including early pregnancy
termination, induction of labour in the second and third trimesters, and postcoital and
prophylactic contraception (Ulmann et al, 1995).
Mifepristone will induce vaginal bleeding in virtually all women when administered in
the early weeks of pregnancy, but its ability to induce complete abortion falls from
100% when given in the prenidatory stage of pregnancy (Glasier et al, 1992) to <40 %
at greater than 56 days of amenorrhoea (Van Look and Bygdeman 1989), ie. the rate
of complete abortion is inversely related to the gestation of pregnancy. The
introduction of "combination" therapy, following the important observation that
mifepristone increases the sensitivity of the uterus to prostaglandins (Bygdeman and
Swahn, 1985), has led to a complete abortion rate of 95% in women <63 days
gestation treated with mifepristone 600 mg and gemeprost 1 mg 48 hours later (UK
Multicentre Trial, 1990).
Mifepristone's use is not confined to the first trimester of pregnancy. In the second
trimester, mifepristone pretreatment will significantly reduce the induction-to-abortion
interval compared with prostaglandin therapy alone, and will reduce the dose of
prostaglandin required to effect abortion (Urquhart and Templeton, 1990; Rodger and
Baird, 1990). It is also successful in inducing abortion in the presence of intrauterine
fetal death when administered alone (Cabrol et al, 1990).
Mifepristone's mechanism of action is two-fold. Firstly, it increases myometrial
responsiveness to oxytocic agents as a result of increased gap junction formation
(Garfield and Beier, 1989) and possibly a negative effect on nitric-oxide dependent
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myometrial relaxation (Yallampalli et al, 1993). Secondly, it promotes cervical
ripening. Evidence for this is provided indirectly by the shortened induction-delivery
interval in women undergoing medical termination of pregnancy who are pretreated
with mifepristone, and directly by studies demonstrating the reduction in force
necessary to dilate the cervix prior to surgical termination of pregnancy following
mifepristone pretreatment (Durlot et al, 1988; Radestad et al, 1988). Because
mifepristone induces cervical ripening and myometrial responsiveness without
stimulating uterine contractions there are indications for its use as a cervical ripening
agent in women with an unfavourable cervix at term, where uterine contractility in the
face of an unripe cervix is inefficient and stressful for the fetus. In addition,
mifepristone will induce cervical ripening in the non-pregnant cervix (Gupta and
Johnson, 1990).
Frydman et al (1992), have investigated the role of mifepristone in cervical ripening at
term and demonstrated that significantly more women went into "spontaneous" labour
in the mifepristone treated group and that, of those undelivered at the end of the
treatment interval, significantly fewer had an unfavourable cervix in the treatment
group. Also, the total dose of oxytocin administered was significantly less in the
mifepristone treated group. These findings were reproduced in a study of similar
design investigating induction of labour in women with a single transverse caesarean
section scar (Lelaidier et al, 1994). These studies provide encouraging information
with regard to a role for mifepristone in induction of labour at term. In neither study
was there maternal or neonatal complications. However, as mifepristone crosses the
placenta (Hill et al, 1990), and has an antiglucocorticoid effect it has the theoretical
risks of hypotension and hypoglycaemia in the neonate. In view of this, larger trials,
including dose-finding studies, are required to confirm the efficacy and safety of this
agent, and the lowest dose at which it is effective. This chapter describes the first arm
of one such dose-finding study.
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The aim of this study was to compare mifepristone, in an oral dose of 50 mg, with
placebo for induction of labour at term. Part II of the study (not discussed here) was
to investigate a lower (20 mg) or higher (200 mg ) dosage of mifepristone, depending
on the results obtained with the 50 mg dose.
Subjects and Methods.
This was a double-blind, placebo-controlled trial carried out in a single centre in the
UK. Local ethical approval was granted. A total of 50 patients were recruited, 25
subjects randomised to receive mifepristone 50 mg and 25 subjects to receive placebo.
Primigravid women at term (> 37 completed weeks gestation) with a cephalic
presentation, an indication for induction of labour and a modified Bishop score
(Calder, 1979) of <4 were invited to take part in the study. Written informed consent
was obtained prior to entry to the study.
The following were exclusion criteria for the study:
• Signs or symptoms of labour onset.
• An indication for delivery within 72 hours.
• Previous attempt to induce labour in this pregnancy.
• Signs of placental insufficiency.
• Contraindication to vaginal delivery.
• History of ruptured membranes.
• Concurrent illness: renal failure, hepatic disorder, adrenal insufficiency,
diabetes mellitus, coagulation disorders.
• Treatment with corticosteroids, anticoagulants, non-steroidal anti¬
inflammatory agents.
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Women were recruited from the hospital's antenatal clinics. The most common reason
for inclusion in the study was prolonged pregnancy (gestation > 40 completed weeks):
72 % and 88 % in the mifepristone and placebo groups respectively. Pregnancy
induced hypertension was the second most common reason for inclusion: 24 % and
16% in the mifepristone and placebo groups respectively.
Subjects attended the hospital 72 hours prior to the scheduled day of induction. At this
visit a routine medical history, physical examination and biochemical and
haematological screening were carried out. A cardiotocograph (CTG) was performed
and the modified Bishop score recorded. Subjects were allocated a study number and
the corresponding treatment was administered to the patients in the presence of the
clinician. Pre-determined randomisation codes were generated by Roussel
Laboratories Statistical Unit, and subjects were allocated a study number, and
therefore treatment, in strict numerical order as they were entered into the trial.
Subjects were then managed as outpatients, returning to hospital every 24 hours for
repeat assessments of blood pressure, pulse, modified Bishop score, CTG and fetal
movements. Subjects were asked to complete a fetal kick chart recording the length of
time taken to feel ten fetal movements in each 24 hour period.
If labour occurred spontaneously within 72 hours of study medication subjects were
managed according to normal hospital protocol. If labour was not established 72
hours following study treatment, the modified Bishop score was assessed and labour
induced with prostaglandin gel, in an initial dose of 1 mg. If required, a repeat dose of
prostaglandin gel (1 or 2 mg) was administered after a six hour interval. Amniotomy
was performed when the cervix was 3 cm dilated and fully effaced, and oxytocin was
administered intravenously four hours later if clinically indicated. Cardiotocography
was performed continuously throughout labour.
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Cord blood was taken at delivery for measurement of adrenocorticotrophin hormone
(ACTH), Cortisol and mifepristone concentrations, blood gases, pH and base excess,
biochemistry and haematology. Birth weight and 1 and 5 minute Apgar scores were
recorded. Neonatal blood glucose levels were measured with Dextrostix from heel
stab samples at 1, 3 and 12 hours following delivery. Maternal blood was taken at 24-
48 hours following delivery for measurement of haematological and biochemical
indices. Clinical assessments of the mother and neonate were made at 24 and 48
hours, and one and four weeks post delivery.
For the ACTH and Cortisol measurements 4 mL of cord blood was drawn into a
heparinised tube, and placed in an ice bath. The sample was immediately centrifuged
at 1500 g at 4 C for ten minutes and plasma separated into two dry tubes and frozen at
-20 C pending assay. ACTH and Cortisol concentrations were assayed at the Royal
Infirmary, Glasgow and the Royal Infirmary, Edinburgh respectively. The
mifepristone assays were carried out by the Department of Pharmacokinetics, Rousel
Uclaf Laboratories, Compiegne, France.
The primary outcome measures for the study were the success or failure of labour
induction and the degree of cervical ripening as measured by the modified Bishop
score. Secondary outcome measures included time to membrane rupture, full
dilatation and delivery; requirement for prostaglandin and oxytocin administration,
including total dose; need for amniotomy and mode of delivery. Maternal and neonatal
adverse events were recorded.
Statistical Analysis.
Continuous variables were analysed using ANOVA and categorical data were analysed
using the Chi-squared test.
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Results.
Fifty patients were recruited to the study and allocated to two treatment groups:
mifepristone 50 mg (n=25) or placebo (n=25). The characteristics of the women
enrolled are illustrated in table 8.1, and there were no statistically significant
differences between the two groups apart from weight which was accounted for in the
efficacy analysis.
The primary outcome measures were divided into the following three categories: total
success, partial success and failure. Total success was defined as onset of labour or
modified Bishop score of > 6 within 72 hours of treatment administration without
further intervention. Partial success was defined as onset of labour or modified
Bishop score > 6 within 72 hours of treatment administration with further intervention






















































































Mifepristone 50 mg Placebo
Total success 2 2 1.00
Partial success 10 4 0.059
Failure 13 19 0.077
Table 8.2. Primary outcome measure by treatment group. Values are given as n.
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Only 2 subjects (8%) in each treatment group had a successful outcome without the
need for further intervention. There was no significant difference for primary outcome
in either of the three categories between the treatment groups. However, the number
of subjects with a successful outcome after further intervention (partial success) was
notably higher in the mifepristone group compared with placebo (40% versus 16%
respectively).
There was no significant difference in the length of the first and second stages of
labour between the two treatment groups (Table 8.3). The times from treatment to
membrane rupture, treatment to onset of labour, and from treatment to delivery were
also similar between the two groups (Table 8.3). Similar numbers of women in the
mifepristone and placebo groups required treatment with prostaglandin gel, and the
total dose administered was the same for the two groups. The number of women
requiring oxytocin augmentation was also similar, and there was no significant
difference in the total dose of oxytocin infused (Table 8.4).
There was no significant difference in the number of women achieving a spontaneous
vertex delivery between the two groups (mifepristone 64%; placebo 44%), and the
same was true for the instrumental delivery rate (mifepristone 28%; placebo 24%)
(Table 8.4). However, the caesarean section rate was significantly lower in the




































































































































































































Study medication was well tolerated by the subjects. Maternal adverse events such as
postpartum haemorrhage, anaemia, placental disorder, fever and abnormal labour were
reported with a similar frequency between the two groups. All were considered by the
clinical investigators to be mild or moderate in severity, and only one event, headache,
was considered to be possibly related to treatment. There were no maternal deaths in
the study. Haematological and biochemical parameters assessed ante- and postnatally
were considered to be normal for pregnancy or the given clinical situation eg. anaemia
following postpartum haemorrhage. There were no abnormal clinical findings at the
24 and 48 hours check ups, or the one and four week postnatal reviews.
Fetal Safety
Maternal assessment of fetal movement 24, 48 and 72 hours after treatment is
illustrated in table 8.5. There was no significant difference in the results between the
two groups.
Reporting of fetal adverse events was similar for the two treatment groups. Such
events included acute fetal distress, bradycardia, fetal heart rate (FHR) abnormality,
meconium stained amniotic fluid and fetal tachycardia. Three serious adverse events
were reported in the study: one case of FHR abnormality in the mifepristone group,





24 hours 3.18 3.23 0.951
(1.96 -4.41) (2.02 -4.44)
48 hours 3.46 4.81 0.267
(1.94 - 4.98) (2.88 - 6.74)
72 hours 3.63 5.23 0.206
(2.08 - 5.19) (3.22 - 7.25)
Table 8.5. Maternal assessment of fetal movement - mean time (95% CI) to fetus
kicking 10 times, measured in hours.
Neonatal safety
The frequency of neonatal adverse event reporting was also similar for the two groups.
The percentage of neonates with a one minute Apgar score of 6 was 40% and 30% in
the mifepristone and placebo groups respectively. Immediate resuscitation with
intermittent positive pressure ventilation was required by 12% and 10% of neonates in
the mifepristone and placebo groups respectively. There were no neonatal deaths in
the study.
The normal range for blood glucose was defined as 2.2 to 4.4 mmol/L. Glucose
concentrations transiently below 2.2 mmol/L were accepted without further
investigation. However, persistently or markedly low glucose levels were investigated
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with a glucose oxidase test at the discretion of the neonatal paediatricians. As shown
in table 8.6 three hour Dextrostix results were significantly lower in the mifepristone
group compared with placebo (p< 0.05). Two cases of hypoglycaemia were reported
as serious adverse events - one in each treatment group (mifepristone - 1.0 mmol/L,
placebo - 0.6 mmol/L). In both instances glucose levels were within the normal range
at the 12 hour assessment.
There were no significant differences in cord pH, ACTH and Cortisol results (Table
8.7). The laboratory reference range for ACTH was <65mU/L, and the reference
range for Cortisol was 0 - 695 mmol/L. The limit of detection for the mifepristone
assay was <0.01 mg/L. There were no significant abnormalities on biochemical or


























































































































Ideally the aim of induction of labour should be to mimic the physiological process as
closely as possible. The onset of labour is not abrupt, but rather the end point of a
gradual change in uterine contractility, as elegantly demonstrated by Caldeyro-Barcia
(1958). In this work he defined the phase of prelabour which is a prerequisite of
successful parturition. Not only are important changes occurring with regard to
uterine contractility during this time, but in addition, and independent from this,
biochemical changes are taking place within the cervix to promote cervical ripening.
The importance of cervical ripening is highlighted by the crucial role the state of the
cervix plays in determining the success of labour induction. Women with an
unfavourable cervix, that is those who have not gone through the stages of prelabour,
present the greatest challenge with regard to labour induction where acceleration of the
normal physiological changes is required.
The key to successful induction of labour is therefore to replicate pharmacologically
the process of physiological cervical ripening. The most effective cervical ripening
agents currently employed are the prostaglandins (Keirse, 1993). However, they do
not have a selective effect on the cervix, but may promote ripening at the expense of
stimulating uterine contractility, which in the face of an unripe cervix will be inefficient
and stressful for the fetus and mother.
As discussed in chapter one, a number of biochemical changes take place within the
cervix with advancing gestation of pregnancy. These include increased tissue
hydration, a reduction in collagen concentration, altered composition of the
extracellular matrix and infiltration of inflammatory mediators. Although there is no
direct evidence to link progesterone with the timing of labour onset in humans, there is
a considerable wealth of indirect evidence from investigation into the effects of various
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progesterone antagonists to support a major role for this hormone in the control of
parturition.
The mechanism of action of antiprogestins in promoting cervical ripening has been
extensively investigated in a number of animal models. In pregnant rats treatment with
three different antiprogestins, onapristone, lilopristone and RU 486, resulted in a
dose-dependent increase in cervical softening 15 hours post treatment, and importantly
these changes occurred long before the onset of labour suggesting that cervical
changes precede labour after antiprogestin treatment (Chwalisz et al, 1991). Similarly,
dramatic softening and dilatation of the cervix occurs in onapristone-treated guinea
pigs prior to the onset of labour (Chwalisz et al, 1991). Histological examination of
guinea pig cervices treated with onapristone demonstrates that these changes are
associated with dissolution and disaggregation of collagen fibrils and increased
hydration of the inter-fibrillar spaces (Hegele-Hartung et al, 1989). In addition there
was an inflammatory cell infiltration of polymorphonuclear granulocytes, mast cells
and active fibroblasts. In these experiments similar findings were seen in control
animals just before term, that is animals undergoing physiological ripening. The
mechanism of antiprogestin-induced ripening therefore appears to mirror the
physiological process. These authors also found that there was no difference in the
number of gap junctions between smooth muscle cells in the cervix in the treated and
control groups, in contrast to the effect of antiprogestin treatment on myometrial cells
which induces a massive increase in gap junction formation (Garfield et al, 1987).
The efficacy of RU 486 for induction of labour at term was first demonstrated by
Frydman et al (1992). In this double-blind, placebo-controlled trial 120 women with
an unfavourable cervix (modified Bishop score <4) were randomised to receive
200 mg RU 486 daily for two consecutive days or placebo. Induction of labour was
planned for day four, and PGE2 or amniotomy and oxytocin were employed. 54% of
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women in the RU 486 group established in spontaneous labour without further
intervention compared with 18% in the placebo group (pcO.OOl). We were not able to
confirm this finding in the present study which is perhaps not surprising given the
much smaller dose in the active treatment group (50 mg versus 400 mg in total). Of
those women who had not gone into labour in Frydman's study (1992) significantly
fewer in the mifepristone group had an unfavourable cervix on day four compared
with placebo. In our study partial success was defined as the onset of spontaneous
labour within the treatment period with the intervention of amniotomy or syntocinon
infusion (or both), or a modified Bishop score >6 at the 72 hour assessment.
Although failing to reach significance (p=0.059) there were more partial successes in
the mifepristone group. This finding does suggest that mifepristone may be having
some preparatory effect on the cervix over this time period even in a dose of 50 mg.
In view of the fact that the 50 mg dose of mifepristone appears to be too low to
promote any major effect with regard to cervical ripening and induction of labour, it is
not surprising that there was no significant difference in the labour characteristics of
the treatment groups. There was a significant difference in the caesarean section rate
for the two groups: 8% and 32% for the mifepristone and placebo groups respectively.
The indication for caesarean section in the placebo group was arrest of labour in 50%
of the cases. One attractive theory to explain the lower section rate in the mifepristone
group is that the uterus has been "primed" and is therefore more responsive to
exogenous oxytocic agents as a result of treatment. However, numbers are small and
it is difficult to draw firm conclusions from this finding, particularly given the similar
labour characteristics of the two groups.
Transplacental passage of mifepristone has been established. Frydman et al (1985)
demonstrated that mifepristone crosses the placenta in the second trimester and that the
concentration of mifepristone in fetal cord blood increases exponentially with time.
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The lowest concentration (20 ng/mL) was found 30 minutes after administration, with
the highest concentration (400 ng/mL) occurring 18 hours after oral administration.
The authors suggested that these findings indicate an active transport mechanism, with
fetal concentrations on average one third of maternal levels. Similar findings have
been demonstrated in nonhuman primates (Wolf et al, 1988) where the maternal: fetal
ratio of mifepristone fell from 3:1 in the second trimester to 6:1 in the third trimester.
The authors concluded that the efficacy of placental transport may decrease with
advancing gestation and that the theoretical risks of fetal side effects could be reduced
in the third trimester.
The importance of transplacental passage lies in the fact that in addition to its
antiprogestagenic action, mifepristone is known to possess antiglucocorticoid activity
(Spitz and Bardin, 1993). In nonhuman primates the administration of mifepristone
results in potent inhibition of prolactin secretion and marked elevation of circulating
ACTH and Cortisol concentrations (Healy et al, 1983). The increase in ACTH and
Cortisol is dose-dependent, with peak ACTH elevation occurring 1-2 hours post
administration, and peak Cortisol concentrations occurring 3-4 hours after mifepristone
treatment. Similarly, in humans mifepristone will induce a sustained elevation of
Cortisol and lipotropin, which behaves in parallel with ACTH (Bertagna et al, 1984).
Because of the antagonism of glucocorticoid action at target tissues there is the
potential for hypotension and hypoglycaemia in the neonatal period.
In this study hypoglycaemia was reported as a serious adverse event in two infants;
one in each treatment group. In both cases the blood glucose concentrations had
returned to within the normal range by the 12 hour assessment. There was no
significant difference in blood glucose monitoring in the neonatal period between the
groups apart from the three hour assessment at which glucose concentrations were
significantly lower in the mifepristone group compared with placebo. However, the
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concentrations at this time point were still within the normal range. These findings are
therefore reassuring with regard to the theoretical risk of problems with glycaemic
control in the newborn period following mifepristone therapy, and are in accord with
the rate of transient hypoglycaemia identified in Frydman's trial. Also reassuring is
the finding that there was no significant difference in ACTH and Cortisol
concentrations in samples from cord blood at delivery, and that these results were
within the normal range.
This study has demonstrated that a 50 mg dose of mifepristone is insufficient to
promote cervical ripening and induction of labour in women with an unfavourable
cervix. However, some preparatory changes appear to be taking place within the
cervix in response to treatment suggesting that although a higher dose is required, this
may not need to be as high as the total dose employed in Frydman's trial. We have
also been able to confirm that mifepristone is not associated with any adverse events in
the neonatal period. In particular there were no complications resulting from its
antiglucocorticoid effect. The study concentrated on blood glucose monitoring and
hypoglycaemia, but although blood pressure was not formally assessed there were no
adverse events reported relating to problems with blood pressure control. Similarly,
there were no differences in ACTH and Cortisol measurements, although it is
acknowledged that levels obtained at delivery do not give a direct indication of the
response of the fetal pituitary-adrenal-axis in utero, particularly in the hours
immediately following treatment. However, there was no difference in fetal
monitoring tests such as cardiotocography and assessment of fetal movement over the
time period for the study which is again a reassuring observation.
Mifepristone is clearly an effective cervical ripening agent but further dose-finding
studies are required to establish the optimal dose for this clinical indication at term.
Certainly it has been demonstrated that a variety of doses are equally effective in
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facilitating termination of pregnancy in the first trimester (Baird, 1993), and obviously
the risk of side effects for both mother and fetus is reduced the smaller the dose
employed. Not only is further investigation into the use of antigestagens at term
required in order to widen our options for achieving pharmacological ripening of the
cervix, but also to advance our understanding of the mechanisms involved in the
control of parturition which in turn has important implications for the management and
prevention of preterm labour.
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Conclusions
The inappropriate timing of parturition confers a number of significant sequelae.
Preterm labour is associated with considerable perinatal morbidity and mortality, and
represents the major cause of death in structurally and karyotypically normal babies. It
is, therefore, a cause of considerable emotional distress, and has important
implications for health service resources. Alternatively, clinical situations can arise
which indicate interruption of pregnancy, namely induction of labour, necessitating
pharmacological intervention. Labour induction is associated with increased morbidity
for both mother and baby, and it is recognised that success is more likely if
physiological mechanisms are replicated. In order to make any impact on these clinical
problems, further knowledge regarding the mechanisms that control parturition is
required.
Prostaglandins are thought to play a major role in the process of labour, although the
precise stimulus for their production has yet to be established. The fetal membranes,
comprising amnion and chorion, and decidua are an important site of prostaglandin
synthesis and metabolism (Okazaki et al, 1981a). The increase in prostaglandin
concentrations seen in association with labour could therefore be the result of increased
prostaglandin synthesis, a reduction in prostaglandin metabolism, or a combination of
the two within these tissues. Previous work has investigated changes in each tissue in
isolation. Clearly it is important to look at potential changes in synthesis and
metabolism in parallel. Such parallel experiments investigating amnion and chorion
demonstrated that prostaglandin synthesis by amnion is increased in spontaneous
labour compared with elective caesarean section, but that there is no alteration in
prostaglandin metabolism between the two groups (chapter four). These findings are
in accord with Okazaki et al (1981a) and Cheung and Challis (1989), the former
investigating amnion and the latter investigating chorion.
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The increase in prostaglandin synthesis by spontaneous labour amnion may reflect
increased COX activity within this tissue. Phorbol esters, via their action on protein
kinase C, can stimulate prostaglandin production by increasing substrate availability
and COX activity. Spontaneous labour and elective section tissue produced
significantly more prostaglandin E2 in response to treatment with phorbol ester
compared with baseline production, but the significantly higher baseline production by
spontaneous labour amnion compared with elective section amnion was not
maintained. These findings suggest that substrate availability, lower concentrations of
COX, or a combination of both, are limiting factors in prostaglandin production by
elective section tissue. The stimulatory effect of phorbol ester on elective section
tissue may be due to an increase in inducible COX (COX-2) activity, which in
spontaneous labour tissue may already be maximally stimulated, hence the lack of
difference in prostaglandin production by the two groups of tissue following this
treatment.
The importance of COX-2 activity in the generation of prostaglandins is highlighted by
a number of studies. Using reverse transcriptase polymerase chain reaction
technology Slater et al (1994) have demonstrated an approximate 100-fold increase in
COX-2 mRNA compared with COX-1 mRNA in human amnion at term. An increase
in COX-2 expression, with no change in COX-1 expression, in assocation with labour
has been confirmed by further investigations (Slater et al, 1995; Hirst et al, 1995). In
addition, it has been demonstrated that factors capable of inducing COX such as PMA,
EL-1(3 and EGF do so at the level of COX-2 (Trautman et al, 1996).
There was no difference in the metabolism of exogenous prostaglandins by chorion
tissue in association with labour, which implies that there is no change in PGDH
activity, and is in keeping with the findings of Cheung et al (1990) regarding placental
PGDH localisation in labouring and non-labouring tissue. However, this may not
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accurately reflect the in vivo situation since there is evidence to suggest regional
differences in PGDH activity within the uterus. Van Meir et al (1997a) have
demonstrated that PGDH activity was highest in chorion from the region of the internal
os in patients not in labour, but was significantly lower in this area compared with
other regions of the fetal membranes in association with labour. This loss of PGDH
activity, and hence reduced prostaglandin metabolism, near the internal os would
facilitate prostaglandin transfer to the myometrium and cervix to promote contractility
and ripening respectively. There is also evidence to support a reduction in PGDH
activity in fetal membranes in association with some cases of preterm labour (Van Meir
et al, 1997b).
Progesterone and dexamethasone were without effect on prostaglandin metabolism
(chapter four). Treatment with the progesterone antagonist mifepristone (RU 486)
resulted in a significant reduction in the metabolism of exogenous PGE2 in
spontaneous labour tissue, and was without effect in elective section tissue. This
suggests that PGDH activity is reduced by treatment with mifepristone, which agrees
with the in vivo decidual studies of Cheng et al (1993). The finding that mifepristone
had no effect on elective section tissue implies that an endogenous factor specific to
labour is integral to this process. Chorion expresses 3(3-hydroxysteroid
dehydrogenase (3(3 HSD) which converts pregnenolone to progesterone. Since
progesterone may maintain PGDH expression it would be interesting to determine
whether there is a localised reduction in progesterone concentrations, for example due
to decreased 3(3 HSD activity, occurring in parallel with reduced PGDH expression.
The concept that the fetus has a role in the timing of parturition is an attractive one,
with labour occurring once the fetus is appropriately mature. However, whilst there is
evidence to suggest a role for the fetus and placental unit in the timing of labour onset,
(section 1.8.2), no direct evidence for fetal control is as yet available in human
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parturition, in contrast to the ovine model. One route by which the fetus might
potentially control the onset of labour is via the amniotic fluid. A substance(s) in
amniotic fluid could stimulate prostaglandin production by amnion, with which it is in
direct contact. Alternatively, or additionally, transfer across the amnion could occur of
a factor which can inhibit prostaglandin metabolism by chorion, the net result being an
increase in prostaglandin concentrations. The effect of amniotic fluid on prostaglandin
production by amnion has been investigated (Dowling et al, 1991; Cohen et al, 1991),
but no work has studied the effect of amniotic fluid on metabolism by chorion, or
investigated both tissues in parallel.
Spontaneous labour and elective caesarean section amniotic fluid stimulated
prostaglandin production by amnion (chapter five). The stimulatory effect was
significantly greater for spontaneous labour fluid, suggesting that there is a factor
present in labouring fluid which is either absent from non-labouring fluid, or present
in lower (stimulatory factor) or higher (inhibitory factor) concentrations compared with
labouring fluid. Amniotic fluid had no effect on the metabolism of exogenous
prostaglandins by chorion (chapter five) demonstrating that any increase in
prostaglandin concentrations occurring in response to a substance in amniotic fluid
results from an increase in prostaglandin synthesis and not a reduction in prostaglandin
metabolism.
Potential regulatory mechanisms involved in the stimulatory effect of amniotic fluid
were investigated in chapter six. These experiments demonstrate that new protein
synthesis and protein kinase C are involved in basal production of prostaglandins by
amnion and chorion. The stimulatory effect of amniotic fluid on prostaglandin
synthesis is also mediated, at least in part, by protein kinase C activation and new
protein synthesis. The inhibition of amniotic fluid's stimulatory effect on
prostaglandin synthesis by cycloheximide may reflect inhibition of COX production /
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activity. As discussed earlier the role of protein kinase C may be to increase substrate
availability for prostaglandin production, and / or stimulate COX activity. The
stimulatory effect of amniotic fluid was not completely abolished by cycloheximide or
staurosporine suggesting that additional mechanisms may play a part. The
experiments also demonstrated that tyrosine kinase is involved in the stimulatory effect
of amniotic fluid lending further support to the importance of signal transduction
mechanisms in this process.
No attempt has been made to characterise the substance(s) present in amniotic fluid
which is responsible for the stimulatory effect on prostaglandin production.
Cytokines, which are present in increased concentrations in amniotic fluid of labouring
compared with non-labouring women at term, are possible candidates. They are
capable of stimulating prostaglandin production by amnion and chorion, and it has
been demonstrated that the mechanisms whereby this is achieved involve protein
kinase C and COX-2. The fetal membranes produce a number of cytokines which, as
discussed previously, are able to induce expression of each other. Whether the
cytokines present in amniotic fluid are the result of a signal from the fetus, or whether
their original source is the chorion and amnion, produced as a result of a trigger
independent of the fetus remains unknown. However, there is potential for a complex
cascade of events at the feto-maternal interface which could be crucial to the timing of
parturition.
The process of cervical ripening is central to the appropriate timing of labour. The
cervix is known to ripen during the phase of prelabour, described by Caldeyro-Barcia
(1958), during which time it changes from a rigid sphincter responsible for
maintaining the uterine contents, to a soft compliant structure which enables easy
passage of the fetus during labour. These important changes in the cervix occur in the
weeks prior to the onset of labour. This suggests that the trigger for labour onset is
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not simply an acute event resulting in immediate regular uterine contractility, but rather
that there are regulatory mechanisms that allow a gradual build up to active labour.
What these mechanisms are in humans remain to be accurately defined, as does the
switch from prelabour to labour.
In order to replicate physiological ripening, pharmacological agents should promote
cervical ripening without having a significant effect on uterine contractility, thus
reducing the maternal and fetal morbidity associated with labour induction in the
presence of an unripe cervix. Relaxin is a hormone that has the potential to achieve
this effect since it facilitates connective tissue remodelling, and has an inhibitory effect
on myometrial contractility in some species. However, the exact role, if any, of
relaxin in human parturition remains unclear. Chapter seven presents a randomised,
double-blind, placebo-controlled trial investigating the efficacy of recombinant human
relaxin as a cervical ripening agent, which because of its structure may produce
superior results to those obtained in earlier trials employing porcine relaxin
(MacLennan et al, 1980; Evans et al, 1983). The trial specifically investigated its use
in women with an unfavourable cervix (modified Bishop score <4) since this group
presents the greatest challenge with regard to labour induction. This trial demonstrated
no effect of human recombinant relaxin on cervical ripening at the three doses tested
(1,2 and 4 mg). This could be due to inappropriate dosage or route of administration,
or may simply reflect the fact that relaxin is not a significant hormone in human
parturition. The success of the earlier studies with porcine relaxin may be explained
by an immunological reaction leading to inflammatory cell infiltration of the cervix and
collagenase release, which would be in keeping with the large body of evidence
suggesting that physiological ripening is an inflammatory-mediated process (Liggins et
al, 1981).
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There is an infiltration of neutrophils and macrophages into the human cervix at term
(Junqueira et al, 1980; Osmers et al, 1992), and since these cells are a source of
collagenases (Ito et al, 1987) they may provide an important link in the ripening
process. Similar findings have been demonstrated in animal models (Hegele-Hartung
et al, 1989), and interestingly this infiltration appears to be under the control of
progesterone, since administration of progesterone antagonists increases the
inflammatory response (Chwalisz et al, 1991). There is evidence demonstrating that
the effect of progesterone withdrawal is cytokine mediated, with progesterone
inhibiting the production of cytokines in a number of tissues (Kelly et al, 1992; Kelly
et al, 1994). In addition pharmacological ripening with topical cytokines in the animal
model results in histological changes within the cervix that are similar to those induced
by antiprogestational agents (Chwalisz et al, 1994).
It has been suggested that progesterone withdrawal, either physiological or
pharmacological, may activate the cytokine cascade and hence cervical ripening
(Chwalisz et al, 1994) and the above findings go some way to explain the efficacy of
mifepristone for interruption of pregnancy at all gestations. In addition to its effect on
cervical ripening mifepristone increases myometrial responsiveness to endogenous and
exogenous prostaglandins and therefore has a dual effect of preparing both
myometrium and cervix for labour. Additional prostaglandin therapy will increase the
number of women delivering following mifepristone therapy at all gestations and this
would seem an appropriate approach therefore to induction of labour at term. In view
of the more physiological approach that mifepristone may provide for cervical ripening
it has been investigated for this indication in human pregnancy at term (Frydman et al,
1992), when it was demonstrated that a dose of 400 mg promoted spontaneous labour
in significantly more women compared with placebo.
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Chapter eight presents the results of the first part of a dose-finding placebo-controlled
trial with the aim of establishing the lowest dose of mifepristone necessary for cervical
ripening and labour induction in women with an unfavourable cervix at term. The
results demonstrate that a dose of 50 mg is not sufficient to promote cervical ripening
and labour onset without further intervention. However, the number of women
labouring successfully with further intervention (eg. amniotomy +/- syntocinon) was
higher in the mifepristone group suggesting that mifepristone may be having some
preparatory effect on the cervix. Thus a slightly higher dose may produce a significant
effect, and in fact in the second stage of this dose-finding study, which did not form
part of the work of this thesis, a 200 mg dose of mifepristone was significantly more
effective than placebo in promoting spontaneous labour and an improvement in Bishop
score when analysed in combination (Elliott et al, 1998). Importantly, there was no
difference in monitoring of fetal and neonatal safety between the treatment and placebo
groups.
Mifepristone is an attractive cervical ripening agent because it promotes histological
changes, at least in animal models, within the cervix that are similar to physiological
ripening. In addition, there is evidence for an effect on intrauterine tissues, as
discussed earlier. There is a reduction in PGDH immunoreactivity in decidua from
women treated with mifepristone in early pregnancy (Cheng et al, 1993), and a
reduction in the metabolism of exogenous prostaglandins by chorion explants collected
from spontaneous labour at term treated with mifepristone in vitro (chapter 3). Both
of these effects would lead to an increase in prostaglandin concentrations within the
uterus with the potential for stimulating myometrial contractility. Thus progesterone
withdrawal, induced by mifepristone, may have an action on myometrial gap junction
formation, prostaglandin production within fetal membranes and decidua, and cervical
ripening. There is no direct evidence to support the theory of progesterone withdrawal
in human parturition. However, it has been suggested that events may occur within the
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intrauterine tissues to effect local progesterone withdrawal which would not be
reflected in peripheral progesterone concentrations. These changes could then facilitate
mechanisms such as cytokine infiltration leading to cervical ripening and important
interactions at the feto-maternal interface resulting in the production of myometrial
stimulants, namely prostaglandins.
Our understanding of the mechanisms governing the onset of parturition in humans is
fragmentary. There is at present no direct evidence indicating that the process is under
the control of the fetus, which would initiate labour when appropriately mature,
although this is likely at least in part. It may be that the intrauterine tissues, the feto-
placental-membrane unit, including amnion and chorion are of major importance in
determining events leading to the onset of labour. Prostaglandins are thought to be
central to the process of labour and the work presented in this thesis demonstrates that
prostaglandin synthesis by fetal membranes is increased in association with
spontaneous labour, while prostaglandin metabolism by chorion is unaffected by this
process.
Amniotic fluid is capable of stimulating prostaglandin synthesis by amnion, and this is
significantly greater in response to spontaneous labour fluid, perhaps indirectly
indicating a role for the fetus in the increased production of prostaglandins. Amniotic
fluid has no effect on the metabolism of prostaglandins by chorion lending further
support to the hypothesis that the increase in prostaglandin concentrations seen in
association with labour is a result of increased synthesis and not a reduction in
metabolism. Mechanisms by which amniotic fluid stimulates prostaglandin production
include activation of protein kinase C, tyrosine kinase and new protein synthesis.
Candidates for these effects include members of the cytokine family such as the
interleukins -1,6 and 8 which are known to be present in amniotic fluid in increased
concentrations in association with labour at term, and which are capable of stimulating
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prostaglandin production by human fetal membranes. This leads to the concept that
labour may also be the result of an inflammatory reaction, as has been suggested for
cervical ripening. A combination of hormonal changes are likely to prime the uterus
and cervix for this proinflammatory process in turn mediated by candidates such as
cytokines and prostaglandins which promote ripening and uterine contractility. The
preparatory changes within the cervix and uterus which culminate in spontaneous
labour occur in concert and are likely to be orchestrated by the feto-placental-
membrane unit.
The work described in this thesis raises a number of areas for continuing research. It
would be important to investigate the effect of in vivo treatment with mifepristone at
term on prostaglandin synthesis and metabolism by amnion and chorion, and to
establish any modification in the response to inflammatory mediators. In view of the
dramatic inhibition of amniotic fluid-stimulated prostaglandin production following
treatment with staurosporine the role of protein kinase C in parturition merits further
investigation. In addition, phospholipase inhibitors could be employed to determine
the role of phospholipase A2 in amniotic fluid-stimulated prostaglandin production,
and the role of COX could be more accurately assessed using specific COX-2
inhibitors. It would also be interesting to explore the hypothesis that there may be
regional variations in prostaglandin synthesis and metabolism depending on the site
from which the membranes are sampled. Further clinical trials are required to
determine the correct dose of mifepristone for induction of labour at term and to
establish the safety of this agent. The optimal combination of mifepristone and PGE2
requires investigation and consideration might be given to the potential of the PGEi
analogue misoprostil in combination with mifepristone. Another approach to cervical
ripening might be topical application of cytokines which could have a local effect on
the cervix and perhaps influence prostaglandin production by the fetal membranes
adjacent to the cervix promoting a cascade resulting in uterine contractility.
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The following abbreviations have been employed throughout.
AA Arachidonic Acid










mrna Messenger ribonucleic acid




PGEM Prostaglandin E metabolite
PGF2a Prostaglandin F2a
PGFM Prostaglandin F metabolite
PGHS Prostaglandin endoperoxide synthase
PKC Protein kinase C
pla2 Phospholipase A2
PMA Phorbol myristoyl acetate
SD Standard deviation
27 1
SEM Standard error of the mean
TPA Teradecanoyl phorbol acetate
TNF Tumor necrosis factor
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The objective was to compare the changes in prostaglandin synthesis and metabolism occurring
within the fetal membranes that are associated with the onset of parturition and to study the effect of
steroid hormones on prostaglandin metabolism. A tissue explant study was made of discs of amnion
and chorion obtained from 24 pregnant women at 37-42 weeks' gestation following spontaneous
labour and delivery (12 women) and elective caesarean section (12 women). Significantly more
prostaglandin E2 (PGE2) and PGF2tt were synthesized by amnion obtained following spontaneous
labour than elective caesarean section. Arachidonic acid stimulated both PGE2 and PGF2q synthesis by
amnion in both groups. Phorbol myristoyl acetate stimulated PGE2 synthesis in both groups. There
was no difference between the groups in the capacity of the chorion to metabolize prostaglandins.
Mifepristone (RU 486) reduced the metabolism of added PGE2 following spontaneous labour, while
dexamethasone and progesterone had no effect on prostaglandin metabolism. In conclusion, the
increase in concentration of PGE2 and PGF2q associated with the onset of spontaneous labour is the
result of an increase in synthesis rather than a reduction in metabolism. There was no decrease in
metabolism to account for the increase in prostaglandin concentrations and, with the exception of
mifepristone, metabolism was not altered by the addition of steroid hormones.
Janet Brennand, Department of Obstetrics and Gynaecology, Glasgow Royal Maternity Hospital, Rottenrow,
Glasgow G4 ONA, UK
Prostaglandins are intimately involved in the process
of parturition. This is evidenced by the increase in
concentrations of PGE2, PFG2a and their metabolites in
maternal plasma (1-3), urine and amniotic fluid (3, 4)
at the onset of spontaneous labour. The fetal mem¬
branes appear to be the source of the increase in
prostaglandins seen with labour. The amnion produces
PGE2 and has little metabolizing activity (5), whereas
the chorion is the major site of prostaglandin metabo¬
lism, being rich in prostaglandin dehydrogenase (5-7).
This enzyme converts PGE2 and PGF2(t to their
respective metabolites 13,14-dihydro-15-keto-PGE2
(PGEM) and 13,14-dihydro-15-keto-PGF2ll (PGFM).
There are two mechanisms by which this increase in
prostaglandin levels can be effected: firstly, an increase
in their synthesis, or secondly, a decrease in their
metabolism.
It is well established that prostaglandin production by
amnion is increased in spontaneous labour (6, 8, 9).
However, in order to exert their uterotonic effect on
the myometrium, prostaglandins synthesized by the
amnion would have to escape the metabolic activity of
prostaglandin dehydrogenase within the chorion, and
there are conflicting reports as to whether or not this is
possible. Some reports have confirmed that transfer of
prostaglandins across full-thickness membranes does
occur, with the majority of the prostaglandin remaining
intact (10, 11), whereas others have shown that
transfer does not take place (12). Any reduction in the
metabolizing capacity of the chorion could potentially
enhance prostaglandin transfer. There is little informa¬
tion available on changes in prostaglandin metabolism
associated with labour, with one report suggesting that
there is no difference in the metabolizing capacity of pre-
and post-labour tissues (6).
Although the effect of steroid hormones on prosta¬
glandin production has been examined extensively (13,
14), this is not the case for prostaglandin metabolism
and no previous study has examined prostaglandin
metabolism in parallel. It has been shown that
antiprogestagenic steroids alter prostaglandin metabo¬
lism in the guinea-pig (15), but there is little informa¬
tion on the effect of progesterone and corticosteroids on
prostaglandin metabolism in chorion.
The aim of this study was to assess, in parallel, the
alterations in prostaglandin synthesis and metabolism
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in amnion and chorion, respectively, that are associated
with spontaneous labour and to investigate the effect of
steroid hormones on prostaglandin metabolism.
Subjects and methods
Fetal membranes were obtained from women at term
with uncomplicated pregnancies. Group one laboured
spontaneously and achieved a vaginal delivery without
oxytocin augmentation (N = 12), and group two
underwent elective caesarean section for either breech
presentation or previous caesarean section (N — 12).
The membranes were trimmed from the placenta
immediately following delivery and transported in
Dulbecco's phosphate-buffered saline solution (DPBS)
containing heparin (lOU/ml). The amnion and chorion
were separated manually and the decidua peeled from
the chorion with fine-tissue forceps. The amnion and
chorion were soaked in DPBS containing 40mg/500ml
gentamicin (Sigma, UK) and amphotericin B 2.5 mg/
500ml (Sigma, UK) for 1 h. Previous work in the
laboratory has shown that neither heparin nor the
antibiotics affect prostaglandin synthesis or metabolism.
The tissues then were rinsed thoroughly with DPBS.
Chorion tissue culture
Chorion explant discs, 9 mm in diameter, were set up in
culture medium as described for the amnion experiment
and treated with one of the following (final concentra¬
tions): 1 pmol/l dexamethasone (Sigma, UK): 1 /rmol/1
progesterone (Sigma, UK); 1 /uuol/1 RU 486 (Roussel
Laboratories) or complete culture medium, the latter to
act as control. All steroid solutions were made up in
complete culture medium. The explants were incubated
for 18 h in humidified 5% CO; in air at 5°C.
The following solutions were added (final concentra¬
tions): lOO/tmol/l arachidonic acid. 500 ng of PGEs
(Upjohn Ltd, UK), 500 ng of PGF2n (Upjohn Ltd, UK)
and complete culture medium, the latter to act as
control. Again, the solutions were made up in complete
culture medium and the total volume of culture fluid
was maintained at 1 ml. All experiments (N = 12 in
each group) were performed in duplicate (i.e. two discs
per experiment per patient, giving eight discs in total
per patient). The explants were incubated for a further
4h and then 0.5 ml of incubation medium was
aspirated from each well for oximation, as described
previously.
Amnion tissue culture
Discs of amnion, 12 mm in diameter, were cut with a
cork borer and each suspended on a l-cm~ piece of
sterile capillary matting. Each disc then was submerged
in a standard culture plate well containing 900/d of
complete culture medium. Complete culture medium
consisted of RPMI 1640 (Gibco, UK) with 25mmol/l
HEPES buffer plus L-glutamine with the following
additions: 50ml/500ml fetal calf serum (Gibco, UK);
5 ml/500 ml Penstrep solution (5000IU/ml penicillin
and 5000mg/ml streptomycin: Gibco, UK); 5 ml of
insulin-transferrin-sodium selenite media supplement
(Sigma, UK).
The explant discs of amnion were treated with the
following (final concentrations): 100/imol/l arachido¬
nic acid (Sigma, UK); 100nmol/l phorbol myristoyl
acetate (PMA) (Sigma, UK): 2.8/tmol/I indomethacin
(Sigma, UK) or complete culture medium, the latter to
act as control. The solutions of arachidonic acid, PMA
and indomethacin were made up in complete culture
medium. The volume added was 100/d and the discs
therefore were cultured in a total fluid volume of 1 ml.
All experiments (N = 12 in each group) were performed
in duplicate (i.e. two discs per experiment per patient,
giving eight discs in total per patient).
The plates were incubated for 18 h in humidified 5%
CO2 in air at 37°C. Following incubation, 0.5ml of
incubation medium was aspirated from each well and
oximated with an equal volume of methyl oximating
solution. These samples were mixed thoroughly and


























Fig. 1. Basal production of PGE,, PGF,„. 1 3.14-dihydro-15-keto-PGE2
(PGEM) and 1 3.14-dihydro-l 5-keto-PGF,„ (PGFM) by amnion and
chorion following spontaneous labour If1 '\T =12) and elective
caesarean section (□) (N = 12). Results expressed as means (sum).
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Radioimmunoassay
A competitive binding radioimmunoassay was used to
determine the PGE2, PGF2rt, PGEM and PGFM content of
the media. The technique has been described previously
in detail (16, 17). In summary, up to 50 p\ of the
oximated culture medium was assayed. The labels
employed are the iodinated (12'I) methyloximes of
PGE2, PGF2(t, PGEM and PGFM (Pro-Gly-Tyr conjugate
in each case). Antisera to the respective labels were
raised in the rabbit. The assay was left overnight prior to
separation of the antigen-antibody complex from the
free antigen by a second antibody magnetic separation
procedure. The intra-assay coefficient of variation was
12.3% for PGE2, 10.5% for PGF2q. 8.4% for PGEM and
7.3% for PGFM. The interassay coefficients of variation
were 13.3%, 13.9%, 13.9% and 13.3% for PGE2,
PGF2a, PGEM and PGFM, respectively. The sensitivity
of the assay was 2 pg in all assays. This gives a limit of
detection of approximately 40 pg per well.
Statistics
Analysis of variance (ANOVA) was used to analyse the
data. Where the data were not distributed normally, log
transformation was employed prior to ANOVA.
Results
Effect of labour on prostaglandin synthesis in amnion
(Fig. 1)
Basal production of PGE2 and PGF2a was significantly
higher in amnion obtained following spontaneous
labour compared with elective caesarean section
(p < 0.05). Neither PGEM nor PGFM production
differed significantly between spontaneous labour and
caesarean section. Production of PGF2a was substan¬
tially less than that of PGE2.
Effect of arachidonic acid, phorbol myristoyl acetate
and indomethacin on prostaglandin synthesis in
amnion (Fig. 2)
The addition of arachidonic acid resulted in significant
stimulation of PGE2 and PGF2q synthesis by amnion
obtained following both spontaneous labour and


















Fig. 2. Production of PGE2 (ng/ral) (A) and PGF2„ (pg/ml) (B) by
amnion following the addition of 100/tmol/l arachidonic acid (AA),
100nmol/l phorbol myristoyl acetate (PMA) and 2.8/<mol/l indo¬
methacin (INDO), compared with control (Cl: (W) spontaneous labour
(N = 12): (□) elective caesarean section (X = 12). Results expressed

















Fig. 3. Metabolism of added PGE2 (500 ng) to 13,14-dihydro-l 5-keto-
PGE, (PGEM) (A) and PGF,„ (500ng) to 13.14-dihydro-15-keto-
PGF2„ (PGFM) (B) by chorion following spontaneous labour (H)
(N = 12) and elective caesarean section (□) (N = 12). Results
expressed as means (sat).
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in the two groups (p < 0.05) (Note: PGE2 in ng/ml;
PGF2a in pg/ml). The percentage increase in prosta¬
glandin production over basal levels was greater in the
caesarean section tissue and this was significant for
PGF2q (p < 0.01). Phorbol myristoyl acetate stimulated
PGE2 production from amnion in both groups
(p < 0.05). There was no significant stimulation of
PGF2a production following the addition of PMA in
either group. Indomethacin inhibited PGE2 production
in both groups (p < 0.05). Also, PGF2a production was
inhibited by indomethacin in amnion obtained follow¬
ing spontaneous labour (p < 0.05).
Effect of labour on prostaglandin metabolism in chorion
(Figs 1 and 3)
The major product of the chorion in both spontaneous
labour and caesarean section groups was PGEM, and
production was significantly higher in the spontaneous
labour tissue (p < 0.05) (Fig. 1); PGFM was produced in
smaller amounts and only minimal levels of PGE2 and
PGF2a were recorded. There was no significant differ¬
ence in the production of either primary prostaglandin




































Fig. 4. Metabolism of added PGE2 (500 ng) and PGF2n (500 ng) to
their respective metabolites by chorion following spontaneous labour
(N = 12) and elective caesarean section (N = 12): control (E3) versus
1 /iinol/1 RU 486 (□), 1 /imol/1 dexamethasone (H) and 1 /imol/1
progesterone (U). Results expressed as means (sem).
PGE2 to PGEM was the same in chorion from both
groups (Fig. 3). Similarly, there was no difference in the
metabolism of added PGF2q to PGFM between the
groups.
Effect of steroids on prostaglandin metabolism in
chorion (Fig. 4)
Dexamethasone and progesterone had no effect on
prostaglandin metabolism. However, RU 486 decreased
the metabolism of added PGE2 in chorion obtained
following spontaneous labour, but not in elective
section tissue.
Discussion
The aim of this study was to compare changes in
prostaglandin synthesis and metabolism in parallel by
looking at both the amnion and chorion collected from
each subject. The major product of the cultured amnion
explants was PGE2, which is in keeping with reports
from others (5, 18). We were able to demonstrate a
significant increase in PGE2 production by amnion
obtained following spontaneous labour, in keeping with
the findings of previous studies (6, 8, 9). Although
measured in much smaller concentrations, we also
found a significant increase in the production of PGF2a
by the amnion following spontaneous labour, which
could not be explained by any cross-reactivity because
the PGE2 cross-reactivity with PGF2q assay was
<0.02%. Okazaki et al. (5) were unable to demonstrate
PGF2q production by the amnion. However, Mitchell et
al. (18) detected small amounts of PGF2q in their
superfusates of amnion tissue. The main source of
PGF2a is the decidua and any contribution that the
amnion makes to increased PGF2q concentrations is
likely to be negligible. Indeed, the presence of PGF2q in
the culture system could be explained by non-enzymatic
conversion from PGE2. or by production by fibroblasts
or macrophages present within the deeper layers of the
amnion. Production of both PGEM and PGFM by the
amnion was minimal, reflecting the virtual absence of
prostaglandin dehydrogenase activity in this tissue (7).
In our experiment, the addition of arachidonic acid
resulted in significant stimulation of PGE2 and PGF2a
production hv amnion obtained both before and after
labour compared to basal concentrations. The mobiliza¬
tion of arachidonic acid from membrane glycerophos-
pholipids by phospholipase A2 is the rate-limiting step
in prostaglandin production. An increase in the activity
of this enzyme with advancing gestation, but not with
the onset of labour, has been described (19). Following
the addition of arachidonic acid there was no longer
a significant difference in prostaglandin production
between the two groups, which suggests that the
availability of arachidonic acid is a limiting factor in
prostaglandin production by the elective section tissue.
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The difference in basal production of PGE2 and PGF2a
between the groups could be explained by a difference in
the activity of prostaglandin H synthase (cyclooxygen-
ase) in pre- and post-labour amnion. Lopez Bernal et al.
(20) have suggested that maturation of the activity of
PGHS occurs toward term. Further results supporting
this theory come from Olson et al. (21). Increased
expression of the cycloxygenase gene has been demon¬
strated in human fetal membranes and placenta with
the onset of labour (22). If there was increased
cyclooxygenase activity in the spontaneous labour
tissue we would expect the significant difference in
prostaglandin production between the two groups to
persist following the addition of arachidonic acid. Our
findings suggest that, provided adequate substrate is
available, both groups have similar capacities for
prostaglandin production. However, the effect of
exogenous arachidonic acid on cyclooxygenase activity
is not known, and it is possible that the arachidonic acid
may have induced and saturated the enzymes, thus
abolishing any differences seen previously.
Addition of the phorbol ester PMA resulted in
increased production of PGE2 by amnion in both
groups compared to control values. Phorbol esters act
by stimulating the activity of the enzyme protein kinase
C (PKC), a calcium- and lipid-dependent protein kinase
that is involved in the regulation of many cellular
functions. The presence of PKC has been identified in
human amnion and decidua vera tissues (23) and it is
involved in arachidonic acid release and the activation
of PGHS (24). There are two main isoforms of PGHS
(25-27): PGHS I is the constitutive calcium-dependent
form of the enzyme, whereas PGHS II can be induced by
a number of agents, including phorbol esters. This study
of amnion explants confirmed the stimulatory effect of
phorbol ester on PGE2 production (24). There was no
effect on PGF2q production, but this may simply be related
to a lower level of production in comparison to PGE2.
There was no significant difference in response to PMA
between the spontaneous labour and caesarean section
amnions. These results suggest that PGHS activity is
comparable in both groups. One explanation for this
is that PGHS II activity has been induced maximally by
PMA and any original difference in PGHS activity has
been lost.
Significant PGEM production occurred in the chorion,
which is likely to reflect PGE? production because of the
metabolizing capacity of the chorion for prostaglandins
via 15-hydroxy-prostaglandin dehydrogenase (PGDH),
the predominant enzyme in this tissue (5). Production
of PGFM, reflecting PGF2a production, was substantially
less than PGE2/PGEM. These results are in accordance
with those of Okazaki et al. (5). We found no difference
in the metabolism of added PGE2 and PGF2q to their
respective metabolites, confirming the report of Cheung
and Challis (6) who demonstrated no change in the
metabolism of PGE2 added to cell cultures of chorion
obtained pre- and post-labour. This is compatible with
the finding that PGDH localization in the placenta and
membranes is not altered in association with labour (7).
It therefore appears that the increase in prostaglandin
concentrations associated with spontaneous labour is
not the result of a decrease in metabolic activity within
the chorion.
Mifepristone (RU 486) is a well-established medical
abortifacient and more recently has been employed
successfully as an agent for labour induction at term
(28). In vitro studies exploring the effect of RU 486 on
endometrial (29) and early decidual cells (30) have
shown that prostaglandin synthesis is stimulated, and
metabolism inhibited, by the antiprogestin. In addition,
work in the guinea-pig has shown decreased prosta¬
glandin metabolism in myometrium and chorion
following in vivo treatment with RU 486 (15). In our
experiment, the addition of RU 486 had no effect on
basal prostaglandin metabolite production in either
group. However, the metabolism of added PGE2 to
PGEM was reduced significantly in the spontaneous
labour tissue following RU 486 treatment. These
findings point to a reduction in the activity or amount
of prostaglandin dehydrogenase in the tissue following
treatment with RU 486. Recent work on decidua
obtained from women pretreated with RU 486 in
early pregnancy has shown, by both a direct enzymatic
method and immunohistochemistry, that the activity of
PGDH is reduced in this tissue compared with the
control (31). It was surprising that the reduction in
PGE2 metabolism following treatment with RU 486 was
confined to spontaneous labour tissue. Although basal
levels were comparable, there may still be a lower
degree of prostaglandin dehydrogenase activity in
tissues obtained following spontaneous labour that
may not be evident under basal conditions in the
culture system. When RU 486 is added, an additive or
synergistic effect may result, so explaining the results
seen in the experiments on chorion taken from women
in spontaneous labour. Such a lower degree of
prostaglandin metabolism within the tissue with RU
486 may be in keeping with previous in vivo studies
(31). The increase in prostaglandin concentrations at
the level of the fetal membranes that would result from
such inhibition of metabolism could contribute to the
enhanced uterine activity seen both in spontaneous
labour and following treatment with RU 486. Clearly
an endogenous tissue factor associated with labour is
required, because the effect was not seen with tissues
treated with RU 486 taken from women not in labour.
It is also possible that the difference between changes in
metabolism seen following in vivo treatment compared
with that following in vitro treatment with RU 486 may
reflect an intermediate step in this process.
Dexamethasone has been shown to inhibit prosta¬
glandin production from placental and amnion cell
cultures (32), and it appeared that this steroid is acting
at the level of PGHS activity. Alternatively, an increase
in PGDH activity with an associated increase in
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prostaglandin metabolism would result in a decrease in
prostaglandin concentrations. An increase in the tissue
activity of PGDH in rat lung and kidney following
treatment with prednisolone has been reported (33).
However, we were unable to demonstrate increased
prostaglandin metabolism in response to dexametha-
sone in our chorion explants. Similarly, Gibb et al. (34)
were unable to demonstrate an increase in prostaglan¬
din metabolism to account for the reduction in PGE2
output by their chorion cells incubated in the presence
of dexamethasone.
In sheep, progesterone withdrawal is a prerequisite to
the onset ofparturition. In humans, there is no decrease
in circulating systemic progesterone concentrations
prior to the onset of spontaneous labour. However,
systemic steroid concentrations may not reflect local
changes in steroid environment within the fetal mem¬
branes that may control the process of parturition in a
paracrine fashion. In our experiment the addition of
progesterone had no effect on prostaglandin metabolism.
This is in contrast with the inhibitory effect of RU 486.
One possible explanation for this is that endogenous
progesterone is exerting tonic control over prostaglandin
metabolism, which could not therefore be altered by
additional progesterone but could be overcome by the
antiprogestin.
In summary, this study has shown that prosta¬
glandin synthesis from fetal membranes is increased in
association with parturition but that there is no alteration
in prostaglandin metabolism by chorion in association
with labour. However, metabolism in spontaneous
labour tissue can be inhibited by the addition of RU 486.
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Recombinant human relaxin as a cervical ripening agent
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Objective The aim of this study was to investigate the efficacy and safety of recombinant human
relaxin (rhRIx) as a cervical ripening agent in women with an unfavourable cervix before induction
of labour at term.
Design A multi-centre, double-blind, placebo-controlled trial performed in Edinburgh, Glasgow and
Oxford. Women were treated with 0, 1, 2 or 4 mg of rhRIx in a gel vehicle administered
intravaginally. Analysis of variance tests were performed on all continuous variables, and Cochran
Mantel-Haenszel tests employed for all discrete variables.
Participants Ninety-six women at 37 to 42 weeks of gestation with a singleton pregnancy and a
modified Bishop score of< 4 were recruited.
Results There was no significant difference in the change in modified Bishop score between the four
treatment groups. The lengths of the first and second stages of labour were similar in all 4 groups.
PGE2 and oxytocin requirements were similar in all groups, as was the mode of delivery. There was
no evidence that relaxin was absorbed systemically when given in this way.
Conclusion Recombinant human relaxin 1 to 4 mg, administered as an intravaginal gel, has no effect as
a cervical ripening agent before induction of labour at term.
INTRODUCTION
The success of labour induction is influenced by the
state of the cervix; induction of labour in the presence of
an unripe cervix is associated with an increase in both
maternal and neonatal morbidity'. Cervical ripening
occurs during the phase known as pre-labour. Its exact
mechanism remains unclear but the process results in
structural changes within the cervix making it more
compliant. These include a decrease in collagen con¬
centration, an increase in water content and an alteration
in proteoglycan/glycosaminoglycan ratio within the
tissue. It is this process that we are striving to mimic
when ripening the cervix pharmacologically. The ideal
cervical ripening agent should have a selective effect on
the cervix without any additional effect on uterine
contractility, and in theory the polypeptide hormone
relaxin would meet these requirements.
Relaxin was first identified in 1926 by Hisaw2 who
demonstrated its capacity to promote separation of the
pubic symphysis in guinea-pigs. Relaxin facilitates
connective tissue remodelling, and in some animals also
inhibits myometrial contractility. In most species, cervi¬
cal ripening before the onset of labour is associated with
an increase in serum relaxin concentrations. However,
this is not the case in humans and the exact role of this
hormone in human parturition remains uncertain. Early
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clinical trials3,4 employing porcine relaxin for cervical
ripening in human subjects reported conflicting results
which probably reflected the impurity of the agent at
that time. The subsequent purification of porcine
relaxin5 led to renewed interest in this hormone. A
number of studies showed that porcine relaxin had some
therapeutic benefit as a cervical ripening agent in
women6,7, despite the primary peptide structure of
porcine relaxin having only about 50% homology with
that of human relaxin. The development of recombinant
human relaxin by Genentech Inc (San Francisco, Calif¬
ornia, USA) has provided an agent that could have
superior cervical ripening properties in women and has
stimulated further research in this field.
Phase I studies conducted by Genentech demon¬
strated that recombinant human relaxin was safe and not
associated with serious adverse effects, and that there
was no maternal development of antibody to rhRIx
following treatment8,9. Phase II studies were therefore
initiated in Australia and the UK. This paper reports the
results of the UK double-blind, three-centre study
investigating the effect of recombinant human relaxin,
administered as an intravaginal gel, on cervical ripening
in pregnant women at term with an unfavourable cervix.
METHODS
Ethical approval for this study was obtained from the
local ethics committees of the three participating centres.
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Ninety-six women, comprising nulliparous and
parous patients, were recruited to the study. All women
had a singleton pregnancy of at least 37 weeks of gesta¬
tion with a cephalic presentation and a modified Bishop
score10 of 4 or less. Women with a uterine scar, ruptured
membranes or evidence of placental abruption or
placenta praevia, were not recruited to the study. Other
exclusion criteria were significant systemic disease,
recent ingestion of aspirin or other nonsteroidal
anti-inflammatory drugs, fetal malformation, growth
retardation or macrosomia, and oligo- or polyhydram¬
nios. The decision to induce labour was made by the
woman's attending obstetrician and written informed
consent was obtained before recruitment. The indication
for induction in the majority of cases was either preg¬
nancy induced hypertension or prolonged pregnancy.
The study involved a randomised, double-blind com¬
parison of four treatment regimens: 0 (placebo), 1, 2 or
4 mg of recombinant human relaxin (rhRIx) in a gel
vehicle. The randomisation sequence was generated in
blocks of four by the Genentech Biostatistical Depar¬
tment and the code was stratified according to parity. A
randomisation list accompanied each drug shipment.
Primiparous women were assigned sequential numbers
starting from the top of the list, and multiparous women
were assigned sequential numbers starting from the
bottom of the list. The study medication was supplied
by Genentech, Inc. , as a two-part administration set: a
stoppered 20 cm3 glass vial of lyophilised rhRJx or
placebo and a 5 cm3 syringe of gel. The vial contained
0 mg or 12 mg rhRIx in isotonic citrate buffer. The
syringe delivered 3 inL of sterile 4% methylcellulose
gel in isotonic citrate buffer. The active doses were
made by reconstituting 12 mg of lyophilised study
medication in either 12, 6 or 3 rnL of sterile water and
combining this with the fixed 3 inL volume of methyl-
cellulose gel.
Women were admitted to hospital in the afternoon
before the day of induction. A medical and obstetric
history was taken and a general examination performed.
Fetal weight and amniotic fluid volume were estimated
by ultrasound scan and a cardiotocograph performed.
Blood was taken for haematology, coagulation profile,
biochemistry, serum relaxin level and serum antibody to
relaxin. Upon randomisation, the study medication was
reconstituted using sterile water by one of the hospital
pharmacy staff and delivered to the labour ward. The
baseline modified Bishop score was recorded and the
study gel administered intravaginally to the posterior
fornix that evening. The woman remained recumbent
for 1 hour following gel application. Blood pressure,
pulse, respiration rate, uterine activity and fetal heart
rate were monitored hourly for 4 hours post-treatment,
and then every 4 hours for at least 24 hours or until
delivery. Observations were suspended overnight if the
woman was asleep. Blood was taken at 1, 4, 15 and
24 hours after gel administration for serum relaxin
concentrations.
The following morning, at approximately 15 hour?
post-treatment, a vaginal examination was performed
by the same investigator and the modified Bishop score
recorded after which prostaglandin E2 (PGE2) gel 2 mg
was instilled intravaginally. Further PGE, gel, 1 mg or
2 mg, was given after a 6-hour interval as required.
Amniotomy was performed when the cervix was at least
3 cm dilated and frilly effaced, and oxytocin adminis¬
tered according to hospital protocol. Uterine activity
and fetal heart rate were monitored continuously
throughout labour. If labour occurred before the planned
15 hour assessment, the modified Bishop score was
recorded at the onset of labour and the woman managed
as above. The onset of labour was defined as the
onset of regular painful contractions with evidence of
progressive cervical dilatation of the cervix. For women
delivered by caesarean section before the second stage
of labour, the length of the first stage was taken to be the
total length of labour.
At delivery, umbilical cord blood was taken to assay
relaxin concentration and blood gas analysis, and mater¬
nal blood for serum relaxin concentration. Apgar scores
were recorded at 1 and 5 minutes post-delivery. Twenty
four hours after delivery, maternal blood was collected
for repeat haematology, coagulation profile, routine bio¬
chemistry and serum relaxin concentration. A general
physical examination was also performed. Women were
reviewed 6 weeks post-delivery when serum relaxin
levels were measured and any postnatal problems
documented.
The primary outcome measure was the change in
modified Bishop score between baseline and 15 hours
post-treatment. Secondary outcome measures included
duration of first and second stage of labour, prevalence
of 'spontaneous' labour and caesarean section, and
oxytocin and total PGE2 requirement. Maternal safety
measures included vital signs, haematology and bio¬
chemistry screening. Fetal safety measures included
stillbirth, neonatal death, fetal heart rate disturbances,
Apgar scores, cord blood gases, need for resuscitation
and incidence of neonatal morbidity.
Sample size and power consideration
Ninety-six women were recruited to the study with 24
women in each of the four treatment groups. The
primary outcome measure, change in modified Bishop
score, was first to be analysed by ANOVA to take
account of any effect of dose influencing modified
Bishop score. If a significant effect were found
subsequent pairwise comparisons were to have been
performed. The determination of sample size was based
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Table 1. Subject characteristics at recruitment by treatment group. Age and gestation analysed by ANOVA; parity and baseline modified Bishop
score analysed by Cochran Mantel-Haenszel test. Values are given as mean (SD).
Treatment group
Characteristic Placebo (n = 23) lmg(« = 23) 2mg(« = 25) 4mg(/? = 25) P
Age (years) 27 0 (21-3-32-7) 26-8 (21-3-32-3) 26 7 (22-1-31-3) 25-8 (21-4-30-2) 0-796
Modified Bishop score 2-9 (2-0-3-8) 3-0 (2-3-3-7) 2-8 (1-9—3-7) 2-5 (1-4-3-6) 0 076
Gestation (weeks) 40-0 (38-5^41-5) 39-6 (38-2-41-0) 39-9 (38-8-41-0) 40-1(38-9-41-3) 0-694
Parity
0 18 20 22 19
> 1 5 3 3 6 0-581
Table 2. Labour characteristics by treatment group. All parameters analysed by ANOVA. Values are given as mean (95% CI).
Treatment group
Placebo 1 mg 2 mg 4 mg P
Change in Bishop score 1-64 (1-0-2-3) 1-35 (0-7-2-0) 1-76 (0-5-3-0) 1-32 (0-8-1-9) 0-853
Duration of 1st stage (h) 4-9(3-9-5-9) 5-0(3-7-6-2) 5-3 (4-1-6-5) 6-5 (5-1-7-9) 0-222
Duration of2nd stage (h) 0-7(0-4-1-1) 1-3(0-8-1-7) 1-0(0-5-1-5) 1-1 (0-6-1-5) 0-387
Total duration of labour (h) 5-6 (4-6-6-6) 6-2(4-7-7-8) 6-3(4-9-7-7) 7-6 (5-9-9-2) 0-286
Treatment to 1st stage (h) 22-3 (19 2-25-3) 23-7 (21-0-26-3) 26-9 (22-3-31-6) 23-1 (20-2-25-9) 0-202
Treatment to delivery (h) 28-0 (24-8-31-2) 29-9 (26-7-33-2) 39-3 (26-4-52-2) 36-7 (23-8-49-6) 0-306
on such pairwise comparisons. Assuming that the stan¬
dard deviation and the between-treatment difference
with respect to the change in cervical score are equal, a
two-sided t test with a significance level of 1-67% will
have 84% power to detect such a difference.
Statistical analysis
All data were recorded on standardised case record
forms and analysed at Genentech Inc in California.
Analysis of variance tests were performed on all contin¬
uous variables, and Cochran Mantel-Haenszel tests
employed for discrete variables.
RESULTS
Numbers of women in the four treatment groups were
as follows: placebo: n = 23, 1 mg: n = 23, 2 mg: n = 25
and 4 mg: n = 25. There were no statistically significant
differences in the characteristics of the women in the
four groups (Table 1).
The mean changes in modified Bishop score were
1-64 for placebo, 1-35 for 1 mg relaxin, 1-76 for 2 mg
relaxin and 1 -32 for 4 mg relaxin. There was no statisti¬
cally significant difference in the increase in modified
Bishop score between the four groups (Table 2). In
addition, there was no significant difference between
the four groups when nulliparae and parous women
were analysed separately (data not shown). The length
of the first and second stages of labour was similar in all
treatment groups. There were no differences in the time
from treatment to first stage of labour or from treatment
to delivery between the groups (Table 2). Excluding
the patients delivered by caesarean section from the
analysis did not alter the results for any of the above
variables (data not shown).
The majority of women required induction 15 hours
after study medication and only a few women laboured
before this time (Table 3). The use of PGE2 and oxy¬
tocin is also illustrated in Table 3. There was no statisti¬
cal difference in requirement for either drug between
groups, and the doses employed were similar in each
treatment group. There was no significant difference in
the mode of delivery between the groups with the
majority of women achieving a spontaneous vaginal
delivery. The overall caesarean section rate for the study
was approximately 20% and the apparent increase in
section rate in the 2 mg group did not reach statistical
significance. Again, there was no statistical difference
in the variables displayed in Table 3 when primigravid
and parous women were analysed separately, or when
women delivered by caesarean section were excluded
from the analysis (data not shown).
Maternal and neonatal safety outcomes
There was no significant difference in pre- and post-
treatment measurements of pulse and respirations
between the four groups. There was a tendency to lower
blood pressures in the treatment groups when compared
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Table 3. Delivery characteristics, oxytocin and PGE2 requirements, by treatment group. Total oxytocin and PGE2 use analsyed by ANOVA;
mode of labour and delivery analysed by Cochran Mantel-Haensze! test. Values are given as n and mean (95% CI).
Treatment group
Placebo (n = 23) 1 mg (n = 23) 2 mg (n = 25) 4 mg (n = 25) P
Spontaneous labour *
No 21 22 20 22 0-314
Yes 2 1 5 2
Women requiring PGE, 18 18 21 20* 0-928
Total PGE2 dose (mg) 2-1 (1-5-2-6) 2-1 (1-5-2-6) 2-6 (2-0-3-1) 2-3 (1-8-2-8) 0-553
Women requiring oxytocin 10 13 12 13 0-916
Total oxytocin dose (U) 2-4 (0-4-4-4) 2-7 (1-2-4-1) 2-6 (0-8-4-5) 24 (1-1-3-7) 0-993
Mode ofdelivery: *
Vaginal 16 14 13 16 0446
Operative vaginal 2 6 4 5
Caesarean section 4 3 8 4
*Data missing for one subject in this group.
following the start of treatment. Haematological and
biochemical profiles were within the normal range for
pregnancy. There was no association between treatment
group and maternal outcome measures such as post¬
partum haemorrhage, infection and urinary retention.
There were significantly higher fetal heart rates in the
treatment groups: placebo: 133 beats per minute (bpm);
1, 2 and 4 mg rhRIx: 136, 141 and 137 bpm, respectively
(P < 0-011). This effect was evident for approximately
24 hours post-treatment. There were no significant
differences in 1 and 5 min Apgar scores, or cord blood
gas results between the groups. Neonatal outcome
measures such as meconium stained amniotic fluid,
hypoglycaemia and hyperbilirubinaemia occurred with
the same frequency in all treatment groups. There were
no stillbirths or neonatal deaths in the study.
Relaxin concentrations
Maternal serum relaxin concentrations were assayed by
Genentech. Concentrations following intravaginal
administration of 1, 2 and 4 mg rhRIx were no different
from the endogenous relaxin levels measured in the
placebo group (Fig. 1). There was no correlation
between baseline serum relaxin concentration and base¬
line modified Bishop score, or maximum serum relaxin
concentration and change in modified Bishop score.
Most cord blood relaxin concentrations were below the
level of detection of the assay irrespective of treatment
group. Details of the relaxin assay are 'in house' at
Genentech.
DISCUSSION
with placebo and this was statistically significant for A precise role for relaxin in the physiology of human
diastolic blood pressure: placebo -83 inrnHg; 1, 2 and parturition has yet to be defined. In a number of animals
4 mg rhRIx -77, -77 and 70 mmHg, respectively (eg. pig and rat), the onset of labour is clearly preceded
(P< 0-012). This effect was seen over the first 14 hours by a surge in serum relaxin concentrations and this











Delivery 1 day 3-4
Fig. 1. Maternal serum relaxin concentrations (pg/mL): B = placebo,
□ = 1 mg, 0=2 mg, 0=4 mg, pre- and post treatment (mean,
95% CI).
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appears to facilitate connective tissue remodelling in the
reproductive tract. In human pregnancy serum relaxin
concentrations peak at approximately 10 weeks of ges¬
tation and thereafter concentrations fall progressively
towards term". Labour itself is not associated with any
further change in relaxin concentrations". If relaxin
plays a key role in cervical ripening it would be during
the time of pre-labour that changes in serum relaxin
concentrations might occur.
The corpus luteum is the primary source of relaxin
during pregnancy, although extra-ovarian sites of
production have been identified12. The fact that relaxin
is not a pre-requisite for cervical dilatation has been
demonstrated by the successful induction of labour in a
woman with premature ovarian failure in whom serum
relaxin levels were too low to record13. This finding also
highlights the fact that relaxin production by other
tissues is very small compared with ovarian production.
This study did not show any therapeutic effect of
recombinant human relaxin on cervical ripening when
administered as an intravaginal gel. There was no sig¬
nificant difference in mean change in modified Bishop
score following treatment with 1, 2 or 4 mg of rhRIx
compared with placebo. This is not surprising since pre-
and post-treatment serum relaxin concentrations were
the same in the placebo and active groups suggesting
that relaxin was not absorbed from the preparation
when administered via this route or that the dosages
were too small. There was no association between
endogenous serum relaxin levels and baseline modified
Bishop score, or maximum serum relaxin concentra¬
tions and change in modified Bishop score. In addition,
there was no change in endogenous levels throughout
induction, labour and delivery which confirms previous
findings. RhRIx appears to be safe and not associated
with any clinically significant side effects. In view of
the lack of evidence for absorption of rhRIx, which is
reflected in the absence of clinical effect, the changes in
maternal diastolic blood pressure and fetal heart rate,
which were small and clinically irrelevant, may well
have been spurious.
These findings are in keeping with a smaller study14
employing recombinant human relaxin in a dose of
1-5 mg which also failed to demonstrate a significant
effect on cervical ripening. Similarly, this dose of
recombinant human relaxin was not associated with any
adverse maternal or fetal complications. There could
be a role for relaxin in cervical ripening without any
parallel increase in circulating relaxin concentrations if
it were acting at receptor level. However, to date, a
receptor for relaxin in humans has not been identified.
The reduction in cervical collagen concentration nec¬
essary for cervical ripening can, in part, be explained by
an increase in enzymatic collagen degradation. Labour
is associated with an increase in circulating collagenase
levels15 and collagenase activity within cervical tissue.
It has been reported that relaxin increases collagenase
activity16. Relaxin receptors have been identified on
human fibroblasts17, which along with leucocytes are
capable of collagenase production. A number of clinical
trials have demonstrated a cervical ripening effect of
porcine relaxin in pregnant women6'7. However, these
trials were small and the women were of mixed parity.
In addition, in one study6, women in the treatment
group tended towards higher baseline Bishop scores
limiting the conclusions that can be drawn. Cervical
ripening has been likened to an inflammatory
response18 and one potential mechanism whereby
porcine relaxin, although purified, could stimulate
cervical ripening is by provoking an immunological
reaction resulting in neutrophil degranulation and
release of collagenase, perhaps mediated by inter-
leukin-8 which has recently been shown to be produced
by the human cervix19.
The effect of relaxin on myometrial contractility
in different species is varied. An inhibitory effect of
purified porcine relaxin on the spontaneous contractility
of nonpregnant human myometrium has been demon¬
strated in vitro20. This effect has been confirmed on
nonpregnant and pregnant myometrium from rats and
pigs, but porcine relaxin had little, if any, effect
on spontaneous or induced, pregnant or nonpregnant,
human myometrial contractility in vitro21. More
recently, human relaxin has been shown to have only a
minor effect on human myometrial contractility in late
pregnancy22. The data for uterine activity in this clinical
trial were not assessed, but as there was no difference in
duration of labour or need for augmentation between
groups it is likely that contractility was unaffected.
Prostaglandins are currently the most successful
agents for ripening the cervix pharmacologically23
but they have the disadvantage of simultaneously stimu¬
lating uterine activity. Although theoretically relaxin
meets the requirements for the ideal cervical ripening
agent, that is ripening without contractility, this study
has not demonstrated any cervical ripening effect of
recombinant human relaxin. This may simply be due to
incorrect choice of dosage. However, it seems more
likely that the route of administration for this large
polypeptide hormone was inappropriate. The intra¬
venous route may be more suitable and deserves to be
investigated before we can discard relaxin as a ripening
agent.
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prostaglandin synthesis and metabolism
in human fetal membranes
Janet Brennand1. Rosemary Leask2, Rodney Kelly3. Ian Greer1 and Andrew Calder2
From the Departments o( Obstetrics and Gynaecology. 'University of Glasgow and 2University of Edinburgh,
and the 3MRC Unit, Centre for Reproductive Biology, Edinburgh
Acta Obstet Gynecol Scand 1997: 76: 00-00. © Acta Obstet Gynecol Scand 1997
Objective. To investigate the effect of amniotic fluid on prostaglandin synthesis and metab¬
olism in the fetal membranes.
Design. A cell culture study of amnion and chorion obtained at elective cesarean section
incubated with amniotic fluid collected following either spontaneous labor and delivery, or
elective cesarean section.
Subjects. Fourty-eight pregnant women at 37-42 weeks gestation: 24 in spontaneous labor
and 24 delivered by elective cesarean section.
Results. Significantly more PGE2 and PGF2a were produced by amnion and chorion treated
with amniotic fluid from spontaneous labor compared with elective cesarean section. Spon¬
taneous labor amniotic fluid favors PGE2 and PGFM production by amnion and chorion
respectively, while elective section fluid stimulates PGE2 synthesis by both tissues (reflected as
PGEM in chorion). Amniotic fluid, from either spontaneous labor or elective section, had no
effect on the metabolism of exogenous PGE2 or PGF2a by chorion cells.
Conclusion. Spontaneous labor is associated with the presence of a substance in amniotic
fluid which facilitates prostaglandin synthesis in the fetal membranes, but which is without
effect on prostaglandin metabolism.
Key words: amniotic fluid; fetal membranes; labor; prostaglandin biosynthesis and metab¬
olism
Submitted 30 January, 1997
Accepted 12 August, 1997
While the mechanisms underlying the process of
parturition remain incompletely understood,
prostaglandins appear to play an integral role.
Supporting evidence includes the finding of in¬
creased concentrations of prostaglandin E2 and
Abbreviations.
COX I: cyclooxygenase I; DPBS: dulbecco's phosphate buffered
saline; EGF: epidermal growth factor; IL-1J3: interleukin-iP;
PAF: platelet activating factor; PG: prostaglandin; PGDH:
prostaglandin dehydrogenase; PGE2: prostaglandin E2;
PGE2M: 13, 14-dihydro-15-keto-PGE2; PGF^: prostaglandin
F2a', PGFM: 13, 14-dihydro-lS-keto-PGF^; PGHS: prosta¬
glandin endoperoxide synthase; TGFa: transforming growth
factor a; TNFa: tumor necrosis factor a.
prostaglandin F2a in amniotic fluid, and their cor¬
responding metabolites in maternal plasma, in as¬
sociation with spontaneous labor (1, 2). In ad¬
dition, prostaglandins are capable of inducing lab¬
or at all gestations (3) and are known to be potent
stimulators of myometrial contractility. This view
is, however, not adopted by all, and it has recently
been suggested that the increase in prostaglandin
concentrations in biological fluids is a result of
events promoting labor, rather than in itself being
a central mediator of the process (4).
The fetal membranes, comprising amnion, chor¬
ion and decidua, are a major source of the primary
prostaglandins PGE2 and PGF^, and their inac-
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tive metabolites 13, 14-dihydro-15-keto-PGE2
(PGEM) and 13, 14-dihydro-lS-keto-PGF^
(PGFM) (5). The amnion, as a result of the action
of prostaglandin endoperoxide synthase (PGHS),
produces mainly PGE2 (6, 7), but production of
PGF2a in lower concentrations has also been dem¬
onstrated (8). PGE2 production by amnion is sig¬
nificantly increased in tissue obtained following
spontaneous labor (6, 7, 9). Negligible amounts of
prostaglandin metabolites are produced by the am¬
nion reflecting the low level of activity of the main
metabolic enzyme 15-hydroxy-prostaglandin de¬
hydrogenase (PGDH) in this tissue (6, 7, 9). Chor¬
ion has the highest PGDH activity of the three
tissues (6, 7) and under basal conditions PGEM is
the major prostanoid of the chorion (9). In associ¬
ation with spontaneous labor there is a significant
increase in the production of PGFM by this tissue
(7). The decidua produces PGE2 and PGF^ in
equal amounts (6) with a significant increase in
PGF2a production with the onset of labor (7).
Concentrations of both primary prostaglandins
and their respective metabolites increase in associ¬
ation with spontaneous labor. However, the major
increase in PGE2 appears to occur prior to the on¬
set of established labor, whereas PGF2a increases
during labor (10). This points to a role for PGE2 in
cervical ripening and the initiation of labor, while
PGF2a may have a role for the maintenance and
progression of labor. This is supported by the
finding that the increase in PGF2ct correlates di¬
rectly with the duration of labor (10), and that am¬
niotic fluid concentrations of PGF2ct are reduced
in women with dysfunctional labor (11). Since am¬
nion is principally involved in PGE2 synthesis it
has been extensively investigated as a potential
regulator of prostaglandin dynamics in association
with parturition.
Amnion is an avascular tissue which is in con¬
tact with both the maternal and fetal environment.
Production of PGE2 could therefore be regulated
by a factor(s) present in amniotic fluid, the nature
of which may be controlled by the fetus. Alterna¬
tively, the decidua, which is maternal in origin, or
the chorion, may influence prostaglandin produc¬
tion by the amnion. Amniotic fluid contains stimu¬
lators and inhibitors of prostaglandin production.
An endogenous inhibitor of prostaglandin syn¬
thase has been demonstrated in amniotic fluid (12),
the activity of which decreases with advancing ges¬
tation and the onset of spontaneous labor. This
suggests that the amnion is under tonic inhibition
which is gradually lost as pregnancy progresses.
Further evidence supporting the role of inhibitory
activities includes the finding that conditioned me¬
dia from amnion obtained at cesarean section will
inhibit endometrial cell prostaglandin output (13),
and that amniotic fluid contains compounds that
appear to inhibit phospholipase activity (14).
Stimulatory activities exist in amniotic fluid (15,
16) and there is an increase in this activity with
advancing gestation. There is therefore a reciprocal
change in the stimulatory and inhibitory prop¬
erties of amniotic fluid that is gestation dependent
(16). Examples of agents that stimulate amnion
cell prostaglandin production include epidermal
growth factor (EGF), transforming growth factor
a (TGFa) and platelet activating factor (PAF), all
of which are present in amniotic fluid in increasing
concentrations during labor (17, 18, 19).
The chorion is an important site of prosta¬
glandin metabolism, and any change in meta¬
bolic activity within this tissue could significantly
alter active prostaglandin concentrations. Since
amniotic fluid contains factors which influence
prostaglandin production by amnion, it is poss¬
ible that these agents could also alter the meta¬
bolic activity of the chorion. As no previous
studies have assessed the effect of amniotic fluid
on production and metabolism simultaneously,
the purpose of this study was to determine the
effect of amniotic fluid on prostaglandin produc¬
tion and metabolism by the fetal membranes,
amnion and chorion.
Material and methods
Amniotic fluid was collected from two groups of
pregnant women at term (37-42 weeks) with an
uncomplicated pregnancy. The first group labored
spontaneously and achieved a vaginal delivery
without oxytocin augmentation (n=24); the second
group was delivered by elective cesarean section for
either breech presentation or previous cesarean
section (« = 24). Fetal membranes were collected
from a third group of women undergoing uncom¬
plicated elective cesarean section at term (n=4).
Because it is known that there can be variation in
the response of these tissues in culture each experi¬
ment was performed twice. Therefore, a total of
four cell culture experiments is described, each one
employing fetal membranes from a different sub¬
ject. Amniotic fluid from different subjects was
used in each of the four experiments.
Amniotic fluid collection andpreparation
Amniotic fluid was collected at elective cesarean
section by transmembranous amniocentesis and
immediately with delivery of the baby following
spontaneous labor under aseptic conditions. The
amniotic fluid was centrifuged at 2000 rpm at
room temperature for 20 minutes and the super¬
natant divided into aliquots for storage at —20°C
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pending the cell cultures experiments. On thawing,
the amniotic fluid was centrifuged again and then
filtered through a sterile 0.20 pm mesh to remove
any contaminating bacteria prior to addition to
the culture system.
Cell culture preparation
The membranes were trimmed from the placenta
immediately following delivery and transported in
Dulbecco's phosphate buffered saline solution
(DPBS) containing heparin (10 u/mL). The am¬
nion and chorion were separated manually and
any excess decidua was peeled from the chorion
with fine tissue forceps. The amnion and chorion
were rinsed thoroughly in DPBS and weighed. The
tissues were soaked separately in DPBS containing
gentamicin (Sigma, UK) 40 mg/500 mL and am¬
photericin B (Sigma, UK) 2.5 mg/500 mL for 1
hour. Following a further four washes with DPBS
the amnion and chorion were shredded into 3-4
mm pieces using skin graft blades. The chorion
was then pre-incubated at 37°C for 10 minutes
with 50 mL of digestion medium (Gibco Culture
Medium RPMI 16/40 with 2.5 g trypsin and 10 mg
DNA-ase (both Sigma, UK) per 500 mL) to re¬
move red blood cells. The amnion and chorion
were incubated with digestion medium (approx. 5
mL/g amnion, and 5-7 mL/g chorion) in Erlenme-
yer flasks with a stirring magnet at 37°C for 40
minutes. Each tissue was filtered through a 0.16
mm nylon mesh and the filtrate, containing the
cells, collected in a sterile container. The remaining
tissue was dispersed mechanically in complete cul¬
ture medium with an adapted Eppendorf pipette
and filtered through the 0.16 mm mesh. This mech¬
anical dispersion and filtration was repeated twice.
Complete culture medium consisted of RPMI 16/
40 (Gibco, UK) with 25 mM Hepes Buffer plus L-
Glutamine with the following additions: 50 mL/
500 mL fetal calf serum (Gibco, UK); 5 mL/500
mL Penstrep solution (5000 iu penicillin/5000 pg
streptomycin/ml, Gibco, UK); 5 mL of insulin-
transferrin-sodium selenite media supplement
(Sigma, UK). The culture medium was centrifuged
at 1500 rpm for ten minutes and the supernatant
decanted. This procedure was repeated three times
and following the third spin the cells were resus-
pended in a fixed volume of complete culture me¬
dium for counting. The cells were counted and vi¬
ability assessed using Trypan Blue exclusion. The
cell preparations were then diluted to give approxi¬
mately 2X105 cells/well. The amnion and chorion
cells were plated out separately in standard 24 well
plates.
All amnion and chorion cells were maintained
in culture for 7 days, at which time the cells re¬
mained at confluence and there was no evidence of
bacterial contamination.
Effect of amniotic fluid on amnion and chorion
prostaglandin production
The purpose of this experiment was to investigate
the effect of amniotic fluid on PGE2 and PGF2a
production, and PGEM and PGFM production by
amnion and chorion cell cultures respectively.
The plates of amnion and chorion prepared as
described above were incubated in humidified 95%
air; 5% C02 at 37°C for 24 hours. Amniotic fluid
obtained at elective cesarean section (n=6) and fol¬
lowing spontaneous labor (n=6) was added to the
cells in volumes of 50, 100, 200 and 400 pL. Cells
were also incubated in media alone, to act as con¬
trol, and with phorbol myristoyl acetate 100 nM
(Sigma, UK) to confirm that prostaglandin syn¬
thesis could be induced in these preparations. The
total volume of each well was maintained at 1 mL.
Amniotic fluid (100 pL) from each subject was also
incubated alone for estimation of background pri¬
mary prostaglandins and their metabolites. All ex¬
periments were performed in duplicate. The plates
were incubated for a further 24 hours and then
0.5 mL aspirated from each well for prostaglandin
measurement. The above experiment was repeated
on a second set of fetal membranes using amniotic
fluid from different subjects (again, n=6 for both
groups).
Amniotic fluid and chorion cell metabolism of
exogenous prostaglandins
The purpose of this experiment was to investigate
the effect of amniotic fluid on the metabolism of
exogenous PGE2 and PGF2a to their respective
metabolites by chorion cell cultures.
A chorion cell culture was prepared as pre¬
viously described and plated out at 2X105 cells/
well. The plates were incubated for 24 hours in hu¬
midified 95% air; 5% C02 at 37°C. Amniotic fluid
collected following elective cesarean section (n= 6)
and spontaneous labor and delivery (n= 6) was
added to the cells and the plates incubated for a
further 24 hours. Chorion cells and 400 pL of each
amniotic fluid sample were incubated alone to en¬
able estimation of background levels of the pri¬
mary prostaglandins and their metabolites. The
following additions were made (final concen¬
trations): 500 ng PGE2 (Upjohn Ltd, UK) and 500
ng PGF2q (Upjohn Ltd, UK). For the final 4 hour
incubation the plates therefore comprised wells
containing: chorion cells alone; cells+400 pL am¬
niotic fiuid+500 ng PGE2; cells+400 pL amniotic
fiuid + 500 ng PGF^; cells+500 ng PGE2 (control);
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cells+500 ng PGF2ci (control); 400 pL amniotic
fluid alone. The final incubation volume in all wells
was 1 mL. All experiments were performed in
duplicate. The incubation fluid (0.5 mL) was oxim-
ated and stored pending radioimmunoassay. The
experiment was repeated on a second set of chor¬
ion with different amniotic fluids (again, n- 6 for
each group).
Radioimmunoassay
A competitive binding radioimmunoassay was
used to determine the PGE2, PGF2ct) PGEM and
PGFM content of the media. The technique has
previously been described in detail (20, 21). At the
time of the experiment 0.5 mL of culture medium
was oximated with an equal volume ofmethyl oxi-
mating solution. These samples were mixed thor¬
oughly, stored at room temperature for 24 hours
and then at 5°C pending radioimmunoassay. In
brief, up to 50 pL of the oximated culture medium
was assayed. The labels employed are the iodinated
(1251) methyloximes of PGE2, PGF2ot, PGEM and
PGFM (Pro-Gly-Tyr conjugate in each case). Anti-
sera to the respective labels were raised in the rab¬
bit. The assay was left overnight prior to separ¬
ation of the antigen-antibody complex from the
free antigen by a second antibody magnetic separ¬
ation procedure. The intra-assay coefficient of
variation was 12.3% for PGE2, 10.5% for PGF^,
8.4% for PGEM and 7.3% for PGFM. The inter-
assay coefficient of variation was 13.3%, 13.9%,
13.9% and 13.3% for PGE2, PGF2a, PGEM and
PGFM respectively.
Statistics
One and two factor analysis of variance (ANOVA)
was used to analyze the data. Where the data were
not normally distributed, log transformation was
employed prior to ANOVA.
Results
The effect of amniotic fluid on prostaglandin
production by amnion and chorion
Fig. 1 illustrates the stimulatory effect of amniotic
fluid, in a dose-dependent manner, on prosta¬
glandin E2 and prostaglandin F2a production by
amnion. Amniotic fluid from spontaneous labor
stimulated significantly greater production of both
prostaglandins compared with elective cesarean
section fluid: PGE2, p<0.001; PGF2ct, /?<0.05.
These findings were reproduced in a second culture
(data not shown). Amniotic fluid from spon¬
taneous labor produced significantly more PGEM
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Fig. 1. The effect of amniotic fluid (AF) on postagladin E2 and
F2a production by cultured amnion cells. ■ AF spontaneous
labor (n=6); ^ AF cesarean section (n=6). PGE2, p<0.001;
PGF2ci, p<0.05. Results expressed as means (s.e.mean).
cesarean section amniotic fluid, p<0.0001 (Fig. 2).
This was not confirmed in a second culture. Pro¬
duction of PGFM by chorion cells, reflecting
PGF2b, was significantly greater in the presence of
spontaneous labor amniotic fluid, compared with
elective section fluid, at all doses, p<0.003 (Fig. 2).
These findings were again reproduced in a second
culture (data not shown).
The effect of amniotic fluid on metabolism of
exogenous prostaglandins by chorion cells
Spontaneous labor and elective section amniotic
fluid, in a dose of 400 pL, significantly stimulated
PGEM and PGFM production compared with
control, /?<0.05 in chorion cell culture (Fig. 3) (re¬
produced in a second cell culture, data not shown).
The production of both PGEM and PGFM was
significantly greater in the presence of spontaneous
© Acta Obstel Gynecol Scand 76 (1997)
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There was no difference in PGEM production
by chorion, following the addition of 500 ng PGE2,
when cultured in the presence of amniotic fluid
from spontaneous labor or elective section com¬
pared with control (cells+500 ng PGE2) in both
cultures (Fig. 5). Similarly, there was no difference
in the production of PGFM, following the ad¬
dition of 500 ng PGF2a, by chorion cells cultured
in the presence of amniotic fluid from elective sec¬
tion (both cultures) (Fig. 5). Amniotic fluid from
spontaneous labor had no effect on PGFM pro¬
duction, following addition of PGF2a, iff one cul¬
ture, and stimulated significantly greater PGFM
production compared with control (cells+500 ng
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Fig. 2. The effect of amniotic fluid (AF) on postagladin metabo¬
lite production by cultured chorion cells. H AF spontaneous
labor (n=6); £3 AF cesarean section {n=6). PGEM, p<0.0001;
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Fig. 3. The effect of amniotic fluid (AF) on postagladin/meta-
bolite production by cultured chorion cells. □ control, 13 AF
cesarean section (n=6); M AF spontaneous labor (n = 6). V.
phorbol myristoyl acetate. *=significantly different from con¬
trol, p<0.05; I I p<0.05. Results expressed as means (s.e.¬
mean).
labor amniotic fluid compared with elective section
fluid, /?<0.05. In addition, the responsiveness of
the chorion cells to phorbol myristoyl acetate, a
stimulator of protein kinase C, is illustrated in Fig.
3. In both cultures, amniotic fluid from elective
section stimulated significantly more PGEM pro¬
duction compared with PGFM, p<0.0005 (Fig. 4;
data from one culture). Amniotic fluid from spon¬
taneous labor stimulated significantly more PGFM
production in comparison to PGEM, p<0.05 (Fig.
4), but was not statistically significant in the sec¬
ond culture (p=0.056; data not shown). The ratio
of PGFM to PGEM production was 0.38 for chor¬
ion cells cultured with elective section amniotic
fluid, compared with and FM:EM ratio of 4.6
when cultured in the presence of spontaneous lab¬
or amniotic fluid. This represents a 12-fold in¬
crease in FM:EM ratio.
Metabolite
pgArt
AF CS (400 Hi) AF spon (400 pi_)
Fig. 4. The effect of amniotic fluid (400 pL) from elective sec¬
tion (n=6) and spontaneous labor (fl=6) on PGEM compared
with PGFM production by chorion cells. 13 PGEM, ^ PGFM.
Results expressed as means (s.e.mean).
© Acta Obslel Gynecol Scand 76 (1997)








Ce*s + PGE2 C ♦ E2 +AF cs C ♦ E2 ♦AF spon
Cells -fPGF2a C +F2a +AF cs C +F2a + AF spon
Fig. 5. The effect of spontaneous labor and elective amniotic
fluid (both n—6) on the metabolism of exogenous PGE2 and
PGF2a. ■ PGEM, H PGFM. Results expressed as means (s.e.-
mean).
Discussion
We have demonstrated that amniotic fluid from
spontaneous labor and elective cesarean section at
term is capable of stimulating prostaglandin pro¬
duction by amnion cell culture. This is in keeping
with other workers who have shown increased
PGE2 production by amnion cells (15) and bovine
seminal vesicles (16) incubated with amniotic fluid.
In our experiments PGE2 production was stimu¬
lated by amniotic fluid in a dose-dependent man¬
ner, confirming the findings of Mitchell et al. (22)
who demonstrated PGE2 stimulatory activity in
amniotic fluid at all gestations. However, these
workers did not find a difference in PGE2 produc¬
tion in relation to parturition, unlike our experi¬
ments where amniotic fluid obtained at spon¬
taneous labor had a significantly greater stimu¬
latory effect than elective section fluid. Similarly,
PGF2a production was stimulated in these experi¬
ments and again responded to amniotic fluid in a
dose-dependent manner. The response to spon¬
taneous labor fluid was significantly greater than
elective section fluid. It has previously been dem¬
onstrated that amniotic fluid will stimulate PGF^
production by amnion, chorion and decidua (23)
but in these experiments there was no difference
between spontaneous labor and elective section
fluid. Reddi et al. (24) revealed that amniotic fluid
obtained late in labor significantly stimulated
PGF2o production by sheep seminal vesicle prosta¬
glandin synthase, whereas fluid obtained before
labor had no such effect. In our amnion cells cesa¬
rean section fluid had little effect on PGF2a pro¬
duction, although a significant dose-response
curve was achieved in one culture. In all cultures
significantly more PGE2 was produced compared
with PGF^ in response to both spontaneous labor
and elective section fluid confirming that this is the
major prostanoid synthesized by amnion (6, 7).
There was some variability in the response of
the chorion cell cultures to amniotic fluid. PGEM
production, reflecting PGE2 synthesis, was stimu¬
lated by spontaneous labor amniotic fluid in a
dose-dependent manner in one culture. Elective
section amniotic fluid had a dose-related stimu¬
latory effect on PGEM production in both cul¬
tures. Similarly, PGFM production, reflecting
PGF2a synthesis, was stimulated by amniotic fluid
from the two groups in both cultures. There was a
significant difference in the stimulatory effect of
spontaneous labor amniotic fluid compared with
that of elective section with regard to PGFM pro¬
duction. In the metabolism studies we confirmed
the stimulatory effect of amniotic fluid (400 mL)
from spontaneous labor and elective section on
PGEM and PGFM production in both chorion
cultures, although elective section fluid had no sig¬
nificant effect on PGFM production in one cul¬
ture. Spontaneous labor amniotic fluid stimulated
significantly more PGEM and PGFM production
compared with elective section fluid in both cul¬
tures. In all chorion cultures elective section fluid
stimulated significantly greater PGEM production
than PGFM, whereas spontaneous labor fluid, al¬
though not significant in all cultures, tended to
favor PGFM production.
We have shown, therefore, that amniotic fluid
obtained at elective section and spontaneous labor
is capable of stimulating prostaglandin production
by both amnion and chorion and that there is a
preference for which prostaglandin is produced:
spontaneous labor favors PGE2 and PGFM pro¬
duction by amnion and chorion respectively, while
elective section fluid stimulates PGE2 synthesis by
both tissues (reflected as PGEM in chorion). These
findings are in keeping with the fact that under
basal conditions PGEM is the main product of the
chorion (9), whereas PGF^ is thought to be inte-
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gral to the maintenance of established labor, with
increasing concentrations of this prostaglandin as
cervical dilatation advances (25, 26). There is a sig¬
nificant difference in the stimulatory activity of the
amniotic fluid in relation to parturition, but we do
not know from these experiments whether this is a
result of gestationally related changes in inhibitory
or stimulatory properties of the fluid. These find¬
ings are not dissimilar from those of Reddi et al.
(24) who found, that as labor progressed, there was
a simultaneous reduction in stimulatory activity
and increase in inhibitory activity in amniotic fluid
with respect to PGE2 production, whilst the con¬
verse was true for PGF2a production.
It has been postulated that changes in the meta¬
bolic capacity of the chorion may be just as im¬
portant in the regulation of prostaglandin concen¬
trations as any direct stimulatory effect on prosta¬
glandin synthesis (27). In this study amniotic fluid
from spontaneous labor or elective section had no
effect on the concentration of PGEM or PGFM
recovered from the chorion cell cultures, following
the addition of PGE2 and PGF^ respectively,
compared with control (cells+PG alone). These
findings suggest that amniotic fluid has no signifi¬
cant effect on the metabolic pathway for prosta¬
glandins in chorion, and in particular that there is
no reduction in metabolism in relation to labor
which could result in the increased prostaglandin
concentrations seen at this time. This is in keeping
with previous reports showing no change in prosta¬
glandin metabolism in association with spon¬
taneous labor (7, 28). This also accords with the
finding that the localization of immunoreactive
PGDH in chorion does not change with labor (29).
In contrast, in cases of preterm labor associated
with chorioamnionitis, it has been demonstrated
that immunoreactive staining for PGDH is sig¬
nificantly reduced as a result of trophoblast de¬
struction (30). This would enable prostaglandins to
escape metabolism and thus facilitate myometrial
contractility. In the present study, the metabolism
by chorion of exogenous PGE2 to its inactive
metabolite PGEM was significantly greater than
that of exogenous PGF2ct to PGFM (/?=0.0001).
The same was true in the presence of spontaneous
labor amniotic fluid (p<0.005) and elective section
fluid (p=0.0001). This is in keeping with the fact
that the prostaglandin metabolizing enzymes are
more able to inactivate PGE2 compared with
PGF2a (31, 32).
We have confirmed that amniotic fluid can
stimulate prostaglandin production by fetal mem¬
branes and demonstrated that it has no effect on
prostaglandin metabolism in these tissues. What
factor(s) present in amniotic fluid is responsible for
the increased production has still to be clarified. It
has been hypothesized that, since amniotic fluid at
term is largely composed of fetal urine, the signal
for the onset of parturition may come from the
appropriately mature fetus (33). Fetal urine has
been shown to stimulate PGE2 production by am¬
nion in a concentration dependent manner (34),
and urine obtained from fetuses following spon¬
taneous labor stimulates greater production of
PGE2 compared with fetuses delivered by elective
cesarean section (35). Alternatively, recruitment of
mediators such as interleukins and TNFa, result¬
ing in an inflammatory process, may play a role in
the onset of parturition, and prostaglandins will
enhance the inflammatory role of such cytokines.
Indeed, such a mechanism has been proposed for
the changes associated with cervical ripening (36).
An example of cytokine recruitment is the in¬
creased concentration of IL-ip which has been re¬
ported in women in preterm labor associated with
infection (37) and in women in spontaneous labor
at term (38), and this cytokine is known to be cap¬
able of stimulating PGE2 production by amnion
cell culture (39).
Although we have looked at prostaglandin syn¬
thesis and metabolism by fetal membranes in paral¬
lel, it must be remembered that the in vitro situation
is not necessarily a true reflection of events occur¬
ring in vivo. The amnion and chorion were separated
in these experiments and therefore any modulatory
effect that these tissues may exert on each other will
have been lost. Chorion-conditioned medium
stimulates PGE2 production by amnion (40) and
chorion cells themselves are capable of interleukin
production (41). Importantly, the membranes were
devoid of decidua, which may influence these avas¬
cular tissues in a paracrine fashion. In particular,
studies have shown that a decidual product is cap¬
able of inhibiting prostaglandin production by am¬
nion (42) and that decidual cells contain an inhibi¬
tor of cyclooxygenase I (43).
In summary, our experiments confirm the stimu¬
latory effect of amniotic fluid on prostaglandin
production by amnion and chorion and demon¬
strate that this activity is greater in association
with spontaneous labor. However, labor had no ef¬
fect on the metabolizing capacity of the chorion
suggesting that it is increased production rather
than a reduction in prostaglandin metabolism
which is responsible for the increased prosta¬
glandin concentrations related to parturition.
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Summary This study aims to investigate potential mechanisms involved in the stimulatory effect of amniotic fluid on
prostaglandin production by fetal membranes. A cell culture study of amnion and chorion was obtained following
elective caesarean section, incubated with amniotic fluid collected at term (37-42 weeks' gestation) following either
spontaneous labour (n = 6) or elective caesarean section (rt = 6). The effect of addition of cycloheximide and
actinomycin D (inhibitors of translation and transcription respectively), and staurosporine and genistein (inhibitors of
protein kinase C and tyrosine kinase respectively) to these cultures was investigated. ANOVA was employed for
statistical analysis. Cycloheximide and staurosporine significantly inhibited the stimulatory effect of spontaneous
labour and elective section amniotic fluid on PGE2 production by amnion, and PGEM production by chorion. Genistein
significantly inhibited the stimulatory effect of spontaneous labour amniotic fluid on PGE2 and PGEM production by
amnion and chorion respectively. The stimulatory effect of amniotic fluid on prostaglandin production is dependent on
new protein synthesis, presumably cyclooxygenase (COX), and stimulation of cell signal transduction pathways
involving protein kinase C and tyrosine kinase.
Introduction
Prostaglandins appear to play a major role in the initiation
and/or maintenance of labour in women. Concentrations
of prostaglandins and their metabolites are increased in
maternal plasma, urine and amniotic fluid in association
with spontaneous labour.1'2 In addition, prostaglandins are
capable of inducing labour at all gestations,3 and chronic
administration of cyclooxygenase (COX) inhibitors such
as aspirin have been shown to result in prolongation of
pregnancy.4 The intrauterine tissues, comprising amnion,
chorion and decidua, are an important site of prosta¬
glandin synthesis and metabolism. Increased prostaglandin
production by amnion has been demonstrated in associa¬
tion with labour,5'6 whereas prostaglandin metabolism
appears to be unaltered by this process.6'7 However, the
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regulation of prostaglandin production within these
tissues remains to be elucidated.
Amnion is an avascular tissue. Thus, the factors capable
of regulating prostaglandin production within amnion
must be present either in amniotic fluid, immediately
adjacent chorion, or maternal decidua. Amniotic fluid at
term is composed largely of fetal urine and this provides
a potential mechanism for fetal control of prostaglandin
production, as would a factor in fetal lung secretions,
which might be linked to maturation. Alternatively, the
interaction between maternally and fetally derived tissues
at the chorio-decidual interface may enable signals that
are maternal in origin to influence prostaglandin
production in the fetal membranes in a paracrine
manner.
It has been demonstrated that amniotic fluid contains
an endogenous inhibitor of prostaglandin synthesis,8 and
a number of stimulatory activities.9'10 There appears to
be a reciprocal change in the activity of stimulatory and
inhibitory factors, which is gestation-dependent, such
that amniotic fluid obtained from women in spontaneous
369
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labour at term will stimulate significantly greater
prostaglandin production by amnion than amniotic fluid
collected at elective caesarean section.
The amnion is the most extensively investigated of the
intrauterine tissues with regard to the control of prosta¬
glandin production. Since prostaglandins are not stored,
but rather released immediately following synthesis
in response to external stimuli, the major control of
prostaglandin action lies with the regulation of its syn¬
thesis. The release of arachidonic acid, the obligatory pre¬
cursor of prostaglandins of the 2-series, from membrane
phospholipids, is thought to be a rate-limiting step in
prostaglandin synthesis in the presence of COX. Protein
kinase C (PKC) is a calcium- and lipid-dependent enzyme
which has a crucial role in cell surface signal transduc¬
tion, leading to the activation of many cellular functions.
PKC activity has been identified in human amnion, and it
has been suggested that PKC participates in the mobiliza¬
tion of arachidonic acid, and the activation of COX, thus
facilitating prostaglandin synthesis.
Two isoenzymes of cyclooxygenase have been identi¬
fied. Expression of the inducible form of the enzyme
(COX-2) is increased in association with labour," suggest¬
ing that increased COX-2 activity may be of principal
importance in producing the increase in prostaglandin
concentrations seen in association with spontaneous
labour. The purpose of this study is to investigate poten¬
tial mechanisms involved in the stimulatory effect of
amniotic fluid on prostaglandin production by fetal
membranes.
MATERIAL AND METHODS
Amniotic fluid was collected from two groups of pregnant
women at term (37-42 weeks) with an uncomplicated
pregnancy. The first group laboured spontaneously and
achieved a vaginal delivery without oxytocin augmenta¬
tion (n = 6); the second group was delivered by elective
caesarean section for either breech presentation or
previous caesarean section (n = 6). Fetal membranes were
collected from a third group of women undergoing
uncomplicated elective caesarean section at term (n = 2).
Amniotic fluid collection and preparation
Amniotic fluid was collected at elective caesarean section
by transmembranous amniocentesis and immediately with
delivery of the baby following spontaneous labour under
aseptic conditions. The amniotic fluid was centrifuged at
2000 rpm at room temperature for 20 min and the super¬
natant divided into aliquots for storage at -20°C pending
the cell culture experiments. On thawing, the amniotic
fluid was centrifuged again, then filtered through a sterile
0.20 pm mesh prior to addition to the culture system.
Mechanisms of stimulation of prostaglandin production
by amniotic fluid
Amnion and chorion cell cultures were prepared as previ¬
ously described.12 The amnion and chorion cells were
plated out separately in 24 well plates at a density of 2 x
105 cells per well. All amnion and chorion cells were
maintained in culture for 7 days, at which time the cells
remained at confluence and there was no evidence of
bacterial contamination.
The plates were incubated in humidified 95% air; 5%
C02 at 37°C for 24 h. Amniotic fluid obtained at elective
caesarean section (« = 3) and following spontaneous
labour and delivery (n = 3) was used in the experiment.
400 pi of amniotic fluid was added to each well before
addition of the following treatments (final concentra¬
tions): 1 pM and 10 pM staurosporine (inhibitor of PKC);
1 pM and lOpM genistein (inhibitor of tyrosine kinase):
2 pg and 4 pg actinomycin D (inhibitor of transcription);
lOpg and 20 pg cycloheximide (inhibitor of translation).
Cells were incubated in culture medium alone and in the
presence of amniotic fluid to act as control. In addition,
400 pi of amniotic fluid was incubated alone for estima¬
tion of background primary prostaglandin and metabolite
concentrations. The final incubation volume in all wells
was 1 ml and all experiments were performed in dupli¬
cate. The plates were incubated for a further 24 h in
humidified 95% air; 5% C02 at 37°C. The incubation
medium was oximated and stored pending radioimmuno¬
assay. The experiment was repeated on a second set of
amnion and chorion cell cultures with different amniotic
fluids (again, n — 3 for each group).
Radioimmunoassay
Radioimmunoassay was used to determine the PGE2,
PGF2a, PGEM and PGFM content of the media, and this
has previously been described.13''4 At the time of the
experiment 0.5 ml of culture medium was added to an
equal volume of methyl oxime solution, resulting in con¬
version of prostaglandins to their respective stable methyl
oxime derivatives. These samples were mixed thoroughly,
stored at room temperature for 24 h and then at 5°C
pending radioimmunoassay. In brief, up to 50 pi of the
oximated culture medium was assayed. The labels
employed are the iodinated (125I) methyloximes of PGE2,
PGF2o, PGEM and PGFM (Pro-Gly-Tyr conjugate in each
case). Antisera to the respective labels were raised in the
rabbit. The assay was left overnight prior to separation
of the antigen-antibody complex from the free antigen
by a second antibody magnetic separation procedure. The
intra-assay coefficient of variation was 12.3% for PGE2,
10.5% for PGF2a, 8.4% for PGEM and 7.3% for PGFM.
The inter-assay coefficient of variation was 13.3%, 13.9%,
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13.9% and 13.3% for PGE2, PGF2„, PGEM and PGFM,
respectively.
Statistical methods
One and two factor analysis of variance (ANOVA) were
used to analyse the data. Where the data were not nor¬
mally distributed, log transformation was employed prior
to ANOVA. Background prostaglandin and metabolite




Spontaneous labour and elective section amniotic fluid
significantly stimulated PGE2 production by amnion in
both cultures (PC0.05), and this effect was significantly
greater in the presence of spontaneous labour fluid
compared with elective section fluid (PC0.05) (Fig. 1).
The same was true for PGEM production by chorion cells
in both cultures (P< 0.05). Spontaneous labour amniotic
fluid significantly stimulated PGFM production by chorion
in both cultures (P< 0.05), but elective section amniotic
fluid had no effect in either culture (data not shown).
Cycloheximide
Cycloheximide significantly inhibited baseline PGE2
production by amnion (P< 0.05) (Fig. 2). The stimulatory
effect of amniotic fluid was also significantly inhibited
but not abolished in the presence of cycloheximide, at









Fig. 1 The effect of amniotic fluid on PGE2, PGEM and PGFM
production by amnion and chorion cell cultures. (■) control, (W.)
amniotic fluid (AF) spontaneous labour (n = 3), (□) AF caesarean
section (n = 3). Significantly different from control, P< 0.05. Results
















B Control CyclolO pg Cyclo 20 pg
Fig. 2 The effect of cycloheximide on prostaglandin/metabolite
production. (A) PGE2 production by amnion cells. (B) PGEM
production by chorion cells. (■) baseline, (H) AF spontaneous
labour (n = 3), (□) AF caesarean section (n = 3). * = significantly
different from control, P< 0.05. Results expressed as means
(SEM).
Similarly, cycloheximide 10 pg and 20 pg significantly
inhibited baseline PGEM production by chorion, and
significantly inhibited PGEM production previously
stimulated by spontaneous labour and elective section
amniotic fluid (P<0.05). Cycloheximide, at either con¬
centration, had no effect on baseline or amniotic fluid
stimulated PGEM production by chorion (data not
shown).
Actinomycin D
Actinomycin D, 2 pg and 4 pg, significantly inhibited
baseline PGE, production by amnion (P< 0.05). The stim¬
ulatory effect of spontaneous labour amniotic fluid was
significantly inhibited at doses of 2 pg and 4 pg, and that
of elective section fluid was inhibited at a dose of 4 pg
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Fig. 3 The effect of actinomycin D on prostaglandin/metabolite
production. (A) PGE2 production by amnion cells. (B) PGEM
production by chorion cells. (■) baseline, (M) AF spontaneous
labour (r = 3), (□) AF caesarean section (n = 3). * = significantly
different from control, P< 0.05. Results expressed as means
(SEM).
(P< 0.05). Actinomycin D had no effect on baseline PGEM
production by chorion, but significantly inhibited the
stimulatory effect of spontaneous labour amniotic fluid at
doses of 2 pg and 4pg (P<0.05). However, there was a
variability in the response between different cell cultures
in that actinomycin D did not significantly inhibit the
stimulatory effect of spontaneous labour amniotic fluid
in the second cell culture. Actinomycin D 2 pg inhibited
baseline PGFM production (P< 0.05), but otherwise had
no effect on PGFM (data not shown).
Genistein
Genistein 10 pM significantly inhibited baseline PGE2
production (P< 0.05) (Fig. 4). In addition, the stimulatory








B Control Gen 1 ^iM Gen 10 ^iM
Fig. 4 The effect of genistein on prostaglandin/metabolite
production. (A) PGE2 production by amnion cells. (B) PGEM
production by chorion cells. (■) baseline, [W) AF spontaneous
labour {n = 3), (□) AF caesarean section (n = 3). * = significantly
different from control, P < 0.05. Results expressed as means
(SEM).
inhibited but not abolished by genistein 10 pM. Genistein
inhibited baseline PGEM production (P< 0.05) and the
stimulatory effect of spontaneous labour amniotic fluid
was inhibited by genistein 1 pM and 10 pM (P< 0.05).
Genistein had no effect on elective section amniotic fluid-
stimulated PGEM production. Genistein had no effect on
PGFM production by chorion (data not shown).
Staurosporine
Staurosporine 1 pM and 10 pM significantly inhibited
baseline PGE2 production (P< 0.05) (Fig. 5). The stimula¬
tory effect of amniotic fluid from both groups was also
inhibited in the presence of staurosporine (P< 0.05). At a
dose of 10 pM staurosporine completely abolished the
stimulatory effect of elective section amniotic fluid. This
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Fig. 5 The effect of staurosporine on prostaglandin/metabolite
production. (A) PGE2 production by amnion cells. (B) PGEM
production by chorion cells. (■) baseline, (H) AF spontaneous
labour (n = 3), (□) AF caesarean section (n = 3). * = significantly
different from control, P< 0.05. Results expressed as means
(SEM).
was not the case for spontaneous labour fluid which con¬
tinued to stimulate greater PGE2 production compared
with cells treated with staurosporine alone. Staurosporine
1 pM and 10 pM significantly inhibited baseline PGEM
production by chorion (P<0.05), and also inhibited
the stimulatory effect of amniotic fluid from both
spontaneous labour and elective section (P<0.05).
Staurosporine had no effect on baseline PGFM production
by chorion, but significantly inhibited the stimulatory
effect of spontaneous labour amniotic fluid (P<0.05)
(data not shown).
DISCUSSION
The results of these experiments demonstrate the stimu¬
latory effect of amniotic fluid obtained at spontaneous
labour and elective caesarean section on PGE2 production
by amnion, as previously reported.6,7 Spontaneous labour
amniotic fluid promoted significantly greater prostaglan¬
din production compared with caesarean section fluid,
suggesting the presence of either increased stimulatory
activity or decreased inhibitory activity in association
with labour. In addition, spontaneous labour amniotic
fluid significantly stimulated EM and FM production in
chorion, reflecting increased prostaglandin synthesis
within this tissue, which is in keeping with our previous
findings.12 .
Prostaglandin synthesis is regulated at a number of
points. Protein kinase C can increase arachidonic acid
availability directly by acting on phospholipase A2 (PLA2)
or indirectly, via diacylglycerol at the level of the enzyme
phospholipase C. In addition to its effect on substrate
release, PKC is also able to stimulate transcription and tran¬
slation, resulting in de novo synthesis of COX enzyme.15
Stimulatory factors in amniotic fluid could therefore
increase prostaglandin production by a direct effect on
PKC, resulting in increased substrate release and COX
synthesis. Alternatively, the site of action may be at the
level of the phospholipases, again leading to increased
substrate availability.
We employed staurosporine (a PKC inhibitor) to inves¬
tigate a possible role for PKC in the increased prosta¬
glandin production by amnion seen in response to
amniotic fluid. Phospholipid-dependent PKC activity has
been demonstrated in human amnion,16 and activation of
PKC has been associated with stimulation of prosta¬
glandin synthesis in the initiation and maintenance of
parturition.17 The stimulatory effect of phorbol esters on
prostaglandin production by amnion can be inhibited by
a number of PKC inhibitors including staurosporine.18 In
our experiments, the addition of staurosporine to the
amnion cultures resulted in significant inhibition of basal
prostaglandin synthesis, and inhibition of amniotic fluid-
stimulated prostaglandin synthesis, both spontaneous
labour and elective section, suggesting that in amnion
cultures PKC has a role in maintaining basal prosta¬
glandin production, but is not the sole mechanism
involved, since production was not abolished by stauro¬
sporine. Other investigators have shown that staurosporine
had no significant effect on unstimulated prostaglandin
production,18,19 and may reflect differences in the dura¬
tion of the cell cultures as the cell's ability to respond
changes with time.20
The inhibition of amniotic fluid-stimulated prosta¬
glandin synthesis by staurosporine suggests that PKC is
involved in this process. However, spontaneous labour
amniotic fluid continued to stimulate significantly greater
prostaglandin production than caesarean section amnio¬
tic fluid, or basal output, suggesting an additional
mechanism(s) in this process. The stimulatory effect of
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caesarean section amniotic fluid was completely abol¬
ished by staurosporine 10 pM. This could be due either to
the presence of lower concentrations of stimulatory fac¬
tors in amniotic fluid prior to the onset of labour, or to
the absence of stimulatory factors necessary to activate
alternative or additional mechanisms of prostaglandin
synthesis.
Cycloheximide significantly inhibited baseline prosta¬
glandin production in our cultures, indicating that new
protein synthesis is occurring in the amnion cultures at
this time. This is in keeping with the findings of Zakar and
Olson,18 and confirms that the PGE2 accumulating in the
medium was produced de novo in a protein synthesis-
dependent manner. Cycloheximide consistently inhibited
the stimulatory effect of amniotic fluid, spontaneous and
elective section, on prostaglandin production, indicating
that new protein synthesis is necessary in this process.
Actinomycin D, an RNA synthesis inhibitor, signifi¬
cantly inhibited basal prostaglandin production by
amnion suggesting that continuous RNA synthesis was
contributing to prostaglandin output by these cell cul¬
tures at that time point in the culture system. This is in
contrast to the findings of Zakar and Olson,18 who found
that unstimulated prostaglandin output was not affected
by actinomycin D. Our findings with regard to the effect
of actinomycin D on amniotic fluid-stimulated prosta¬
glandin production were inconsistent between the two
different cultures and may reflect culture variability.
The effect of actinomycin D is known to be dose-depen¬
dent,17'18 and at the doses employed in our experiments
we would have expected inhibition if RNA synthesis was
essential for the effect seen with amniotic fluid, and this
reached significance in one culture. The finding that new
protein synthesis, and perhaps mRNA production, are
required for the stimulatory effect of amniotic fluid on
prostaglandin production suggests that this effect is
mediated by new enzyme synthesis, and it may be pro¬
duction of cyclooxygenase that is being inhibited by
these agents. However, it cannot be assumed that cyclo¬
heximide and actinomycin D are inhibiting transcription
and translation processes specific to amniotic fluid since
these agents will inhibit all such mechanisms within the
cell cultures.
Again, the finding that spontaneous labour amniotic
fluid continued to stimulate significantly more prosta¬
glandin production by cells treated with cycloheximide
than caesarean section amniotic fluid suggests the pres¬
ence of additional factors in spontaneous labour fluid
which may be stimulating alternative pathways. Or, this
may simply reflect an increased concentration of a single
stimulatory factor in association with labour. Alterna¬
tively, caesarean section fluid may promote translation of
existing mRNA leading to increased protein synthesis,
presumably COX-2, whereas spontaneous labour amnio¬
tic fluid may stimulate both transcription and translation
resulting in greater total protein production. Further¬
more, fluid from spontaneous labour may have a greater
effect on substrate availability (PLAi/PKC) which would
promote increased prostaglandin production without
increasing the amount of COX in the cell.
The results of the experiments suggest that in amnion
the stimulatory effect of amniotic fluid on prostaglandin
production is mediated, at least in part, by protein kinase
C activation and new protein synthesis. In our chorion
cultures, the stimulatory effects of amniotic fluid, sponta¬
neous labour and elective section, were also inhibited by
staurosporine and cycloheximide, again implicating PKC
activity and new protein synthesis. It is possible that a
dual mechanism is operating, one increasing enzyme
production and one increasing substrate availability, and
PKC could be responsible for both.
In addition to PKC, tyrosine kinase has a pivotal role in
controlling signalling within the cell, and hence influ¬
encing cellular metabolism, the cell cycle and growth.
The receptors for a number of growth factors including
insulin and the cytokine epidermal growth factor (EGF)
have been shown to possess tyrosine kinase stimulatory
activity.21 We investigated a potential role for tyrosine
kinase in the amniotic fluid-stimulated increase in prosta¬
glandin production by employing the tyrosine kinase
inhibitor genistein in our cell cultures. The effect of spon¬
taneous labour amniotic fluid was consistently inhibited
in both amnion and chorion cell cultures. This finding
demonstrates that activation of tyrosine kinase, either
directly or indirectly, is occurring in response to amniotic
fluid, and confirms that signal transduction processes
are important in mediating amniotic fluid's stimulatory
effect.
We have not attempted to characterize regulatory sub¬
stances in amniotic fluid and therefore can only speculate
as to what these agents might be. There is considerable
interest in the role of cytokines in the process of parturi¬
tion, concentrations of which are increased in amniotic
fluid of labouring women at term compared with non-
labouring women.22 It has been suggested that parturition
is an inflammatory-mediated process, similar to the events
taking place during cervical ripening. Cytokines could be
involved in the regulatory process of prostaglandin pro¬
duction through PKC and tyrosine kinase stimulation,
and stimulation of transcription and translation for essen¬
tial enzymes such as cyclooxygenase.
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The Effects of Mifepristone on Cervical Ripening
and Labor Induction in Primigravidae
CATHERINE L. ELLIOTT, MB CUB, jANET E. BRENNAND, MB CUB. AND
ANDREW A. CALDER, MD
Objective: To compare the effects of 50 mg or 200 nig of oral
mifepristone with placebo on cervical ripening and induc¬
tion of labor in primigravid women at term with unfavor¬
able cervices.
Methods: This was a double-blind study in which 80
primigravidae at term vvitli a modified Bishop score of 4 or
less were randomly assigned to one of three treatment
groups. They were assessed at 24-hour intervals for 72 hours,
after which labor was induced if it had not occurred spon-
taneo usly.
Results: Two hundred milligrams of mifepristone resulted
in a favorable cervix (with a Bishop score greater than 6 or in
spontaneous labor) in significantly more women than pla¬
cebo (/' = .01). An improvement in cervical ripening was
seen in the group given 50 mg of mifepristone, but this was
not statistically significant. There were more cesarean deliv¬
eries performed for fetal distress in the group treated with
200 mg of mifepristone than placebo, but this was not
statistically significant and was not associated with any
differences between groups in terms of neonatal outcome.
Conclusion: Mifepristone, a progesterone antagonist, is
known to cause softening and dilation of the human early
pregnant cervix and an increase in uterine activity. It is
theoretically attractive for use as an adjunct in cervical
priming and labor induction. In this study, 200 mg of
mifepristone was significantly more likely to result in a
favorable cervix than placebo. (Obstet Gynecol 1998;92:
804-9. © 1998 by The American College of Obstetricians
and Gynecologists.)
Induction of labor involves promoting softening and
dilation ("ripening") of the cervix and producing effec¬
tive myometrin! contractions. It lias been shown that
induction is more likely to have a successful outcome if
the cervix can be ripened before the onset of contrac¬
tions, whether spontaneous or augmented.1 Prostaglan-
I'roni the DcfmIntent of Obstetrics mnt Co/nttccologi/. Centre tor
Kepri slue I toe liiolog i/. University ol Idinlnirgli, Edinburgh. United
Kingdom.
din 1:: (PCE;.) is now widely used to prepare the
unfavorable cervix for parturition.1" Howev er, prosta¬
glandin preparations may cause uterine hyperstimula-
tioiv or may fail to produce sufficient cervical ripening
for labor induction to proceed.
Mifepristone (RU 48b, Hoechst-Roussel, Uxbridge,
UK) is a potent progesterone and glucocorticoid antag¬
onist acting on the progesterone receptor."' Its main
clinical application has been as an abortifacient; how¬
ever, it has been noted that its administration causes
marked cervical softening in the first trimester, either in
conjunction with prostaglandins promoting medical
abortion or when used alone before vacuum aspiration
(if the uterus/''' Mifepristone shows synergism with
prostaglandins in causing termination of pregnancy in
the first or second trimester.58 It seems reasonable,
therefore, to propose mifepristone as an agent for
cervical ripening in the third trimester, particularly in
conjunction with prostaglandins. In primates, mifepris¬
tone has been demonstrated to be efficacious, in combi¬
nation with oxytocin, in achieving cervical dilation and
induction of labor/' In humans, Frydman et al1" have
shown that administration of 200 mg of mifepristone on
2 consecutive days to women at term significantly
increased the number entering labor and decreased the
prostaglandin requirements of the remainder, as com¬
pared with placebo.
Our study evaluated two doses of mifepristone
(50 mg and 200 mg) as compared with placebo for their
effect on cervical ripening and subsequent induction of
labor in primigravid women whose cervices were ini¬
tially unfavorable for induction. We also evaluated the
maternal, fetal, and neonatal safety of mifepristone
when used for this purpose. Because mifepristone is
also a potent glucocorticoid antagonist4 and because it
is known to cross the placenta,"12 we also assessed
whether there was an increased risk of neonatal hypo¬
glycemia after its antepartum use.




We conducted a placebo controlled double-blind trial in
which two single oral doses (50 mg and 200 mg) of
mifepristone were compared with placebo in a dose
escalation study to assess their efficacy and safety for
the induction of labor in primigrc :J v.- -rr.cn at term. In
the first part of the study, the efficacy of a dose of 50 mg
of mifepristone was compared with placebo. On the
basis of an interim efficacy analysis of this dose com¬
pared with the placebo, we then determined whether a
higher or a lower dose of mifepristone should be used
in the second part of the study. Twenty-five women
were included in each treatment arm in the first part.
On the basis of the interim efficacy analysis, an in¬
creased dose of 200 mg was used in the second part of
the study. In the second part of the study, 25 women
received the higher dose of mifepristone and another
five were randomly assigned to receive the placebo (the
placebo groups from both parts of the study were
pooled for the final analysis). The sample size was
calculated to detect a 40% difference in the number of
patients who went into spontaneous labor or who had a
Bishop score greater than or equal to 6 comparing
patients receiving mifepristone and patients receiving
placebo with a power of 90% at the 5% significance
level. Randomization was achieved by predetermined
randomization code. Patients were allocated a number,
and therefore treatment, in strict numeric order as they
entered the study. The study was approved by the
Lothian Research Ethics Reproductive Medicine Sub¬
committee.
The inclusion criteria for the study stated that pa¬
tients were primiparous women aged 18 to 40 years
with a normal, live, single, cephalic presentation. Ges¬
tation length was between 37 and 41 weeks 4 days as
determined by a first-trimester ultrasound scan. Labor
induction was scheduled 72 hours after treatment.
Patients were offered the option of inclusion in the
study if they had a modified Bishop score13 of 4 or less.
After written informed consent was obtained, neither
the patient nor the physician had knowledge of whether
a single oral dose of mifepristone or placebo was given.
Patients were excluded if they showed signs or symp¬
toms of the onset of labor, of placental insufficiency, or
if they had any contraindication to the use of mifepris¬
tone. Before study medication was given, a modified
Bishop score was assigned by vaginal examination. In
most women, subsequent cervical assessments were
performed by the same investigator, each of whom was
blinded to the treatment allocations.
After entering the study, the women were examined
as outpatients after 24 and 48 hours. Fetal wellbeing
was assessed by the women keeping a 'kick-chart' for
each 24-hour period and by a further cardiotocograph
at each review visit. At the 24- and 48-hour reviews
maternal blood pressure and pulse were recorded, the
vaginal examination was repeated, and a Bishop score
calculated.
If labor had not occurred within 72 hours after taking
the allocated treatment the woman was admitted for
induction. An initial dose of 1 mg of PGE2 gel was
inserted into the posterior fornix of the vagina unless
the cervix was more than 3 cm dilated and fully effaced,
in which case artificial rupture of the membranes was
performed. The cervix was reassessed after 6 hours and
(unless labor was established) a further dose of 1 or
2 mg of PGE2 was given intravaginally. The examina¬
tion was repeated every 4 hours, and when appropriate,
artificial rupture of the membranes was performed.
Oxytocin was administered as clinically indicated. The
fetal heart rate was monitored continuously once labor
was established.
A cord blood sample was obtained at delivery for
blood gas analysis, biochemical and hematologic fac¬
tors, and for assay of Cortisol, ACTH, and mifepristone
levels.
Neonatal blood glucose was monitored 1, 3, and 12
hours after delivery by means of a heel prick sample.
Neonatal weight, pulse, and temperature were re¬
corded after 24 and 48 hours, as were any adverse
clinical findings in the mother or infant. A further
sample of maternal blood was taken 24 hours after
delivery. Both mother and baby were reviewed 1 week
and 1 month after delivery; standard observations were
recorded, and any adverse events were noted.
Data were stored on computer database, and analysis
was performed using the Statistical Analysis Software
(SAS) package (SAS Institute, Cary, North Carolina).
Differences between the treatment groups were com¬
pared using the t test for continuous data and the x1 test
for categoric data.
The primary efficacy measure was successful cervical
ripening (ie, modified Bishop score of 6 or greater or the
onset of spontaneous labor) within 72 hours of treat¬
ment administration.
Residts
The patient characteristics are given in Table 1. One
woman was 17 years old at inclusion into the study and
one was at a gestation of 41 weeks and 5 days when she
received treatment. Although these constituted viola¬
tions of. the protocol, both were included in the efficacy
analysis. Proportional odds models were fitted to the
data, with and without factors for maternal age, gesta¬
tional age, weight gain, weight at booking, and pretreat-
ment Bishop score. None of these factors were found to
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?d from the final model.
11 three treatment groups the most common
for inclusion was prolonged pregnancy (longer
J weeks). The next most common reason was
tnsive disorders.
main outcome measures are summarized in
!. Cervical ripening was deemed successful if
leous labor had ensued or if the Bishop score
jater than 6 before induction of labor 72 hours
te treatment administration. Cervical ripening
ccessful for 64%. 48%, and 30% of the patients
with 200 mg, 50 mg of mifepristone, and pr¬
ospectively. This difference was statistically sig-
for the 200 mg group (P — .01, odds ratio (OR)
i% confidence interval (CI) 1.34, 12.84). There
statistically significant difference between the
nifepristone group and the placebo group (P -
2.36, 95% CI 0.66, 8.37). The number of patients
itaneous labor after 72 hours was 9 (36%), 8
ind 7 (23.33%) in the 200-mg, 50-mg and placebo
respectively.
subsequent course of labor is summarized in
and the modes of delivery in Figure 1. Similar
Outcome at 72 Hours After Treatment
Mifepristone Mifepristone
Placebo 50 mg 200 mg
(ir - 30) (" = 25) (n = 25)
aus labor 7 (23.3) 8(32) 9(36)
vith a BS 2 (6.7) 4(16) 7(28)
1 cervical
g*
9 (30) 12 (48) 16 (64)f
ishop score
e given as number (%).
csful cervical ripening was defined as Bishop score greater
being in spontaneous labor.
II compared with placebo.
numbers of women in all three groups were given
PGH2, had an artificial rupture of membranes, and
received oxytocin. The median amount of oxytocin
required was 1095 ml', 5198 ml', and 5780 mU for the
200-mg, 50-mg, and placebo groups, respectively. This
reduction in the requirement bv the former group is not
statistical!)' significant. Significantly fewer women who
received 50 mg of mifepristone had a cesarean delivery
than those who were given placebo (P = .033, )C =
4.55); however, in the group given 200 mg of mifepris¬
tone there was no statistically significant difference
from the placebo group in the overall number requiring
cesarean delivery (P = .075). In the 200-mg treatment
group, eight of nine cesareans were performed for fetal
distress and the other for failure to progress. In the
placebo-treated group, three of eight cesareans were for
distress and five for failure to progress.
A wide range of maternal minor adverse events were
reported in all treatment groups, most of which were
complications of pregnancy, such as hemorrhoids or
headache. There were no marked differences across the
groups in the reporting of these. One patient in the
200-mg mifepristone treatment group had transiently
increased liver function tests.
There were no episodes of antepartum fetal distress
after recruitment to the study. In labor, fetal distress
was considered severe if it required medical interven¬
tion (such as fetal blood sampling) or delivery. There
were 12 (48%), 6 (24%), and 4 (13.3%) cases of fetal
distress in the 200-mg mifepristone, 50-mg mifepris¬
tone, and placebo groups, respectively.
Blood was taken from the umbilical vein at delivery.
Because of practical problems, this was not possible for
all infants in the study. The blood gas levels, ACTH,
and Cortisol values from these samples are summarized
in Table 4. There were no statistically significant differ¬
ences between the groups in any of the cord gas levels.
The analysis of ACTH and Cortisol in the cord blood
showed a wide range of values; the values for ACTH, in
particular, show wide standard deviation. There was no
significant difference between the 200-mg mifepristone
group and the placebo group. The mean levels of
mifepristone in the cord blood were .048 mg/L (stan¬
dard deviation [SD] = .038) and .054 mg/L (SD = .047)
after 50 mg and 200 mg of mifepristone, respectively.
Figure 2 illustrates the relationship between the length
of time to delivery after mifepristone administration
and the cord blood levels of mifepristone. The Apgar
scores of the infants were recorded at 1 minute and 5
minutes in all of- the infants and at 10 minutes in eight
infants. There were no significant differences in these
scores across the treatment groups.
Hypoglycemia in the neonates was monitored after
delivery by means of a heel-prick sample at 1, 3, and 12
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Table 3. Course of Subsequent Labor
Mifepristone Mifepristone
Placebo 50 mg 200 mg
(it = 30) (« = 25) (n = 25)
Time to onset of labor, median 81 h 15 min 80 h 20 min 75 h 50 min
Range (17 h 40 min to 104 h 30 min) (6 h 55 min to 100 h) (9 h 45 min to 101 h 15 min)
Time to delivery, median 88 h 14 min 85 h 15 min 84 h 6 min
Range (27 h 21 min to 113 h 35 min) (15 h 12 min to 113 h 47 min) (13 h 1 min to 110 h 49 min)
PGE, given 23 (76.7%) 17(68%) 16 (64%)
Total median PGE, dose (mg) 3 3 3
Oxytocin administered 14 (46.7%) 8 (32%) 12 (48%)
Total oxytocin dose (mU), median (range) 5780 (210-19,650) 5198 (2060-20,800) 1095 (210-14,220)
PGE, = prostaglandin E2.
hours after delivery. Hypoglycemia was defined as a
reading of less than 2.2, which was the case in a total of
10, 11, and 10 infants of mothers who received 200 mg
of mifepristone, 50 mg of mifepristone, and placebo,
respectively. Only one infant in the study population
was admitted to the Special Care Unit as a result of
hypoglycemia; the mother of this infant had received
placebo. Figure 3 illustrates the mean glucose levels in
the neonates.
Neonatal jaundice was reported in seven (28%), two
(8%), and two (6.7%) of the infants of mothers who
received 200 mg of mifepristone, 50 mg of mifepristone,
and placebo, respectively. All of these cases resolved
spontaneously and were not considered clinically sig¬
nificant.
Discussion
Mifepristone was deemed to have successfully pro¬






















Figure 1. Mode of delivery after treatment with 200 mg, 50 mg of
mifepristone, or placebo.
with an initially unfavorable cervix if after 72 hours the
woman was in spontaneous labor or the cervix had
become favorable (Bishop score greater than 6). By these
criteria, 200 mg of mifepristone had a significant effect
on cervical ripening, whereas the effect of 50 mg was
just below the level of statistical significance compared
with the placebo. An improvement in the Bishop score
confers an increased chance of successful labor induc¬
tion13 which may be of particular benefit to this group
of women. These findings confirm those of Frydman et
al10 who gave 200 mg of mifepristone on 2 consecutive
days to women at term. As the effect of 50 mg of
mifepristone in our study just failed to reach signifi¬
cance levels, it seems likely that a slightly increased
dose, such as 75 mg or 100 mg, may also significantly
Table 4. Umbilical Vein Blood Parameters
Mifepristone Mifepristone
Placebo 50 mg 200 mg
(n = 30) (n = 25) (it = 25)
po2 (mmHg) it = 6 1! = 6 n= 12
Mean (SD) 32.3(11.0) 30.3 (6.0) 38.9 (36.5)
Range 22.5-53.3 24.0-39.8 9.0-137.3
pco2 (mmHg) II = 6 ii = 6 n = 12
Mean (SD) 39.5 (96) 40.9 (40) 41.4(10.5)
Range 24.0-52.0 34.3-45.3 13.1-52.0
PH it = 16 ii = 21 1! = 14
Mean (SD) 7.3 (0.1) 7.3 (0.1) 7.3(0.1)
Range 6.9-7.4 6.9-7.4 7.1-7.4
Base excess ii = 5 1! = 6 n = 12
(mmol/L)
Mean (SD) -4.7(5.8) -5.3 (2.1) -7.7 (5.5)
Range -14.6 ± -0.7 -7.9—2.3 -22.2—1.7
ACTH (mU/L) i! = 25 n = 21 n = 19
Mean (SD) 51.5 (91.5) 41.8 (43.9) 20.7 (22.6)
Range 3-433 3-208 3-84
Cortisol (mmol/L) n = 24 n = 21 n = 19
Mean (SD) 484.5 (223.2) 498.6 (158.9) 522.1 (190.2)
Range. 234-1037 295-894 211-885
po2 = partial pressure of oxygen; SD = standard deviation; pco2 =
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Figure 2. Mifepristone levels (ng/mL) in cord blood obtained at the
time of delivery compared with the time to delivery after administra¬
tion of 50 mg or 200 mg of mifepristone.
ripen the cervix and that doses greater than 200 mg
could have a more pronounced effect.
As pregnancy progresses mifepristone becomes less
efficacious at inducing abortion but its action in promot¬
ing cervical ripening is maintained.4 This effect has been
noted previously in Rhesus monkeys, in whom mife¬
pristone alone induced cervical ripening but did not
produce sufficient myometrial activity to affect deliv¬
ery.14 In combination with oxytocin, however, mifepris¬
tone was effective at inducing delivery in these mon¬
keys.9 As shown by this study, the most pronounced
effect of mifepristone in the third trimester was in
causing cervical ripening and increased sensitivity to

















Time after delivery (h)
Figure 3. Mean neonatal blood glucose levels 1, 3, and 12 hours after
delivery following antenatal administration of 50 mg or 200 mg of
mifepristone.
study were initially given only 1 mg of PGE2 after
treatment administration because of concerns that in¬
creased uterine responsiveness and synergism between
the two agents could lead to a risk of hyperstimulation.
However, there were no episodes of hyperstimulation
reported in any group.
The cervical changes after mifepristone administra¬
tion have clinical implications. In addition, this finding
may help to elucidate the processes whereby cervical
ripening and the onset of labor occur spontaneously.
The effect of antiprogesterones in causing cervical soft¬
ening indirectly supports the role of progesterone in the
maintenance of pregnancy.
In addition to efficacy, the other main outcome mea¬
sures of the study were fetal and neonatal safety.
Mifepristone has already been used extensively in
women at higher doses than used here without major
concerns regarding its safety. Our data showed no
serious maternal side effects. Previous studies of pla¬
cental transfer in the late second and third trimester of
pregnancy in monkeys11 showed that a steady-state
equilibrium was relatively quickly established with a
gradient between mother and fetus possibly limiting
flux. It was also noted that the efficiency with which
mifepristone crossed the placenta was significantly de¬
creased in the third trimester compared with the second
trimester of pregnancy. In the present study there was
no evidence of altered glucocorticoid or mineralocorti-
coid action in the cord blood values obtained. As would
be expected, the levels of mifepristone in the cord blood
samples were higher in the group treated with 200 mg
ofmifepristone than in the group given 50 mg. The level
of mifepristone in cord serum is inversely correlated
with the length of time after administration that deliv¬
ery occurs.
Fetal and neonatal wellbeing were assessed at each
stage of the study. There was no antepartum evidence
of fetal distress after administration of mifepristone, as
assessed by cardiotocograph and by maternal record of
fetal movement. Intrapartum distress was assessed clin¬
ically and was more often diagnosed in the women who
received 200 mg of mifepristone than in women in the
other two groups. In the 200-mg group, there were
more cesarean deliveries for fetal distress and fewer for
failure to progress, although there was no overall
increase in the number of cesareans performed. In the
group of women who received 50 mg of mifepristone
there were fewer cesarean deliveries. No difference was
found in cord pH values or Apgar scores between the
three groups. Although this finding relates to small
numbers of women, the possibility of increased fetal
distress after treatment with 200 mg of mifepristone
should be carefully evaluated in a larger trial before its
use is recommended. In each group that received mife-
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Dristone, there was a decreased incidence of women
•equiring cesarean delivery as a result of failure to
progress in labor as compared with placebo. In contrast
o monkeys, labor induction after mifepristone admin-
stration in humans may result in a more efficient
>rocess, thus decreasing dystocia.
A dose of 200 mg of mifepristone had a significant
•ffect on cervical ripening in this group of women, but
t was associated with an increase in clinically suspected
etal distress, an effect not found with 50 mg of mife-
iristone. An intermediate dose may provide benefits in
erms of cervical ripening without affecting fetal well-
>eing. A larger trial is needed to ascertain more fully
hese effects.
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